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Introduction and Overview
C. Nora Chiang and Charles C. Lee
It has become obvious from both animal experiments and clinical
observations that the placenta does not act as a barrier to protect the
fetus from exposure to xenobiotics taken by the mother. Nearly all drugs
or foreign chemicals, following maternal exposure, enter the fetus and
may exert adverse effects, depending on the reactivity (dynamics) of the
drug in the fetus and the extent of fetal drug exposure, which may be
assessed from the kinetics of the drug in the maternal-fetal unit. The
fetus may be affected through the direct action of a drug as well as
indirectly due to drug effects on the mother. Hence, it is a primary
health concern to understand the adverse effects of a drug, taken by the
mother, on the fetus. In addition, it is of paramount importance to
determine the kinetics and the dynamics of a drug in the maternal-fetal
unit in order to elucidate the mechanisms of drug action.
Studies in humans regarding drug effects due to prenatal exposure are
usually limited because of ethical and technical considerations. Such
studies are usually restricted to clinical observations of pregnancy
outcomes or the determination of drug concentrations in maternal and
fetal biological fluid samples collected at the time of delivery. Much of
the research assessing the potentially harmful effects of prenatal drug
exposure, and particularly the mechanisms of such effects, is performed
in animals. Because of the continuous morphological and physiological
alterations during pregnancy in the mother, placenta, and fetus, both the
kinetics and dynamics of a drug in the maternal-fetal unit may change
progressively. Studies on the effects and mechanisms of drug action in
the fetus are therefore very complicated and involve a diverse range of
disciplines. Furthermore, there are questions concerning the extra-
polation of animal data to humans since there are anatomical differences
in the structure of placenta and species differences in the pharmacologic
action (dynamics) and the disposition (kinetics) of a drug.
The experimental complexity and broad spectrum of prenatal pharma-
cology and toxicology require the exchange of information as well as
integrated efforts among scientists from different disciplines, including
clinical research, chemistry, biochemistry, pharmacokinetics, pharmacol-
ogy, and physiology. To coordinate an effort for information exchange
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and interdisciplinary interaction, the National Institute on Drug Abuse
sponsored a technical review on September 24 and 25, 1984. This volume
presents the proceedings of the preclinical portion of the technical
review. It focuses primarily on the current research findings of prenatal
drug effects and current approaches for the investigation of mechanisms
of prenatal drug effects through applications of state-of-the-art
technology. In addition, an appendix containing a comprehensive review
of literature data regarding the dynamics and kinetics of drugs in the
maternal-fetal unit has been added as a supplement. Research articles
presented of the clinical portion of the meeting are collected in a
separate volume entitled “Current Research on the Consequences of
Maternal Drug Abuse.”
Various animal preparations have been used for the investigation of
prenatal drug effects. An overview of animal models was presented by
Dr. Rudolph. The presentation highlighted the pregnant ewe as an animal
model for quantitative assessment of the extent of drug exposure and the
intensity of pharmacological/physiological responses of the fetus.
Techniques for the preparation of the pregnant ewe for such investiga-
tions were illustrated. This preparation is highly praised and indeed
provides a useful model for studies of drug effects in the fetus.
Nevertheless, an extrapolation to the human situation must be made with
caution.
Drug disposition plays an important role in the elicitation or termination
of a pharmacologic effect. The biotransformation of drugs or other
exogenous chemicals in the placental-fetal unit was presented by Dr.
Juchau. Recent findings indicate that fetal liver and placenta of human
and nonhuman primates develop drug-metabolizing enzyme activities
during gestational maturation, while other subprimate animals in general
lack enzyme activities at this stage. One set of drug-metabolizing
enzymes (monooxygenases) in the placenta has been found to exhibit
increased activity in tobacco smokers. Preliminary evidence suggests
that these enzymes may catalyze the generation of highly reactive
metabolic intermediates capable of eliciting deleterious effects in the
fetus and newborn. Since research in this area is still in a developmental
stage, continuing efforts are required to establish the toxicological or
pharmacological significance of these drug-metabolizing enzymes.
The application of pharmacokinetics, a quantitative description of the
time course of a drug in the body, to studies of drug transport mechanisms
between the mother and fetus and the elicited pharmacological effects
was discussed by Dr. Benet. Using the ewe model, pharmacokinetic
principles were demonstrated with acetaminophen as a model drug for
studies of the transfer of drug and metabolites between the mother and
fetus as well as fetal disposition of all chemical entities. Pharmacoki-
netics, as applied in drug abuse research, will certainly help to provide
insight into the extent of fetal exposure and toxic consequences.
Prenatal effects of diazepam on rodents were discussed by Dr. Miller.
Reports indicate that persistent and selective alteration of the central
nervous system is induced in rats following low-dose diazepam exposure
during the last week of gestation and that coadministration of a diaze-
pam antagonist effectively prevents these alterations. The data suggest
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that administration of diazepam during pregnancy may result in perma-
nent, selective, receptor-mediated alterations in behavioral and
transmitter functions in the neonate.
The overall opiate effects on the somatic and neurobiological devel-
opment of the fetus and/or the infant were summarized by Dr. Zagon.
Laboratory investigations revealed that the actions of opiate agonists
were stereospecific and subject to blockade by coadministration of opiate
antagonists. This suggests that the locus of opiate action is at the level
of the opiate receptor. Recent research findings, which suggest that
opioid antagonists affect fetal development, led to the speculation that
endogenous opioid peptides may serve to regulate growth through
interaction with opiate receptors. The role of endogenous opioids on fetal
development clearly needs further investigation.
The adverse effects of opioids on the offspring due to maternal drug
exposure have been well documented, although the mechanisms of action
are not clear. In utero monitoring, utilizing the pregnant ewe model, of
the direct effects of morphine exposure on fetal behavioral, respiratory,
and cardiovascular functions was presented by Dr. Szeto. Results showed
that morphine exhibited a biphasic dose-response relationship, excitation
at low dose and suppression at high dose, and the fetal narcotic abstinence
symptom was precipitated in utero after a short 2-hour low-dose
morphine exposure. These findings suggest that the fetus may undergo a
cycle of acute physical dependence and withdrawal when opiates are
administered to normal clinical patients. Further research in this area is
needed to provide further insight into mechanisms for the neurobehavioral
disturbances observed in children born to pregnant narcotic users.
Noninvasive methods are clearly preferable for the study of drug distri-
bution in maternal and fetal tissues. The use of the new and noninvasive
technique, Positron Emission Tomography (PET) for the study of morphine
and heroin distribution in pregnant monkeys was illustrated by Dr.
Lindberg. Following drug administration, both drugs readily distribute to
the fetus, with heroin reaching the fetus more rapidly than morphine. In
combination with pharmacokinetic modeling, PET may prove to be a
powerful tool for the evaluation of rapid distribution and disposition of
drugs in the maternal-fetal unit. It is also a potentially useful means for
the determination of specific sites of drug action in the fetus.
Clinical reports on infants born to tobacco-smoking mothers suggest
several adverse effects. According to Dr. Kuhnert, three components of
cigarette smoke--cadmium, lead, and thiocyanate--were present at
substantially higher than normal concentrations in the newborn of
cigarette smokers. These components were shown to exhibit some
deleterious biological activities. For example, cadmium was shown to be
placental-toxic in both animal studies and in the in vitro human placenta
preparation, as presented by Dr. Miller. The factors that clinically affect
the infant or fetus are not yet identified. Dr. Kuhnert also reported
adverse effects for infants born to mothers who used phencyclidine,
meperidine, or alcohol during pregnancy. Quantitative analysis of these
drugs in the biological fluids of infants at birth demonstrated their
presence.
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All data gathered to date support the notion that nearly all drugs taken by
the pregnant mother readily cross the placenta to the fetus. Research
efforts to determine the concentrations of drugs/chemicals in body fluids
of the newborn of maternal drug users have provided valuable information
for the assessment of potential adverse effects to the infants. These
efforts should be continued with particular emphasis on the application of
new analytical technologies which enable drug determination in microliter
volumes of sample fluid.
It is well recognized that information on perinatal effect of drugs of
abuse is very limited. In many instances, the available data are confusing
or contradictory. Discrepancies may be attributed to different method-
ologies employed, different animal species studied, and varying routes of
drug administration, doses, and dosage forms. Despite the limitations of
the animal model, it is generally agreed that animal studies do provide
valuable information on prenatal drug effects. It is recommended,
however, that researchers be cautious about the selection of the animal
model as well as the route, dose, and dosage form of the drug to be
administered. It is further emphasized that a dose-response curve should
be generated for the selection of a proper dose for the animal studies, as
some drugs may exert multiphasic pharmacological effects.
In summary, it is clear that further research efforts are needed in this
critical area to further contribute to the substantial base of knowledge on
prenatal drug effects due to maternal drug exposure which has been
generated over years of research. As new technologies advance, more
sophisticated means for the investigation of the mechanisms of drug
action can be implemented. Of particular importance is integrated
research involving interdisciplinary collaboration which will certainly
contribute to the overall understanding of the preclinical and clinical
facets of the subject. Combining clinical and laboratory findings can be
anticipated to yield an improved basis for the prediction and minimization
of toxicities in humans through more effective treatment and prevention
efforts on the part of both physicians and the lay public.
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Animal Models for Study of Fetal
Drug Exposure
Abraham M. Rudolph
Increasing concerns have developed regarding the potential harmful effects
on fetal developrnent of drugs injected into or ingested by the mother, and
from her exposure to chemicals encountered in occupations or the envi-
ronment. Much of the earlier work regarding these potential hazards was
done in humans, and involved the detection of drugs or their metabolites in
umbilical cord blood at the time of delivery, or in urine in the newborn
infant soon after birth. Although detection of the parent drug reflected
passage across the placenta, the presence of metabolites did not confirm
that the drug itself was transferred, because the placenta may have been
permeable to the metabolite but not to the drug itself. Additional earlier
studies in the human were concerned with the effects that drugs taken by
the mother had on fetal function. Moya and Thorndike (1962) reviewed the
work done on detection of drugs in umbilical cord blood, and on observation
of behavior and certain physiological parameters of the human infant after
birth.
Another major interest in drug effects on the fetus concerned the
examination of their teratogenic effects. Considerable attention has been
directed toward studying the potential of drugs administered to the mother
at different stages of embryonic and fetal development to induce
congenital defects or even embryonic or fetal death. Most of this work has
been done in small rodents (Warkany and Takacs 1959). In addition, much
knowledge has been derived from examination of the coincidental
occurrence of specific congenital defects and administration of certain
drugs to the human mother.
More recently, interest has been directed toward obtaining more specific
information about factors that influence drug transfer across the placenta
and drug distribution in the fetus, and about the effects of drugs on fetal
physiological and biochemical functions. The perfused human placenta in
vitro has been used extensively to examine transfer of metabolites and
drugs (Schneider et al. 1972). There are several major concerns regarding
these studies. First, the perfusion medium has usually been an electrolyte
solution, sometimes with low molecular weight dextran; the flow rates are
usually quite low compared with what might be expected in vivo raising
questions about the degree of vasoconstriction present. Also, the duration
of viability of the preparation has not been established.
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Physiological responses of the human fetus to drugs have been difficult to
assess. Heart rate responses can be monitored, and Schifferli and
Caldeyro-Barcia (1973) studied effects on fetal heart rate after admin-
istering atropine or beta-adrenergic drugs to the mother. Recently, it has
also become possible to monitor human fetal respiratory movements by
ultrasound techniques, and it will be possible to examine the effects of
drugs on this activity.
In this presentation, I will not address the use of animal models for
assessing the teratogenic effects of drugs. I plan to discuss some models
that have been used, and some that have the potential to be used for
studying pharmacokirretics and pharmacodynamics in the fetal placental
unit, and to address some of the limitations of these studies. The following
issues will be considered, along with models available for their study:
1. Placental transfer of drugs and their metabolites;
2. Fetal distribution;
3. Intrauterine distribution and excretion of drugs and metabolites;
4. Fetal drug metabolism;
5. Pharmacological effects of drugs and metabolites.
PLACENTAL TRANSFER
The influence of physical properties on the diffusibility of substances
across the placenta has been reviewed by Faber (1973). Lipid soluble
materials diffuse readily across the placenta. Rate of movement is largely
affected by umbilical and uterine blood flow rates rather than by
permeability, because this determines the rate of delivery and removal of
the substance at the exchange site. However, transfer of lipid insoluble
substances is dependent on molecular size and on the morphology of the
placental membrane. The rate of transfer of lipid insoluble substances is
proportional to their coefficient of free diffusion in water. If molecular
size is very large, there may be no diffusion. Since placental morphology is
very different in different species, pore size will be quite variable, and
diffusibility is markedly affected. Thus, the rabbit and guinea pig have a
hemoendothelial placenta: the fetal and maternal blood streams are
separated only by fetal endothelium. Because of this, molecules larger
than plasma albumin can diffuse across the placenta. The sheep placenta is
syndesmochorial; it has five layers separating fetal and maternal blood:
maternal endothelium and connective tissue, and fetal trophoblast,
connective tissue, and endothelium. The placentae of the human and the
primate are hemochorial, consisting of three fetal layers. Thus, because of
the histology of the membrane, the sheep placenta presents a considerably
greater diffusion barrier than the human placenta, which in turn is less
permeable than the rabbit or guinea pig placenta. These potentially
enormous differences in placental diffusing capacity must be appreciated
in experimental studies of drug transfer.
Diffusion rate is dependent on the mean concentration difference between
maternal and fetal blood. As Faber points out, the relevant concentrations
are those of physically dissolved material, not the total content. Thus,
protein binding of drugs. will have a marked effect on placental transfer,
either from mother to fetus, or fetus to mother. Potentially, fetal and
maternal protein-binding capacities may be different, apart from the fact
that, at least in some speceies, albumin concentrations are lower in fetal
blood.
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Several animal models have been used to study drug transfer across the
placenta. Mirkin (1973) described a technique for examining transfer and
tissue distribution of a drug in the fetus by injection of an isotopically
labeled drug into the mother. After killing the animals at various intervals
after injection, whole fetuses were examined by radioautography.
Although this technique does demonstrate which fetal tissues are labeled,
there are several drawbacks. First, only small rodents can be used; second,
caution would have to be exercised that the tissue labelling was not caused
by passage of labeled metabolites rather than the parent drug; and third,
the technique does not provide quantitative data regarding drug transfer.
Several investigators have used techniques for studying drug transfer to
and from the fetus by placing intravascular catheters in the fetus and
mother, and administering drugs either to the fetus or mother. Maternal
and fetal plasma concentrations were measured either after a bolus
injection or after infusion. Many of these studies were done acutely in
anesthetized animals; this raises serious concerns regarding the reliability
of any quantitative measurements of transfer rates because anesthesia or
acute stress could greatly modify circulatory dynamics in both mother and
fetus and also influence hormonal and metabolic activity. Fouron (1973)
studied placental transfer of digoxin in the dog acutely under anesthesia
after either acute or chronic administration of the drug. Cosmi (1976)
studied transfer of anesthetic agents and other drugs in sheep; and
Ruckebusch et al. (1976) reported on the transfer of thiopental,
meperidine, and acepromazine (a phenothiazine) in sheep, as well as
monitoring some fetal responses to these drugs. Also, Szeto et al. (1978)
studied some aspects of pharmacokinetics of meperidine in the fetus and
mother in a chronically catheterized pregnant sheep model.
Numerous studies of similar type have been performed in chronically
catheterized fetal and maternal sheep, in which a fetal hindlimb artery and
vein and maternal artery and vein have been catheterized. This model is
useful for determining the rapidity of transfer of drugs in either direction
across, the placenta and the relative fetal and maternal plasma concen-
trations. Thus, Morishima et al. (1972, 1975) showed that lidocaine, when
injected into the mother, appears in fetal plasma very quickly. With this
model, it is also possible, after a bolus of the drug is injected into the
fetal or maternal circulation, to determine its biological half-life in the
fetus or mother, as well as the presence of, and rates of disappearance of,
metabolites. However, the information derived does not differentiate
between actual placental transfer and removal by metabolism or excretion
by other routes.
Transfer rates of drugs across the placenta can be measured more specif-
ically by application of the Fick principle. Meschia et al. (1966) first
applied this approach to measure umbilical and uterine blood flows in
pregnant sheep by infusing antipyrine into the fetus. The rate of removal
of drug to the uterus and its contents is measured by the equation
A= Qut x (Cuta - Cutv)
where A is amount removed  Qut is uterine blood flow, and Cuta and Cutv
are concentrations of drug in uterine artery and vein at steady state. This
technique has limitations because the sheep uterus has several draining
veins, and sampling from a single vein may not be representative of mixed
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uterine venous blood. Also, uterine venous blood is a mixture of blood
derived from placental site perfusion as well as uterine musculature.
Myometrial blood flow in the sheep in mid- to late-gestation accounts for
only about 15% of total uterine blood flow, but this must be considered in
estimates of placental transfer.
The amount of a drug that is removed or taken up at the placenta on the
fetal side can be calculated similarly from the equation
A = Qun x (Cumv - Cuma)
where Qum is umbilical blood flow and Cumv and Cuma are concentrations
of drug in umbilical vein and artery, respectively, at steady state. Prob-
lems with umbilical venous sampling may present difficulties in making
accurate measurements. A technique used commonly to catheterize the
umbilical vein is to pass a catheter from a peripheral cotyledonary vein
centrally into one of the two main veins (Rudolph and Heymaun 1980). It is
possible that the sample obtained may not reflect mixed umbilical venous
blood. To overcome this, we developed a method for chronically cathe-
terizing the common intra-abdominal segment of the umbilical vein (Young
et al. 1974). but recent experience has shown that there is no significant
difference in concentrations in the common vein as compared with the two
main veins.
Uterine and umbilical blood flow can be measured by several techniques.
The antipyrine steady-state diffusion method mentioned above suffers
from the inability to make repeated measurements after any manipulation
without waiting a considerable period for a new steady state to be
achieved. Techniques for applying electromagnetic flow transducers to the
vessels have been described for both the mother and fetus. Flow
transducers can be applied to the branches of the uterine artery, but to
measure total flow, the transducer can be applied to the distal aorta
beyond the origins of the common iliac arteries. In the sheep, this segment
of the aorta gives rise to the two uterine arteries, from which also arise
some small branches to the pelvis. Thus, measurement of flow at this site
slightly overestimates the uterine blood flow. In the fetal lamb, we
demonstrated that the umbilical arteries arise from a short distal segment
beyond the common iliac artery origin. We have described the technique
for applying a flow transducer to this segment to measure total umbilical
blood flow (Berman et al. 1975). Because some small arteries arising from
the umbilical arteries supply pelvic tissue, the measured flow slightly
overestimates actual umbilical blood flow. The great advantage of this
technique is that blood flow can be measured instantaneously and rapid
alterations can be monitored.
The radionuclide-labeled microsphere technique is a useful method for
measuring both umbilical and uterine blood flows (Rudolph and Heymann
1967; Heymann et al. 1977). In the mother, a catheter must be introduced
retrograde through a peripheral artery and advanced to the left ventricle.
If the placental portion of the uterus is separated from the surrounding
myometrium at autopsy, it is possible to measure uterine blood flow to
each portion separately. In the fetus, the microspheres can be injected
into a peripheral vein while a reference sample is collected from the
descending aorta or one of its branches. It is also feasible to measure
umbilical blood flow to the placental cotyledons separate from the
amniotic and chorionic membranes.
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The placenta has high metabolic activity and a fairly large volume. Drugs
delivered to the placental site either from the maternal or fetal
circulations will be distributed in the placental volume. Also, some of the
drug may be metabolized by the placenta. Thus, even at steady state, the
calculated uptake of drug by the placenta on the fetal side may not equal
the calculated amount leaving the uterine circulation at the placental site.
The difference is a reflection of placental removal of drug.
It should also be appreciated that the uptake or release calculated from the
Fick equations above represents net transfer. Some of the drug in the
umbilical artery may cross to the maternal circulation, whereas some in
the uterine artery may enter the fetal circulation.
FETAL DISTRIBUTION AND EXCRETION OF DRUGS AND METABOLITES
The fetal circulation is characterized by the presence of shunts which
provide preferential distribution of oxygen and substrates to upper body
organs and also function as a partial bypass of the lungs. The
radioautography studies developed by Mirkin (1973) are not quantitative
enough to define distribution patterns of drugs in fetal tissues. The blood
flow patterns in the fetus are important to our understanding of how drugs
and chemicals delivered to the fetus across the placenta into umbilical
venous blood are distributed in the fetus. It is also important in
experimental studies in which drugs are infused directly into the fetus for
pharmacokinetic or pharmacodynamic studies. Furthermore, because of
the shunting, arterial concentrations of drugs may be very different in
upper and lower body arteries.
The patterns of blood flow in major venous channels have been studied in
fetal lambs by applying the radionuclide-labeled microsphere technique.
Simultaneous injection of microspheres into various peripheral veins has
defined the flow patterns shown in figure 1. Umbilical venous blood
contributes about 40% of total venous return; about 55% normally passes
through the ductus venosus, thus bypassing the liver, while the remainder is
distributed to the left and right lobes of the liver. Portal venous blood is
distributed exclusively to the right lobe of the liver (Edelstone et al.
1978). Distal inferior vena caval blood is joined by blood from the left and
right hepatic veins and the ductus venosus just below the diaphragm.
However, blood does not mix completely in the thoracic portion of the
inferior vena cava. We have shown that ductus venosus blood streams
preferentially through the foramen ovale to the left atrium, whereas distal
inferior vena caval blood preferentially flows through the tricuspid valve
into the right ventricle (Reuss and Rudolph 1980; Edelstone and Rudolph
1979). Superior vena caval blood passes almost exclusively through the
tricuspid valve into the right ventricle. Right ventricular blood largely
flows through the ductus arteriosus to the descending aorta, while left
ventricular blood is ejected into the ascending aorta. These flow patterns
account for the higher oxygen saturation in ascending aortic blood as
compared with descending aortic blood in the fetus, and also could result in
higher concentrations of drugs in ascending aortic blood when they enter
the fetus through the placenta.
We have also shown that left hepatic venous blood follows the preferential
streaming pattern of ductus venosus blood, whereas right hepatic venous
blood is distributed in a similar manner to distal inferior vena caval blood.
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VENOUS FLOW PATTERNS IN THE FETAL LAMB
Figure 1. The course and distribution of venous blood entering the heart
in the fetus is depicted. Umbilical venous blood enters the hepatic hilum
and gives off branches to the left lobe. The ductua venous carries
predomanantley umbilical venous blood driecly to the inferior vena cava.
The umbilical vein then the arches, to the right to join the portal vein. Almost
all portal vnous blood enters the right lobe of the liver. The right hepatic
venous, blood, joins the abdominal inferior vena caval stream to be
preferentilly distributed through the tricuspid valve. Left hepatic venous
blood joins the ductus Venous stream and these two well-oxygenated
bloods are preferentially directed through the foramen orale. The superior
vena caval blood is almost completely directed through the tricuspid calve
(from Rudolph 1983, copyright 1983, American Association for the Study
of Liver Disease)
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These distribution patterns could greatly influence concentrations of drugs
reaching different organs, depending on their route of administration and
on the rate of metabolism in various organs. Thus, if a drug enters the
umbilical circulation it first reaches the fetal liver, but about half passes
directly through the ductus venosus. If the drug is rapidly metabolized by
the liver, up to half of that entering the fetus may be removed on the first
pass. If the drug is administered through the portal vein, it will reach the
right lobe of the liver in highest concentration, with much lower
concentrations reaching the left lobe of the liver. When a drug is infused
into a forelimb vein, it will not be distributed to the brain or heart on the
first pass, and if the drug is readily removed by the placenta, large
amounts may be necessary to have an effect on the heart or brain. In the
same fetus, drugs infused at the same ratio could thus exert very different
effects, depending on the route of administration.
INTRAUTERINE DISTRIBUTION AND EXCRETION
In addition to distribution of drug administered to the mother into the fetal
body, some drugs may enter the chorioallantoic membranes and amniotic
and allantoic sacs. Exchanges between allantoic and amniotic fluids and
the fetal or maternal circulations are not clearly established. The
amniotic fluid surrounds the fetus, but the allantoic sac occupies a small
segment of the uterine space. In the latter trimester of the sheep, the
allantoic space is well defined in the horn of the uterus and in the cervical
region, but in the body of the uterus the allantoic and amniotic membranes
are closely applied and there is little allantoic cavity in this region (Mellor
1980). Because of this, there could well be poor mixing within the allantoic
cavity. Similarly, although the fetus is surrounded by amniotic fluid, the
degree of mixing of substances that enter the amniotic fluid is not well
established. In early gestation in the sheep, the fluid is a clear liquid and
mixing may be good, but beyond about 120 days gestation the fluid becomes
increasingly viscid and considerable mucus is present, and distribution of
materials added to it may be quite poor.
It is possible to place catheters into the amniotic and allantoic sacs and to
maintain them chronically. The amniotic catheter can be readily inserted
adjacent to the fetal body. To catheterize the allantoic sac, the muscle of
the horn of the uterus is carefully incised and the allantoic cavity is
entered; it is recognized by the presence of clear yellowish fluid, in
contrast with amniotic fluid, which is often turbid and, in later gestation,
viscid. Also, the cotyledonary branches of the umbilical arteries and veins
are clearly visible on the chorionic membrane.
The allantoic and amniotic spaces may have a prominent role in kinetics of
the parent drug or its metabolites. if the drug or metabolite enters these
spaces, it could be reabsorbed into the maternal or fetal circulation. The
drug or metabolite may enter the amniotic sac from fetal urinary output
via the urethra, or the allantoic sac from urine via the urachus. In
addition, drugs may enter the amniotic fluid in tracheal fluid, secreted by
the lung, or possibly via the gastrointestinal tract, but the latter source is
not likely.
The excretion of drug or metabolites by the fetal kidney can be measured
readily in the lamb fetus in which a catheter is implanted chronically into
the bladder. This can be done directly through a suprapubic abdominal
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incision (Iwamoto and Rudolph 1983), but can also be readily accomplished
by passing a catheter through the urachus either intra-abdominally or as it
enters the umbilical cord, external to the umbilical ring. I now prefer the
urachus approach because, since the urachus is ligated, urine will not enter
the allantoic sac. Also, to be sure that no urine enters the amniotic sac,
the urethra can be ligated at the skin surface. If this is done, the urinary
catheter must be allowed to drain, so that retention does not occur. When
catheters are placed in the bladder and in the allantoic and amniotic sacs,
it is possible to measure the urinary excretion rates of drugs and their
metabolites, and also examine their rates of entry and removal from the
allantoic and amniotic fluid. As mentioned above, because there may be
problems of even distribution of substances in the allantoic and amniotic
fluid, the information regarding drug and metabolite concentrations and
kinetics in the allantoic and amniotic sacs may not be precise.
FETAL DRUG METABOLISM
A great deal of work has been done on developmental aspects of enzymes
involved in drug metabolism, but most studies have concentrated on
detection of enzymatic activity in vitro in microsomal fractions or
homogenates of fetal organs, or in fetal cell cultures. This work has been
reviewed extensively by Dutton (1978). However, the techniques used may
possibly interfere with activity of some enzymes and, furthermore, may
activate a11 enzyme present in inactive form, but which may not be active
in vivo. Study of metabolism of drugs by the fetus in vivo have taken two
directions. First, analysis of metabolites of the drug in fetal blood provide
an indication that the fetus has the capacity to metabolize the drug,
assuming that the metabolites do not cross the placenta. If they do cross
the placenta, it is difficult to determine whether they are derived from
maternal metabolism. Also, measurement of metabolite concentration
does not indicate where the drug is being metabolized.
We have developed a preperation ion in fetal lambs which allows the direct
measurement of rates of metabolism by the liver. Catheters are implanted
into a lower limb artery and vein, an umbilical vein, a mesenteric venous
tributary of the portal vein, and a left or right hepatic vein. These
techniques have been reported previously (Bristow et al. 1981). Blood flow
to each lobe of the liver from the umbilical veins, to the portal vein, and to
the hepatic artery can be measured using the radionuclide-labeled
microsphere method. By measuring concentrations of drugs or metabolites
in the various vessels and using the blood flow data, rates of hepatic uptake
or release can be calculated by the Fick method. We have shown that, in
the fetus, only a very small percentage of liver blood supply is derived
from the hepatic artery, and it can readily be discounted in these
calculations. Thus, for the left lobe
A = QLuv x Cuv - QLuv x CLhv
and for the right lobe
A = (QRuv x Cuv + QRpv x Cpv) - (QRuv + QRpv) x CRhv
Where A is the amount taken up or released, QLuv is blood flow to the left
liver lobe from umbilical vein, and Cuv and CLhv are concentrations of
drug or metabolites in umbilical venous and left hepatie venous blood.
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Q Ruv and QRpv are blood flows to the right liver lobe from the umbilical
and portal veins. CUV, CPv and CRhv are concentrations in umbilical vein,
portal vein, and right hepatic vein.
These calculations depend for reliability on adequate concentration
differences across the liver; if this does not occur, it may be necessary to
use radioisotopically labeled drugs, with measurement of specific activity
of metabolites in hepatic venous blood.
Recently, we have also developed a preparation in fetal lambs in which the
renal vein is catheterized chronically (Iwamoto and Rudolph 1983). In
association with lower limb artery catheterization and measurement of
renal blood flow either by the microsphere method or by clearance
techniques, the rate of uptake of drugs or release of metabolites from the
kidney can be calculated.
PHARMACOLOGICAL EFFECTS OF DRUGS AND METABOLITES
Numerous fetal physiological and biochemical functions can now be
monitored in the chronically instrumented fetal lamb. Heart rate and
arterial pressure can be monitored from intraarterial catheters, or heart
rate and electrocardiogram can be recorded from chronically implanted
ECG leads sewn to fetal skin. Venous pressures or atrial and ventricular
pressures can be recorded from catheters inserted directly, or via
peripheral vessels.
Continuous measurement of blood flow in several fetal vessels has been
achieved by chronic implantation of electromagnetic flow transducers
around the vessel. Thus, umbilical blood flow can be measured by placing a
flow transducer around the common umbilical artery (Berman et al. 1975)
or the common umbilical vein (Oakes et al. 1976). Transducers around the
pulmonary trunk measure right ventricular output and around the ascending
aorta measure left ventricular output minus coronary flow (Rudolph and
Heymann 1973). The fetal circulatory effects of drugs administered to the
mother or fetus can be examined in these preparations. However, when
drugs are administered to the mother, fetal responses may not be a direct
effect, but may result from interference with uterine blood flow, causing
fetal hypoxemia and possibly aeidemia. Also, drugs that may depress the
fetal circulation or constrict the umbilical-placental vessels could cause
hypoxemia as a result of inadequate oxygen delivery. It is therefore
advisable to exarnine the effects of drugs administered directly to the
fetus as well as to the mother. Also, maternal cardiovascular variables
such as blood pressure and heart rate, and particularly uterine blood flow,
should be measured to assess maternal responses.
The radionuclide-labeled microsphere technique has greatly advanced the
opportunity to exarnine fetal cardiovascular responses to drugs (Rudolph
and Heymann 1967). Injection of microspheres with two different labels
into an upper and lower limb vein with simultaneous sampling from upper
and lower limb arteries allows measurement of cardiac output and blood
flow to every organ and tissue and to the placenta. Currently, we can
discriminate nine different gamma emitters, so that it is possible to obtain
a control measurement and the effects of a drug at three different
concentrations, if desired. The changes in vascular resistance in each
organ can be assessed.
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Some of the effects of drugs on the central nervous system can be
examined by implanting leads to measure electrocortical activity or
electroocular activity and limb or nuchal muscle movement (Ruckebusch et
al. 1976).
The effects of drugs on renal function can readily be examined in the
preparation we reported (lwamoto and Rudolph 1983). Renal blood flow
and urinary output, as well as urinary electrolyte composition, can be
examined. Biochemical and endocrine effects of drugs can be studied by
measuring plasma concentrations of metabolic substrates or hormones.
This review indicates that there have been considerable advances in the
ability to study pharmacokinetics and pharmacodynamics of drugs in the
fetus and mother during pregnancy. At present, the pregnant sheep
preparation provides a useful model for drug studies. It must be
appreciated, however, that there are important species differences in
placental function. Furthermore, the state of maturation of the developing
fetus varies greatly in different species at the time of birth. It is
therefore not appropriate to assume that drug effects can be compared at
similar proportions of the total gestational period.
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Biotransformations of Drugs and
Foreign Chemicals in the Human
Fetal-Placental Unit
M.R. Juchau
Prenatal drug biotransformation has attracted investigative attention
since the late 1950s (Fouts and Adamson 1959; Jondorf et al. 1959) when it
was recognized that differences between mature and developing organ-
isms, in terms of their responses to the pharmacologic/toxicologic actions
of drugs, could be due (at least in part) to developmental differences in
biotransformation. The common biotransformation pathways for drugs
and foreign chemicals are presented in table I. Early studies on fetal
drug metabolism primarily focused on hepatic tissues because the liver
was recognized as the principal site of drug biotransformation reactions in
adult animals. When compared in vitro with hepatic tissues from mature
experimental animals, the corresponding tissues from fetuses and
neonates exhibited extremely low or, in many cases, undetectable drug
biotransforming activities. Based primarily on studies in rats, mice,
rabbits, and guinea pigs, the concept arose that the drug biotransforming
capacity of prenatal animals was virtually negligible. Early studies of
fetal and neonatal drug biotransformation were reviewed by Brodie and
Maickel (1962) and Fouts and Hart (1965). This concept (absence of
prenatal drug biotransformation) persisted until the early 1970s when it
was discovered independently, in three separate laboratories (Pelkonen et
al. l971a, 1971b; Rane and Ackerman 1972; Rane and Sjöqvist 1972; Juchau
1971; Juchau et al. 1972; Juchau and Pedersen 1973), that the human fetal
liver and adrenal gland contained enzymes capable of catalyzing various
monooxygenation reactions--reactions for one of the common biotrans-
formation pathways of drugs and foreign chemicals (table 1), at
reasonable respectable rates and at fairly early stages of gestation.
Several reviews of these findings also have appeared in the literature
(Pelkonen 1973, 1979, 1980d, 1980b, 1982; Yaffe and Juchau 1974; Rane et
al. 1973; Juchau et al. 1980; Juchau 1980a).
Almost simultaneously, it was discovered that human placental tissues
exhibited the capacity to biotransform drugs via each of the major
metabolic pathways. Possibly the most striking aspect of placental drug
biotransformation was the remarkably increased monooxygenase activities
observed in placentas as of tobacco smokers. Such increases were observed
primarily in placentas delivered near term and contrasted with a relative
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TABLE 1. Common biotransformation pathways and enzymes involved in
biotransgermotaion
PATHWAY
I. Oxidation
a) Monooxygenation
b) Dioxygenation
c) Dehydrogenation
d) Peroxidation
e) Monoamine oxidation
Il. Reduction
a) Nitro groups
b) Azo linkages
c) Epoxides
d) Carbonyl groups
e) Unsaturated carbon-
carbon bonds
Ill. Hydrolysis
a) Carboxylic acid esters
b) Amides/peptides
c) Sulphate esters
d) Glucuronic acid esters
e) Epoxides
IV. Conjugation
a) Glycosylation
1. Glucuronidation
2. Riboside formation
3. Glucoside formation
b) Sulphation
c) Acylation
1. Acetylation
2. Clycine/glutamine
conjugation
d) Glutathione conjugation
e) Methylation
ENZYMES
I. Oxidoreductases
a1) Cytochrome P-450-
dependent systems
a2) Flavin-dependent
monoxygenases
b) Dioxygenases
c) Dehydrogenases
d) Peroxidases
e) Monoamine oxidases
II. Oxidoreductases
a) Nitro reductases
b) AZO reductases
c) Epoxide reductases
d) Dehydrogenases
e) Dehydrogenases
III.Hydrolases
a) Esterases
b) Amidases
c) Sulphatases
d) Glucuronidases
e) Epoxide hydrolases
IV. Transferases
a) Glycosyl transferases
1. Glucuronosyl
transferases
2. Ribosyl transferases
3. G1ucosyst transfeases
b) Sulphokinases
c) Acyl transferases
1. Acetyl transferases
2. Amino acid
transferases
d) Glutathione transferases
e) Methyl transferases
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lack of response during the first third of gestation. Fetal livers and
adrenal glands also appeared not to respond significantly to inducing
agents present in tobacco smoke between weeks 7 to 20 of gestation.
Aspects of these researh findings have been reviewed on numerous
occasions. (For recent reviews, see Juchau l980b, 1982, 1984; Chao and
Juchau 1983; Juchau and Rettie, in press).
PHARMACOLOGIC SIGNIFICANCE
A somewhat disturbing aspect of the finding of comparitively high
monooxygenase activities in human placental and fetal tissues is the
indication provided by somewhat preliminary research that various
enzymes deemed extremely important for bioinactivation of drugs and
chemicals are present in low to negligible levels in each of the three
aforementioned. tissues (but particularly the placenta). They also appear
to remain at low levels following esposure to inducing agents. Of
principal cocern is the low to negligible complement of glucuronyl
transferases (in all fetal and placental tissues), enzymes which play a
prime role in terminiatirng the biologic effects of drugs and other
chemicals. Activities of other conjugating enzymes may also be low,
although no generalizations should be made at this time because of the
fact that relatively high activities can be observed depending upon the
substrate under investigation, the tissue preparation being studied, the
stage of gestation, exposure to inducing agents, and a multitude of other
genetic, physiological, and environmental factors known to affect rates of
conjugation.
Under conditions in which the tissue monooxygenase activities are
comparatively high, it can be shown that enzymes from each of these
three organs will catalyze the conversion of promutagens to mutagenic
intermediary metabolites (Jones et al. 1977; Juchau et al. 1978, 1980;
Juchau l980a). Other bioactivation reactions also have been documented
(Rollins et al. 1979; Pelkonen 1979, 1982). The toxicologic significance of
these observations is not fully understood at present but would suggest
that after exposure of pregnant women to drugs or chemicals,
steady-state levels of reactive, toxic intermediates would tend to be high
in fetal and placental tissues with high ratios of monooxygenase to
conjugating activities. Considerable research must be performed in order
to understand the implications of regulatory increases in xenobiotic
monooxygenation in the fetal-placental unit. From the viewpoint of
toxicologic effects of drugs and chemicals, the influence of such changes
will undoubtedly vary depending on the toxic  chemical under
consideration. It is important to emphasize that we are now in possession
of only the barest framework of knowledge of xenobiotic biotransforma-
tion in human fetal and placental tissues and that it is entirely premature
to make predictions concerning the metabolic fate of a given chemical
within the human fetal-placental unit based on currently available
information. Recently, we discovered (Juchau et al. 1982; Namkung et al.
1983a, 1983b; Omiccinski et al. 1980) that additions of micromolar
quantities of hematin to reaction mixtures containing fetal or placental
tissues as enzyme source would increase rates of monooxygenation by as
much or more than a hundredfold, depending upon reaction conditions and
the tissue under investigation. The mechanism for elicitation of these
remarkable increases has not yet been elucidated, but evidence
accumulated to date suggests that the phenomenon may reflect a highly
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important, short-term mode of regulation of P-450-dependent monooxy-
genation reactions. In view of the implications for generation of toxic
reactive intermediates, it would seem important to gain a much firmer
understanding of the phenomenon. We are currently pursuing studies of
“hematin-mediated” regulation of P-450-dependent monooxygenase
activities in fetal and placental tissues with the following working
hypothesis:
Extrahepatic tissues of mature animals and both
hepatic and extrahepatic tissues of immature (pre-
natal and neonatal) animals (including human and
nonhuman primates) contain significant pools of
apocytochrome P-450 isozymes which, under normal
circumstances, exhibit a relatively low affinity for
the corresponding hematin prosthetic group. Fol-
lowing contact with certain small organic chemicals
(not necessarily xenobiotics, as hydroxylation of
estradiol 17B also appears subject to this regulatory
mode), interaction of the apocytochrome with the
chemical and/or its metabolite(s) results in a con-
formational change in the apocytochrome(s) which
increases the affinity for its hematin prosthetic
group. The increased affinity, in turn, results in an
increased steady-state level of active holocyto-
chrome(s) and thus, a marked increase in the corre-
sponding P-450-dependent monooxygenase activities.
Although the hypothesis remains unproven, we have provided substantial
evidence to rule out a large number of possible alternative hypotheses and
also have found that all data obtained to date are consistent with the
stated hypothesis. In addition, we have been able to show (Giachelli et al.
1984) that embryonic tissues contain unusually high quantities of mRNA
which serve as template for P-450 synthesis, suggesting the possibility
that correspondingly high levels of inacative apocytochrome may also he
present prenatally. In view of the importance of the role of P-450-
dependent monooxygenation in the generation of reactive intermediates
and in the potential serious toxic effects of such intermediates, it is felt
that pursuit of these questions could provide considerable light on
mechanisms of chemically initiated toxicity in the fetal-placental unit.
It should he emphasized, however, that our current understanding of drug
biotransformation in the human fetal-placental unit is very primitive. It
is not possible to predict the metabolic fate of drugs and foreign
chemicals within that unit--even for chemicals that have received some
investigative attention. For obvious reasons, investigators have utilized
model substrates (primarily) for the study of the metabolic capabilities of
the pertinent human fetal and placental tissues. Thus, specific infor-
mation on most drugs of abuse is not available at present, nor is it
possible to predict their biotransformational fate within the fetal-
placental unit. Understandably, in view of the ethical questions involved,
progress in the area has been rather slow, with only a few published
artickes appearing each year. For these and other reasons, our
understanding of the effects of drugs of abuse on the prenatal organism
(particularly in terms of the more subtle, nonmorphologic and/or
Long-term effects) is incomplete at best. Future research, however, will
undoubadly help to clarify many of the currently existing questions.
20
SUMMARY
Several communications pertaining to research on human fetal drug
biotransformation have appeared in the literature in the past 3 to 4 years
(Aranda et al. 1979; Cresteil et al. 1982; Pacifici et al. 1981; Pacifici and
Rane 1982, 1983; Schroeter and Amon 1983). In general, research in this
area has produced no major recent surprises, but it has confirmed,
extended, and supported the earliest findings through those of the
mid-1970s and has served to expand our understanding of these important
systems. The important aspects of our current knowledge may be
summarized very briefly as follows:
1. Each of the major drug metabolic reactions (oxidations,
reductions, hydrolyses, and conjugations) can he catalyzed at
generally low rates by enzymes present in human fetal and
placental tissues.
2. Reaction rates appear, in general, to increase with advancing
gestational age.
3. Placental xenobiotic-biotransforming monooxygenases display a
high sensitivity to the effects of MC-type (methylcholanthrene)
but not PB-type (phenobarbital) inducing agents during the later
stages of gestation. Responsivity is minimal during early
gestation.
4. Monooxygenases in other fetal tissues (liver, adrenal gland,
etc.) appear to respond minimally to inducing agents, at least
during the earlier stages of gestation.
5. Glucuronyl transferase activities appear to be very low in all
fetal and placental tissues.
6. Epoxide hydrolase, glutathione S-transferase, and sulfo-
transferase (and perhaps others) activities can be relatively
high in prenatal primate hepatic tissues but, at present, are
difficult to predict. Some of these may respond to environ-
mental inducers in situ, but solid evidence for this is still
lacking.
7. Monooxygenases in all fetal and placental tissues (with the
exception of the liver in certain species) appear subject to a
hematin-Jnediated regulation of activity. Extremely large
increases have been observed.
8. Enzymes/enzyme systems present in human fetal and placental
tissues can catalyze the generation of reactive intermediary
metabolites capable of covalently binding to biomacromolecules
and inducing bacterial mutations.
9. In terms of substrates attacked by human tissue monooxy-
genases, the fetal hepatic enzyme exhibits a rather broad
specificity, the fetal adrenal gland exhibits a narrower spec-
ificity, and the human placenta exhibits an even narrower
specificity.
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10. In comparison with hepatica systems from adult male rodents,
human fetal and placental tissues are virtually unexplored with
respect to knowledge of drug biotransformation.
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Pharmacokinetics of Drugs and Metabolites
in the Maternal-Placental-Fetal Unit:
General Principles
Laurene H. Wang, Abraham M. Rudolph, and Leslie Z. Benet
Drug use during pregnancy may result in both pharmacologic and toxi-
cologic drug effects in the fetus. Prenatal pharmacology defines the
therapeutic use of drugs to treat fetal diseases in utero; while prenatal
toxicology evaluates the risks of drug exposure to the developing fetus.
To correctly assess the pharmacologic and toxicologic effects of a drug,
one must examine hoth the pharmacodynamics and pharmacokinetics of
the drug and its metaholites. Pharmacodynamic parameters which specify
the interaction of a drug or its metabolites with certain specific receptors
and the elucidation of their modes of action determine whether the drug
or its metabolites possess pharmacological or toxicological potential in
the fetus. On the other hand, pharmacokinetic parameters which
characterize the disposition of the drug and its metabolites in the
maternal-placental-fetal unit are of utmost importance in determining
whether an active form of the drug can reach the fetus, after maternal
administration, at a sufficient concentration and for a11 adequate period
to induce pharmacological or toxicological effects during the prenatal
period. Therefore, pharmacokinetic studies in the maternal-placental-
fetal unit which evaluate the rate and extent of drug exposure to the
fetus play an important role in developmental pharmacology and
toxicology.
An index of relative exposure of the fetus to the drug taken by the mother
has been defined as the ratio of the total area under the drug concen-
tration versus time curve for the fetus to that for the mother after a
single-dose administration (Levy and Hayton 1973). If multiple doses of a
drug are administered, the index of relative exposure of the fetus to the
drug can be determined by the ratio of the steady-state drug concentra-
tion in the fetus to that in the mother. Since the metabolite of a drug is,
in many cases, the active species responsible for a pharmacologic or
toxicologic effect, the concentrations of the metabolite should then be
measured to determine the fetal metabolite exposure. In addition, plasma
protein binding measurements should also be determined because the
unbound drug is generally believed to be the moiety that elicits a
pharmacologic or toxicologic action. The factors affecting the rate,
extent, and duration of exposure of a drug or its metabolites to the fetus
include the absorption, distribution,. and elimination of the drug in the
mother; the distribution and elimination of the drug metabolites in the
mother; the transfer of the drug and its metabolites across the placenta;
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the metabolism of the drug or its metabolites in the placenta; and the
distribution and elimination of the drug and its metabolites in the fetus.
Theoretical considerations of all the above processes of drug disposition in
the maternal-placental-fetal unit are presented in this chapter. Pharma-
cokinetic experiments which have been utilized lo assess appropriate
pharmacokinetic parameters for characterizing the kinetic processes are
also discussed.
PHARMACOKINETIC STUDIES DURING PREGNANCY
Pharmacokinetic studies in humans during pregnancy are usually limited
to a single point determination of drug concentrations in the mother and
the fetus (umbilical cord blood) immediately following delivery. These
determinations are carried out in different subjects, at different times
after drug administration, and usually under different conditions. Con-
sequently, pharmacokinetic chararterization of drug disposition in the
maternal-placental-fetal unit derived from these studies is extremely
difficult and by no means is definitive in reflecting in utero rondition.
Based on theoretical considerations, computer simultations various
pharmacokinelic models have been undertaken to predict the time course
of drug concentrations in the mother and fetus (Levy and Hayton 1973;
Gillette 1977). Nonetheless, the most useful information can only be
obtained from properly conducted experiments in which the time course
of maternal plasma concentrations of drug and metabolites is followed
after drug administration; and maternal, cord arterial, and venous blood
samples and amniotic fluid are collected at the time of delivery (Rajchgot
and MacLeod 1983). In addition, the plasma protein binding of the drug
and its metabolites should also be determined.
Since drug studies in pregnant woman are ethically and medically prohib-
ited, most multiple sample pharmacokinetic investigations of drugs and
metabolites have been carried out in animals. Rats, mice, and rabbits
have been frequently utilized with a single time sample obtained in both
the mother and fetus at sacrifice. Pharmacokinetic analyses are then
undertaken with combined data from many animals sacrificed at different
times after dosing. A few multiple time sample studies have been carried
out in monkeys, but the pregnant sheep has evolved as the most frequently
used animal model.
The establishment of a chronically catheterized pregnant sheep model has
allowed complete pharmacokinetic studies in the maternal-placental-
fetal unit in utero. Surgical procedures are used to implant chronic
indwelling catheters, enabling repeated sampling from various maternal
and fetal blood vessels, from maternal and fetal bladders, and from
amniotic and allantoic fluid cavities at predetermined time intervals after
drug administration. Chronic studies with multiple dosing of a drug to the
mother and kinetic studies with direct introduction of the drugs into the
fetal circulation can also be readily carried out. Additionally, the preg-
nant ewe preparation permits pharmacokinetic studies on the develop-
mental aspects of drug disposition in the maternal-placental-fetal unit.
Therefore, the following discussion of the experimental methods utilized
in prenatal pharmacokinetic studies will concentrate on the use of
pregnant sheep as the animal model. However, comparative studies using
different animal models are essential to gain a full understanding of the
overall scheme of drug disposition in the maternal-placental-fetal unit.
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Pharmacokinetic Models
Various compartmental models have been suggested for characterizing the
kinetics of drug disposition in the maternal-placental-fetal unit during
pregnancy (Levy and Hayton 1973; Krauer and Krauer 1977; Szeto 1982;
Szeto et al. 1982; Kajchgot and MacLeod 1983; Cabrielsson and Paalzow
1983). To obtain the pharmacokinetic parameters which best describe the
rate, extent, and duration of drug exposure to the fetus, all accountable
kinetic processes must be considered when constructing the pharmaco-
kinetic model. The compartmental model can be as complicated as that
shown in figure I in which all possible physiological conditions of the
system are considered. However, the practicality of a kinetic model is
usually limited by the availability of sampling sites, and, thus the
experimental data. Therefore, preliminary in vivo and in vitro exper-
iments should always be performed to provide the basis for a particular
model. Furthermore, model independent or noncompartmental methods
should be utilized to substantiate the validity of the derived compart-
mental parameters using the proposed model. If the experimental results
of both methods are not consistent, a model describing more complicated
processes should then be proposed and tested.
At present, it appears that the simplest kinetic model would be a two-
compartment (maternal and fetal) model with transplacental transfer and
nontransplacental elimination occurring in both compartments (Szeto
1982). As depicted in figure 1, complicated situations arise when the drug
is metabolized in the placenta, which constitutes a third compartment, or
when the drug is transferred via nonplacental routes between the fetus
and the mother. This is exemplified by the reversible diffusion of the
drug between the amniotic fluid and the mother across the chorioallantoic
membranes (Mellor 1980). the reversible diffusion of the drug between the
amniotic fluid and the fetus across the fetal skin, chorioamnion, or
respiratory epithelium (Seeds 1981; Carson et al. 1979; Dawes 1973). or the
oral-renal-amniotic fluid recycling (Amon and Amon 1976). The pharma-
cokinetic scheme is further complicated when metabotite kinetics is
considered. Overall, the significance of each process in a kinetic model
depends upon its contribution to the overall estimation of the
pharmacokinetic parameters which govern the rate, extent, and duration
of drug exposure to the fetus.
Experimental Methods
Once a compartmental model is proposed for the disposition of a drug in
the maternal-placental-fetal unit, the rate equations describing the
change of drug concentration in each compartment can be written. When
steady-state infusions of the drug into each compartment are carried out
on separate occasions, the rate of change of drug concentration at steady
state in each compartment is equal to zero for every infusion experi-
ment. The drug concentration in each compartment at steady state and
the infusion rate for each experiment allow one to determine the
clearance of the drug for each process describing the disposition of the
drug in the maternal-placental-fetal unit. A two-compartment open
model with elimination from both the maternal and fetal compartments
has been utilized by Szeto (1982) and Szeto et al. (1982) to determine the
transplacental clearances from both sides of the placental membranes and
the nontransplacental clearance from the mother and the fetus, as
expressed in the following equations:
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FIGURE 1. Schematic Representation of the Drug Transfer and
Elimination Processes in the Mother, Placenta, and Fetus.
Mc = maternal central compartment; Mp = maternal peripheral
compartment; D = drug; and M = metabolite.
Where CLMF and CLFM are the respective transplacental clearances of drug
from the mother to the fetus and from the fetus to the mother; CLMO and
CLFO are the respective nontransplacental elimination clearances of drug
from the mother and the fetus; J and J’ are the respective infusion rates of
the drug into the maternal and the fetal compartments; CM and CF are the
respective steady-state drug concentrations in the mother and the fetus after
maternal infusion; and CM and CF are the respective steady-state drug
concentrations in the mother and the fetus after the fetal infusion.
When experimental techniques permit, direct measurement of these clear-
ance terms should be undertaken independently in the mother, placenta, and
fetus to verify the credibility of the clearance terms obtained with the
compartmental model method. With catheterization of uterine and umbilical
veins in addition to the maternal and fetal femoral arteries, it is possible to
determine clearances across the placenta from either side using the extraction
ratio method by measuring the arterial and venous drug concentrations across
the placenta and the uterine and umbilical venous blood flow rates with
radiolabeled microspheres (Rudolph and Heymann 1980). The placental
clearance determined by the extraction ratio method consists of both the
transfer clearance across the placenta and the metabolic clearance, if any, in
the placenta; while the transplacental clearances (CLMF and CLFM) obtained
from the two-compartment model method solely represent the transfer
clearances. (For the two-compartment model method, placental metabolic
clearance would be included in the CLMO and CLFO terms.) If placental
metabolism does not exist, clearance values obtained from both methods
should be equal. In addition to the in vitro placental incubation experiments,
the extraction ratio method provides justification for incorporating placental
metabolism in the pharmacokinetic model.
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The validity of the nontransplacental clearances in the mother and the
fetus, calculated from the compartmental model method at steady state,
can be verified by determining the metabolic and renal clearances of the
drug in the mother and the fetus following single-dose administration of
drug or metabolite to both the mother and fetus. If the drug metab-
olite(s) is (are) not transferred across the placenta, metabolic clearance(s)
of the drug can be determined using the general methods described by
Benet (1984). Thus, the disposition of the drug metabolite(s) in the
maternal-placental-fetal unit should be characterized prior to the
assessment of metabolic clearances of the drug in the mother and the
fetus. A valid nontransplacental clearance obtained from the model
dependent method should be equal to the sum of the clearances of the
drug via all elimination routes (metabolism and excretion) other than
placental transfer.
Preliminary experiments to provide evidence of drug transfer through
nonplacental routes can be performed by administering single bolus doses
of the drug respectively into the mother, fetus, amniotic fluid cavity, and
allantoic fluid cavity on separate occasions. Samples are collected from
the amniotic fluid and allantoic fluid cavities, the maternal femoral
artery and uterine vein, and the fetal femoral artery and umbilical vein.
The rate and extent of drug appearance at each sampling site, e.g., the
lag time, the peak time, peak concentration, and total area under the
concentration-time curve, can then be compared between the sampling
sites and between the studies. These comparisons allow one to better
understand the mechanism of drug transfer via nonplacental routes, and
they serve as a basis for upgrading a kinetic model to incorporate all the
necessary transfer routes for describing drug disposition in the
maternal-placental-fetal unit.
Metabolite Kinetics in the Fetus
Drug metabolism in the fetus has been extensively studied using in vitro
enzyme preparations (Petkonen 1980; Dutton and Leakey 1982). Very
limited literature information is available regarding the in utero drug
metabolism in the fetus. Since an understanding of the metabolic
activation and deactivation pathways in the fetus is essential to deter-
mine drug effects and toxicity during the prenatal period (Lucier et al.
1979). studies of in utero drug metabolism in the fetus are indispensable in
prenatal pharmacology and toxicology. Pharmacokinetics along with
appropriate animal models provide us with a very useful tool to
investigate fetal drug metabolism in utero.
A drug metabolite detected in the fetal circulation after drug admin-
istration to the mother may not reflect the ability of the fetus to
metabolize the drug. Further investigation is required to determine
whether the metabolite found in the fetus originates from fetal metabolic
activity or results from transfer of the metabolite from the mother across
the placenta. In addition, if a metabolite is formed in the fetus, the
distribution and elimination processes of the metabolite in the fetus must
be examined in order to quantitate the fetal metabolic activity in utero.
To this end, a single dose of the metabolite can be administered to the
mother to determine whether placental transfer of the metabolite
occurs. The metabolite should then be given to the fetus to examine the
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fetal disposition of the metabolite. Upon the identification of all
elimination processes of the metabolite in the maternal-placental-fetal
unit, rate equations describing the change of the metabolite concentration
in the fetus can be written. As stated earlier, if the metabolite is not
transferable across the placenta, the formation clearance for the
metabolite (or metabolic clearance of the drug) can be determined using
general pharmacokinetic methods (Benet 1984). An example of these
methods will be demonstrated in the following section of this paper. If
the metabolite is formed in the fetus and is transferred across the
placenta from both sides, computer simulations and data fitting may be
helpful in obtaining the formation clearance for the metabolite in the
fetus. Studies of in utero metabolite kinetics in the fetus at different
gestational ages can then be carried out to investigate the prenatal
development of various metabolic pathways.
EXAMPLE OF PHARMACOKINETIC STUDIES DURING PREGNANCY
We have chosen acetaminophen as a model compound to carry out
pharmacokinetic studies of drug disposition in the sheep maternal-
placental-fetal unit. These studies are presented here to illustrate the
concepts and methods discussed above. The primary reasons for choosing
acetaminophen are: (1) acetaminophen is the most widely administered
nonprescription drug during pregnancy and clinicians frequently question
the safety of its use in pregnant women; (2) acetaminophen is mostly
glucuronidated and sulfated in various animal species and can thus serve
as a model substrate to study the prenatal development of the two
conjugation pathways; and (3) pure acetaminophen conjugates can be
chemically synthesized in sufficient quantities for metabolite kinetic
studies in the mother and the fetus.
Single bolus doses of acetaminophen were first administered intravenously
(i.v.) into the mother and the fetus on two separate occasions (Wang et al.
1983). Acetaminophen was found to be transferred across the placenta
from both sides of the membrane and its half-life was about 1 hour in
both the mother and fetus. Both acetaminophen glucuronide and sulfate
were measurable in the fetus and their concentrations gradually increased
until the end of study. Both conjugates stayed in the fetal circulation for
a much longer period than in the maternal circulation. Compared to
acetaminophen glucuronide, acetaminophen sulfate had a higher con-
centration in the fetus but a lower concentration in the mother. This
preliminary study revealed the bidirectional placental transfer of
acetaminophen and the presence of its two conjugates in the fetus.
Half-Lives of acetaminophen and its conjugates in both the mother and the
fetus were also determined. Acetaminophen glucuronide and sulfate were
then administered i.v. simultaneously in single bolus doses into the mother
and the fetus on separate occasions to examine the possibility of placental
transfer of the two conjugates and to study the disposition of the two
conjugates in the mother and the fetus (Wang et al. 1985a). Samples were
collected from the maternal femoral artery and the uterine vein and
bladder catheters; and from the fetal femoral artery and the umbilical
vein and bladder catheters. It was found that acetaminophen glucuronide
and sulfate were not transferred across the placenta from either side and
that renal excretion is the predominant route of elimination for both
conjugates in the mother and the fetus. Considering the glomerular
filtration rate and the extent of plasma protein binding, we concluded
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that renal elimination of both conjugates was primarily through
glomerular filtration in the fetus, but through renal tubular secretion in
the mother. The increasing glomerular filtration rate with gestational
age resulted in an increase of total (renal) clearances of both conjugates
with gestational age. Steady-state volumes of distribution were
determined for both conjugates in the fetus and were also found to be
linearly related to the age of the fetus. This study demonstrated that the
two conjugates detected in the fetal circulation following acetaminophen
dosing originated from metabolic conjugation activities in the fetus, but
not from placental transfer. Following the characterization of conjugates
disposition in the fetus, it was then possible to quantitate conjugation
activities in fetal lambs in utero using acetaminophen as the model
substrate.
Since preliminary in vitro and in vivo data suggested negligible placental
metabolism of acetaminophen, we proposed a two-compartment open
model (Szeto 1982). with elimination from both the mother and fetus, to
investigate the bidirectional placental transfer of acetaminophen and the
total nontransplacental elimination of acetaminophen in the ewe and the
fetal lamb (Wang et al. 1985b). Based on the data from steady-state i.v.
infusions of acetaminophen into the mother and the fetus on separate
occasions, the transplacental clearances from both sides of the membrane
and the total nontransplacental clearances in the mother and the fetus
were calculated using the equations stated above (1 to 4). The ratio of
steady-state acetaminophen concentration, fetus to mother, after
maternal infusion was found to be 0.77 and remained unchanged
throughout the gestational age of the fetus. Transplacental clearances
from mother to fetus and vice versa did not differ, indicating that
acetaminophen is transferred across the placenta exclusively through
passive diffusion since the plasma protein binding of acetaminophen is
insignificant and comparable in both the mother and the fetus. The
placental clearance was also determined using the extraction ratio
method and found to approximate the transplacent clearances obtained
from the compartmental model method, indicating that the model
dependent method yields credible results for transplacental clearances,
and that the placental metabolism is either nonexistent or negligible. The
model independent total nontransplacental clearance of acetaminophen in
the mother and the fetus were determined using the plasma and urine
data. Since acetaminophen conjugates are not transferred across the
placenta from either direction and renal excretion is the only elimination
route for both conjugates (Wang et al. 1985a), the metabolic clearance of
acetaminophen in the mother with respect to glucuronidation
or sulfation was determined at steady state as the amount of
the glucuronide or sulfate excreted in the urine divided by the area under
the plasma acetaminophen concentration-time curve at steady state. The
metabolic clearance in the fetus with regard to glucuronidation or
sulfation was estimated based on the following equation:
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Where is the metabolic clearance of acetaminophen to a
particular conjugate; VSSF, C is the steady-state volume of distribution of
the conjugate in the fetus and is obtained from the previous conjugate
dose experiments; CF,C and CF,A are the respective plasma conjugate
and acetaminophen concentration in the fetus; and UF,C is the cumulative
amount of the conjugate excreted in the fetal urine.
The sum of glucuronidation and sulfation clearances and the renal clear-
ance of acetaminophen in the mother accounted for 98% of the nontrans-
placental clearance in the mother obtained from the compartmental
model method. This provides further evidence of the validity of the two
compartment model used for describing acetaminophen disposition in the
sheep maternal-placental-fetal unit. Glucuronidation and sulfation
activities in the fetus in utero were found to be 15% and 50% of the
respective activities in the mother on a body weight basis. However, the
sum of glucuronidation and sulfation clearances and renal clearance of
acetaminophen cannot account for the overall nontransplacental
clearance in the fetus obtained from the model dependent method. We
speculate that diffusion of aretaminophen into the slow equilibrating
amniotic fluid or metabolism of acetaminophen across the amnion, fetal
intestine or lungs may partly explain this discrepancy. We now plan to
collect both amniotic and allantoic fluids in addition to blood samples and
to administer acetaminophen intra-amniotically and intra-allantoically to
study the kinetics of acetaminophen disposition in the two fetal fluids and
the possible drug transfer in relation to the maternal and fetal
circulations. By these means, we hope to be ahle to propose a more
sophisticated model to characterize the disposition of acetaminophen in
the sheep maternal-placental-fetal unit.
FACTORS AFFECTING FETAL DRUG EXPOSURE
The factors which may influence the rate, extent, and duration of drug
exposure to the fetus are essentially the factors that modify the
pharmacokinetic parameters characterizing the absorption, distribution,
metabolism, and elimination of the drug or/and its metabolites in the
pregnant mother, the placenta, and the developing fetus. The
determinants of fetal drug exposure during pregnancy are therefore
categorized as the maternal, placental, and fetal factors. Several review
articles on drug disposition in the maternal-placental-fetal unit have been
published (Mirkin and Singh 1976; Krauer et al. 1980); Juchau and
Faustman-Watts 1983; Bogaert and Thiery 1983), in which the maternal,
placental, and fetal factors affecting fetal drug exposure have been
discussed. Extensive and specific discussion of the maternal factors
which modify the absorption, distribution, and elimination of the drug
or/and its metaholites in pregnant women arc presented in the articles by
Krauer and Krauer (1977). Juchau and Faustman-Watts (1983), and Bogaert
and Thiery (1983). Articles by Mirkin and Singh (1976), Juchau (1976), Nau
and Liddiard (1978), and Goodman et al. (1982) specifically discuss
placental metabolism of drugs and factors affecting placental transfer of
drug or/and its metaholites. The distribution and elimination of drug
or/and its metabolites in the fetus are specifically discussed in the
articles by Mirkin and Singh (1976), Pelkonen (1980), Aranda and Stern
(1983). Juchau and Faustman-Watts (1983), and Rajchgot and MacLeod
(1983). Similar topics are addressed by Drs. Juchau and Miller in this
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volume. The following section summarizes the literature discussions and
presents a brief review of the maternal, placental, and fetal factors
affecting fetal drug exposure.
Maternal Factors
Absorption. The gastrointestinal absorption of drugs in pregnant women
will be influenced by pregnancy-related physiological changes, such as
decreased gastrointestinal motility, delayed gastric and intestinal
emptying, reduction of gastric acid secretion, and increased mucous
secretion. During late pregnancy, an increase in alveolar ventilation as
well as tidal volume is observed (Alaily and Caroll 1978), which may
enhance the pulmonary absorption of drugs given by inhalation. In
addition, the increase in venous pressure in the lower limbs could alter the
absorption rate of drugs administered intramuscularly.
Distribution. The physical changes related to pregnancy which may
modify the distribution of a drug and/or its metabolites include the
increase in total body water (both intra- and extra-vascular), large
accumulation of body fat, the decrease in drug binding to plasma proteins
(albumin), and profound hemodynamic changes.
Metabolism. Maternal drug biotransformation could be a major
determinant of the therapeutic and/or fetotoxic effect(s) of a drug.
Increased hepatic microsomal production of a diol (via epoxide)
metabolite has been found for phenytoin during early pregnancy (Blake et
al. 1978). Increased plasma free fraction due to decreased albumin binding
may increase the rate of metabolism. Pseudocholinesterase concen-
trations fall during pregnancy and may result in an impaired ability to
hydrolyze the muscle relaxant succinylcholine. However, the rates of
maternal drug biotransformation may vary as a function of gestational
age and may be affected differently in various organs of the same
animal. The relative rates of bioactivating versus inactivating reactions
for any given substrate may also be affected by pregnancy. Most studies
on the effects of pregnancy on rates of drug biotransformation have been
performed using in vitro enzyme preparations. Therefore, further studies
need to be carried out various species of whole animal to demonstrate
the pregnancy-dependent differences in drug biotransforming enzyme
systems.
Excretion. Pregnancy-dependent increases in renal plasma flow and
glomerular filtration rate would increase the kidney excretion rates of
drug and/or its metabolites. Decreases in plasma albumin binding may
also increase the rate of renal excretion of the unbound drug or/and its
metabolites. Biliary excretion of the injected dye sulfobromophthalein
was found to decrease during pregnancy (Tindall 1975). Whether the
biliary excretion of other foreign chemicals would be similarly affected is
unknown. Pulmonary excretion of gases and volatile substances would be
increased due to increased respiratory rate, tidal volume, and minute
volume.
Placental Factors
Placental Transfer. The placental transfer of a compound may be
influenced by the following factors: blood flow rates of the placental
circulation--uterine and umbilical; lipid solubility of the compound and
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its degree of ionization in the maternal and fetal circulations; molecular
weight of the compound; protein binding of the compound in the maternal
and fetal plasma and the stage of developement of the placenta. Mirkin
and Singh (1976) have provided a thorough review of this subject.
Placental Metabolism. Placental metabolism of drugs and foreign
chemicals has been thoroughly reviewed by Juchau (1976). The
therapeutic significance of drug biotransformation in in the placenta
remains to be defined under in vivo conditions. However, fetotoxic
effects of drugs or foreign chemicals may be induced by placental
metabolism and this area of research requires further investigation
(Goodman et al 1982). . .
Fetal Factors
Distribution. Nearly all drugs distribute to various tissues after entry into
the fetus. The distribution is influenced by the altered permeability of
specific membranes, or by the content of total body water and lipids in
the fetus, and the altered distribution of fetal circulation. A variable
proportion of umbilical venous hlood will bypass the liver and an
alteration in hepatic hlood flow would occur. Some drugs accumulate in
the amniotic fluid via urinary excretion or by exchange across the
nonkeratinized fetal skin or across the chorioamnion or respiratory
epithelium. Recycling of drugs between the fetus and amniotic fluid may
occur through fetal swallowing of amniotic fluid.
Metabolism. Fetal drug metabolism has been extensively investigated
using in vitro enzyme preperations. Experiments under in vivo conditions
are essential to determine the role of fetal metabolism in eliciting the
therapeutic and fetotoxic effects of drugs in the fetus. The
development aspects of drug metabolizing enzymes at different
gestational ages should also be investigated in utero.
Excretion. Renal function in the fetus is underdeveloped. Both
glomerular filtration rate and renal plasma flow rate are lower on a body
weight basis; tubular secretion of organic compounds is restricted. This
results in prolonged elimination half-life for polar, water soluble
compounds in the fetal circulation.
CONCLUSION
The therapeutic and toxicologic effects of drug exposure to the fetus are
governed by a combination of factors which modify the pharmacokinetics
of drugs and metabolites in the mother, placenta, and fetus. The role of
pharmacokinetic studies in prenatal pharmacology and toxicology is,
therefore, to characterize the essential pharmacokinetic parameters that
determine the therapeutic benefits or/and fetotoxic risks of drug use
during pregnancy. Well-designed and properly conducted pharmacokinetic
experiments will provide valuable information on drug disposition in the
maternal-plac,fetal-fetal unit.
A systematic pharmacokinetic study of drug and metaholite disposition in
the maternal-placental-fetal unit was described. The model drug,
acetaminophen, was found to be transferred across the placenta via
passive diffusion into the fetal circulation and metabolized in the fetus to
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the glucuronide and sulfate conjugates. Transplacental clearances of
acetaminophen from the maternal and fetal circulation were found to be
equivalent. No placental metabolism of acetaminophen was observed. No
transplacental transfer of acetaminophen conjugates was detected. Both
acetaminophen glucuronide and sulfate are predominantly eliminated from
the plasma through renal excretion via glomerular Filtration in the fetal
kidney and by renal tubular secretion and glomerular Filtration in the
maternal kidney. Knowing the disposition of the conjugates, we could
then determine the conjugation activities in the ewes and in the fetal
lambs in utero. Glucuronidation and sulfation activities are much lower in
the fetal lambs than those in the ewes. Therefore, both conjugation
pathways could possibly be saturated in the fetus should a large dose of
acetaminophen be taken by the mother. If a reactive metabolite of
acetaminophen could be formed in the fetus, saturation of the conjugation
pathways could lead to toxic effects in the Fetus. Further studies are
required to characterize the oxidative metabolism and glutathione
conjugation pathways in the fetus in utero before the potential toxicity of
acetaminophen to the fetus can be assessed.
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The Pharmacodynamics of Prenatal
Chemical Exposure
Richard K. Miller and Carol K. Kellogg
Pregnancy represents a unique time in the life cycle of a species. It is a
collage of interacting and interdependent variables in the mother, con-
ceptus, and placenta--modifying all three during the course of gestation in
mammals. If one superimposes the introduction of a chemical in this com-
plex milieu, the number of interactions relating to the distribution,
metabolism, and effects of such an agent in mother and conceptus can be
considerable.
Substantial interest has recently been focused in three major areas of
developmental investigations which relate to: (1) the ability of chemicals to
be metabolized to toxic products which may then produce their effects in
either mother and/or conceptus; (2) specific interactions with developing
processes, e.g., cell-cell interactions necessary for appropriate organ
development, or receptor-specific responses; and (3) organ-specific re-
sponses leading to lethality, or reduced functional or structural capacity,
e.g., the central nervous system (CNS), reproductive system, and placenta.
No single set of experimental tools can be applied to explore such ques-
tions. Most often a comprehensive evaluation of the distribution, metab-
olism, and interactions of a compound, whether drug or environmental
chemical, must be completed for both mother and conceptus before any
understanding of mechanistic actions can be established. These are
common recommendations for or from a pharmacologist or toxicologist;
however, these principles are often not considered critical or widely ap-
preciated by teratologists, obstetricians, or pediatricians. Other clini-
cians not devoted to studies in developmental pharmacology or toxicology
do not appreciate the fact that the conceptus can be a separately
functioning organism from a pharmacological point of view and, therefore,
these investigators are content with extrapolating observations of drug
distribution, metabolism, and interaction from the nonpregnant adult, and
applying them directly to the pregnant patient. This fallacy must be
eliminated forever and in its place must be imprinted the following:
1. There are dramatic and continuing changes in the physiology and
biochemistry of pregnancy, which include both mother and
conceptus and do persist throughout the entire course of gestation.
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2. There are two entirely separate and distinct genomes existing in
the same organism (mother).
3. There are two separate and distinct blood supplies with a unique
interface, the trophoblast.
4. There is rapid and selective growth of specific cell types in the
conceptus at particular stages of gestation.
5. There are direct and indirect interactions among mother,
embryo/fetus, and placenta.
With such sensitivity to basic principles of pharmacology and toxicology, it
is possible to begin to assess the reasons by which certain responses in the
pregnant female may differ from that of the nonpregnant female, and
equally important why the conceptus (whether embryo, fetus, or placenta)
may respond differently at one time from another time in its fife cycle
(figure 1). Yet, to evaluate the effects of chemical exposure during preg-
nancy, one must consider not only the immediate impact of such exposure
on those cells, organs, or systems, but rather the impact on the total
development and life of the mother and conceptus. How persistent or
transient are the effects? Are these effects due to the presence of the
chemical at the time of testing or are these effects the result of per-
manent alterations in system function without the persistence of the agent
at the time of testing? Does the conceptus have mechanisms to guard
itself against such chemical invasions or is it at the mercy and benevolence
of the mother to protect and sustain the growth and development of the
conceptus?
FIGURE 1. The continuum of perinatal pharmacology and toxicology
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These questions of pharmacodynamics will be addressed by evaluating two
classes of compounds and organ systems: (1) Heavy metal toxicity and
placental function; and (2) ataratics and CNS function. Through these
examples, specificity and selectivity of chemical distribution in mother and
conceptus as well as organs/cells will be explored with an emphasis on the
selectivity of chemical response in mother and conceptus either in utero or
as an adult.
Before investigating specific examples, please refer to figure 2 which
presents a general review of the principal variables for consideration
during pregnancy for the mother, placenta, and conceptus. These factors
will be discussed in the following pages only as they relate to the specific
examples presented. For a detailed discussion of these factors, the reader
is referred to Miller et al. (1976) and Miller (1983).
FIGURE 2. Biochemical and pysiological consideration in prenatal
exposure to chemicals (from Miller 1983, Cpoyright 1983, Alan R. Liss,
Inc.)
HEAVY METAL TOXICITY AND PLACENTAL FUNCTION
Heavy metals, in particular lead, mercury, and cadmium, are associated
with birth defects and alterations in growth (cf. Clarkson et al. 1983). The
usual exposure to such metals is considered to be occupational or envi-
ronmental (in air, water, or food); however, it is becoming apparent that
substance abuse in the form of cigarette smoking can result in the accu-
mulation of cadmium within the body. One organ which appears to
concentrate these metals is the placenta (cf. Miller and Shaikh 1983). The
concentration of these metals in the human placenta has been correlated
with such environmental and occupational exposures (Clark 1977;
Hubermont et al. 1978; Lauwerys et al. 1978; Khera et al. 1980).
Placentae from many regions of the world have been evaluated for the
concentration of cadmium (cf. Miller and Shaikh 1983). Unfortunately,
41
there is wide variation within any given locale for the actual levels of
cadmium when compared with lead or mercury. As noted above, the reason
for such variation is attributed to the personal habits of the individuals as
correlated with the amount of cigarette smoking. Studies in multiple
laboratories and geographical regions have confirmed this association
between cigarette smoking and placental concentration of cadmium (table
1). It has been proposed that the placenta be an exposure index for selected
environmental chemicals. Yet, such questions as level of risk, dose-
response relationships, and actual form of the metals have not been
investigated extensively.
Cadmium rapidly appears in the blood when a person inhales it via ciga-
rette smoke. In our laboratory, we have noted cadmium levels hetween 4
and 8 ng/ml in blood after smoking a single cigarette. Thus, besides the
carbon monoxide, nicotine, cyanide, polycyclic aromatic hydrocarbons, and
other metals, cadmium is present in cigarette smoke and found in higher
concentrations in the placenta, whereas other metals are not significantly
altered, e.g., copper and zinc (table 1).
Such interest in cadmium and the placenta was first reported by Parizek
(1964) when he noted that a single injection of cadmium into a near-term
rat resulted in the death of the fetus and the appearance of placental
necrosis. This fetal lethality is now known to result from direct placental
toxicity and reduced placental blood flow rather than a direct effect on the
fetus (Levin and Miller 1980; Levin et al. 1981).
The sequence of toxic response (figure 3) is apparently an initial rapid
uptake of cadmium by the placenta at levels greater than that noted by the
kidney, an index for adult toxicity. The maternal blood levels of cadmium
peak at 18 to 20 nmoles/ml within 5 minutes, while the placental concen-
trations of cadmium reach 60 to 90 nmoles/gm by 1 hour. Interestingly,
only small quantities of cadmium (<0.1 nmoles/gm) actually enter the fetus
(Ahokas and Dilts 1979; Sonawane et al. 1975; Levin and Miller 1980; Levin
et al., in press). By 4 to 6 hours, there is a rise in mitochondrial calcium,
an index of cellular toxicity and ultrastructural damage (Levin et al. 1981,
1983; di Sant’Agnese et al. 1983). By 10 to 12 hours, a 5 percent incidence
of fetal death, a low incidence of histologic placental necrosis, and a 25
percent reduction in utero placental blood flow were all observed (Levin
and Miller 1981). By 18 hours, all of these observations increased
substantially. Recently, cadmium administration during late gestation in
rodents reduced the placental transfer of cobalamin while not significantly
altering neutral amino acid transfer (Danielsson and Dencker 1984). Such
dramatic changes indicate the potential for a single dose of cadmium
administered near term in the rat to produce placental toxicity with
resultant fetal lethality.
Wolkowski (1974) hypothesized that it is not cadmium which produces the
placental toxicity, but rather metallothionein, a 10,000 dalton protein
which binds cadmium and other metals. Metallothionein is a known
nephrotoxin. However, metallothionein injected intravenously into the
mother did not produce fetal death, but did produce nephrotoxicity. While
blood levels of cadmium dropped from 18 nmoles/ml to 1 nmole/ml, the
content of cadmium in the placenta did not increase comparably (Plautz et
al. 1980; Levin et al. 1981).
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TABLE 1. Placental Levels of Cadmium, Copper, and Zinc in Women Who Do or Do Not Smoke
Location
Belgium
Nonsmoker
Smoker
Netherlands
Nonsmoker
Smoker
No-
333
109
31
30
Cadmium Copper Zinc
n g / g u g / g ug/g
12.5 ± 8.6
15.7 ± 9.2*
8.2 ± 3.2
10.6 ± 5.2*
Reference
Roels et al. 1978
Van Hattum et al. 1981
Rochester, NY
Nonsmoker 18
Smoker 24
4.3 ± 2.8 11.76 ± 0.65 1.24 ± 0.10 Miller and Gardner 1981
19.2 ± 4.6* 11.94 ± 0.64 1.36 ± 0.08
Cleveland, Ohio
Nonsmoker
Smoker
31
44
13.7 ± 6.4 Kuhnert et al. 1982
18.1 ± 7.3*
*Significantly different at least at (P < 0.05).
The placenta levels of cadmium in the human study were similar to levels
found in the rodent (Wier et al. 1983b), and the resultant functions of the
placenta during prolonged perfusion with complete transfusions every 4
hours were notably compromised. The fetal circuit began to lose volume
>5 ml/hr) between 8 to 10 hours of perfusion; the production, tissue
content, and perfusate levels of human chorionic gonadotropin were
depressed by 85 percent. Further, the stroma became edematous,
Hofbauer cells were vacuolated, and subsynctiotrophoblastic vacuolization
became widely apparent, as has also been noted for cycloheximide exposure
(Wier et al., in press).
Therefore, besides studying the distribution, metabolism, and transfer of
chemicals between the maternal and fetal circulations, the tissue content
and alterations in both structure and function over periods between 12 to
16 hours can be examined to answer the question: Does a compound appear
in the fetal circulation? In addition, the human question of how chemicals
interact with the placenta and its circulation and function now can be
studied without risk to mother or baby.
MATERNAL CIRCUIT FETAL CIRCUIT
FIGURE 4. Diagram of a dual perfused recirculating human placenta
lobule perfusion
The placenta, whether human or rodent, does result in chemical-induced
pathology (Panigel 1981; Miller and Thiede 1981, 1984). It is proposed that
prolonged perfusion of the human placenta under in vitro conditions may
offer an opportunity for assessing not only transfer and metabolism by
human fetal tissue-trophoblast but also the potential for determining the
toxicity of both drugs and environmental chemicals. The transfer and
metabolism of diazepam has been studied under short-term perfusion
conditions for the human placenta (Guerre-Milo et al. 1982). It was found
that the degree of plasma binding by diazepam and other benzodiazepines
did alter the placental transfer of these ataratics.
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It is apparent that this dose of cadmium, which results in placental toxicity
in the rat, is greater than the levels in placentae from cigarette smokers
(table 1). A dose-response relationship for different species, including
man, presents multiple difficulties in gathering these epidemiologic data
following acute exposure.
et al. (1983).
FIGURE 3. Sequence of observed responses in the near-term pregnant rat
following single subcutaneous administration of 40 umoles/kg of cadmium
chloride. The lines represent a relative change in structure, concentration
or function without direct comparison to absolute values among the
variables measured. This figure summarizes the observation reported by
Levin and Miller (1980, 1981) Levin et al. (1981, 1983, in press), and Miller
To compare the species similarities and differences, an in vitro human
placental system that allows for 12-hour perfusion was developed (Miller et
al. 1985) to explore the direct toxicity of cadmium on the human placenta
(figure 4). This perfusion system is based on the model developed by
Panigel (1962) and Schneider et al. (1972). In the rat, following a subcu-
taneous dose of cadmium chloride of 40 nmoles/kg, the plasma levels of
cadmium were 18 nmoles/ml at 5 minutes and 1 nmole/ml after 1 to 2
hours (Levin et al., in press). These kinetics for cadmium were reproduced
in the in vitro human placental perfusion where initial doses were either 10
or 100 nmoles/ml. In particular, little cadmium passed to the fetal
circulation in either the rat or human study, while the placenta
concentrated cadmium in excess of 100 nmoles/gm.
45
PRENATAL DIAZEPAM AND POSTNATAL FUNCTION
The developing brain can be permanently altered by drugs which have only
acute or transient effects on the adult nervous system. Such permanent
alterations in CNS function following exposure of chemicals to the
developing brain may be different from those effects noted following adult
therapy. The underlying mechanisms for such differences in responses
between the adult and developing brains are reflected in the sequence of
events, e.g., appearance of specific receptors, neurotransmitters, cell
types, and cell-cell interactions, which are spatially related to particular
stages of in utero and neonatal development (figure 5). In the adult, these
relationships are all established and, therefore, drugs affect a complete
system; however, depending upon the species and the growth stage, the
development of neurotransmitters, receptors, cell types, and cell-cell
interactions are different.
FIGURE 5. Prenatal exposure of diazepam to rats during the last week of
gestation and the persistnce of the drug in the brains of the progeny as
related to developmental events in the fetal and neonatal brains. Prenatal
and postnatal age are indicated on the horizontal line. Late gestation in
the rat is characterized by rapid neuronal proliferation and differentation
as well as by the begining of synaptic formation. Specific receptor for
drugs and transmitters begin appearing during this period. Abbreviations:
CS = catecholamine. BZ = benzodiazepine. ACH = acetylcholine. GABBA =
gomma aminobutyric acid.
Even though organogenesis (embryogenesis) in both man and rat can be
compared, the rapid development of the rat suggests that even single
exposure to a drug may be equivalent to multiple exposures in man.
4 6
Malformations of the CNS, such as spina bifida and anecephaly, are
developmental anomalies due to the effects of an agent directly on the
neural tube during embryogenesis. However, during this time of gestation,
the specific receptors and neurotransmitters apparently are not present or
functional. Therefore, the specificity of CNS drug action on the devel-
oping CNS would be predominant when the appearance of these specific
neurochemical processes are present. Such development is seen from
approximately the 10th week in the human and day 10 or 11 in the rat.
Therefore, for a number of functional defects the fetal period may be the
most susceptible time in the life cycle.
Is there though a comparison between the human and the rodent when one
is assessing behavior, function, and the effects of drugs? The answer must
be an emphatic yes with the caveat that one is examining mechanisms of
action and, therefore, the potential species differences are adequately
considered before conclusions are drawn. Such examinations rnust include
pharmacokinetics/dynamics, developmental sequences, intercurrent dis-
ease, and the exact timing of the drug exposures.
The question of whether drugs or environmental chemicals do alter post-
natal function has been reviewed extensively by other investigators (Rodier
1980; Vorhees and Butcher 1982; Hutchings, in press). Many psychoactive
agents act on specific mechanisms of neurotransmitter function, e.g.,
transmitter receptors, reuptake sites, synthesizing enzymes, or release
mechanisms. However, how specifically, selectively, and extensively can a
drug modify postnatal function following in utero drug exposure has not
been resolved.
Diazepam, a minor tranquilizer, has been investigated in animals to explore
these questions because of the variety of regulatory dysfunctions noted in
the human neonate whose mother had taken diazepam during pregnancy
(Scher et al. 1972; Cree et al. 1973; Safra and Oakley 1978; Rementeria
and Bhatt 1982). Even maternal stress itself induces functional impair-
ments in the progeny (Ward 1972). Such functional alterations due to
maternal stress have been prevented by concurrent diazepam therapy
during pregnancy (Barlow et al. 1979). However, does such therapy repre-
sent a specific and permanent interaction within the developing brain?
Diazepam, when administered between days 13 to 20 of gestation in the rat
(where gestation is 21 to 22 days), can modify a number of behavioral end-
points during postnatal development and in adult life, i.e., startle response,
auditory temporal resolution, and coping with stress, without significantly
altering more general behaviors (Kellogg et al. 1980, 1983b; Simmons et al.
1984b). These specific behavioral changes are related to maternal doses of
diazepam (1 to 10 mg/kg). Such selectivity in response indicates a specific
mechanistic interaction. Previous investigations have characterized a
benzodiazepine receptor in the adult which interacts with both the
GABAminergic and catecholaminergic neurons (cf. Gee et al. 1984).
These alterations in adult behavior following prenatal exposure to diaze-
pam are not related to the continued presence of diazepam into adult life
since the pups were fostered to control mothers at birth and diazepam was
undetectable in the neonatal brain or other tissues by day 20 (table 2).
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TABLE 2. The Distribution of Diazepam and its Metabolites in Selected Tissues of the Mother and Neonates
Following In Utero Administration of 2.5 mg/kg of 14C-Diazepam Between Days 13 to 20 of Gestation (Simmons
et al. 1983).
Total Diazepam/Metabolites Proportion of Diazepam and
in Selected Tissues
pmoles/1OOmg
Plasma Liver Heart
Maternal 3.7±0.5 55.8±7.7 2O.1±1.4
Neonatal 0 ND 7.8±0.9 6.3±0.5
Neonatal 10 N D ND ND
Neonatal 20 ND ND ND
Metabolites in Brain
Brain
3.4±0.3
3.2±0.3
3.4±0.3
ND
N-desmethyl-
Diazepam diazepam
24±5% 28±4%
24±9% 25±9%
19±8% 39±9%
ND ND
Oxazepam Glucuronide
0% 49±2%
0% 52±4%
12±6% 32±5%
ND ND
ND - not detectable
Thus, persistent functional alterations are present in the adult progeny
following only prenatal exposure to diazepam, even though the drug is no
longer present.
A mechanistic evaluation of these aberrant behaviors was initiated to
determine: (1) the relationship to stress, (2) the neurochemical impair-
ments (GABA, GAD, norepinephrine), (3) regional specificity of such
changes, and (4) receptor specificity. Since sensory perception was altered
by prenatal exposure to diazepam, does diazepam permanently alter the
ability of the offspring to respond to stress? Following restraint stress, the
adult control progeny demonstrated the typical response for plasma corti-
costerone changes to such stress (figure 6). However, prenatal exposure to
diazepam prevents the surges in this hormone following such stress. Thus,
the ability of these animals treated in utero with diazeparn to respond
normally to stress was impaired.
FIGURE 6. Plasma levels of corticosterone in 90-day-old rat progeny
under basal conditions and following 30 or 120 minutes of restraint stress.
The stressor was restraint stress, which was induced by placing the animal
in a small plastic restraint cage located in a bright lighted room for
specific time intervals. Asterish denotes a significant differnce (p < 0.05)
from conrols at each individual time period as determined by Student's -t-
test. Corticosterone was measured by a specific radioimmunoassay using
dog corticosterone binding globulin as the antibody (from Simmos et al.
1984b, Copyright 1984, Elsevier Science Publishers, B.V).
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Such hormonal regulation would implicate the hypothalamus in the control
of these processes. Regional neurochemical determinations of GABA
receptors, norepinephrine, and glutamic acid-decarboxylase demonstrated
that only norepinephrinre content and turnover were decreased in a dose-
related manner by diazepam in the hypothalamus of the adult progeny
(table 3). These alterations in norepinephrine neurons occured when no
significant changes in the number of binding sites, dissociation constant, or
maximal stimulation by GABA were noted for benzodiazepine binding in
newborns or adults prenatally exposed to 2.5 or 10 mg/kg/day of diazepam
(Kellogg et al. 1983b).
Such selectivity of neurochemical and functional responses would be
consistent with a specific activat ion mechanism. Fortunately, a benzo-
diazepine antagonist for the central binding sites (RO15-1788) is available.
KO15-1788 does not appear to have agonist activity but rat her blocks
diazepam at the receptor (Gee et al. 1984). To determine whether the
benzodiazepine recepot is involved in the product ion of these functional
impairments, RO15-1788 was coadministered to the pregnant dam with
diazepam. Prenatal RO15-1788 blocked the inhibitory effects of prenatal
diazepam on these stress-induced corticosterone surge (figure 6) and the
content and turnover of norcpinephrine in the hypothalamus of the adult
progeny (table 4).
Thus, it is becoming apparent that specific CNS functions may be perma-
nently altered by prenatal exposures to drugs which have selective inter-
actions with the CNS while many other functions may appear normal. Such
selectivity and specificity of interactions between drug and regions of the
brain demonstrate that what may be a transient yet spcific effect in the
adult brain may be just as selective and specific--receptor or mediated--in
the developing brain with a resultant permanent alteration.
CONCLUSION
Cigarette smoking has been associated with small for gestation age infants,
postnatal growth retardation, induction of mixed function oxidases, and
other delays in development. In particular, cadmium has been documented
to be at higher levels in placaentae of (cigarette smokers than in non-
smokers. In both animal studies and in vitro human placenta perfusion
studies, cadmium has been found to be placental toxic. Such specificity for
the placenta appears to be greater than for the organ commonly thought to
represent cadmium toxicity, the kidney. Yet, many other constituents of
cigarette smoke do modify the capacity of the conceptus, e.g., nicotine
affects uterine blood flow, placental transport of nutrients, and fetal
breathing; polycyclic aromatic hydrocarbons affect fetal and placental
metabolism of xenobiotics (cf. Sastry et al. 1983; Juchau 1980, 1982, this
volume; Pelkonen, 1980; Miller et al., 1983).
The metabolism of drugs and environmental chemicals has been implicated
in their developmental toxicity, e.g., benzo(a)pyrene (Nebert 1981),
phenytoin (Martz et al. 1977), cyclophosphamide (Manson and Smith 1977;
Kitchhin et al. 1981), diethylstilbestrol (cf. Metzler 1984), and thalidomide
(Gordon et al. 1981). Such formation of reactive intermediates may mean
that the parent compound has different therapeutic effects compared with
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TABLE 3. Kinetics of Norepinephrine Turnover in Adult Hypothalamus in Rats Exposed In Utero to Diazepam
Between Days 13 to 20 of Gestation (Simmons et al. 1984a).
Prenatal exposure No. NE levels Turnover rate Turnover rate Turnover Linear regression
days 13-20 (ng/g) (ng/g/h) constant(h
-1) time (h) coefficient
Uninjected 23 1895 ± 221 322 0.17 ± 0.01 5.9 0.89
Vehicle 21 1688 ± 108 388 0.23 ± 0.02* 4.4 0.88
Diazepam 1.0 mg/kg 20 1304 ± 130* 241 0.18 ± 0.02 5.6 0.81
Diazepam 2.5 mg/kg 21 1238 ± llO* 112 0.09 ± 0.02 11.1 0.92
Diazepam 10 mg/kg 17 657 ± 108* 46 0.07 v 0.02' 14.3 0.90
*Significantly different from control value, P < 0.05.
Mean + S.E.M.
No. = number of animals
TABLE 4. Kinetics of Norepinephrlne Turnover in the Adult Hypothalamus: Effect of Prenatal Exposure to a
Benzodiazepine Antagonist (Simmons et al. 1984a).
Prenatal exposure No. NE levels Turnover rate Turnover rate Turnover Linear regression
days 13-20 ( n g / g ) (ng/g/h) constant (h
-') time (h) coefficient
Uninjected 15 1719 ± 138 292 0.17 ± 0.01 5.9 0.88
RO-1788 10 mg/kg 15 1695 ± 152 278 0.16 ± 0.02 6.1 0.82
RO-1788 10 mg/kg & 15 1662 ± 133 288 0.17 ± 0.01 5.8 0.92
Diazepam 2.5 mg/kg
Diazepam 2.5 mg/kg 15 1298 ± 112* 117 0.09 ± 0.01* 11.1 0.90
*Significantly different from control value, P < 0.05.
No. = number of animals
Mean ± S.E.M.
the toxicity of their reactive metabolites (arene oxides, epoxides, phen-
oxyradicals). In fact, it may be the metabolic capability of the conceptus
which determines the developmental toxicity of a compound and not just
the maternal capabilities as demonstrated for benzo(a)pyrene metabolism
by embryos in the same litter (Shum et al. 1979). Thus, the pharmaco-
genetics of the conceptus may partially account for why only 1 out of 10
babies have the fetal phenytoin syndrome, especially since electrophilic
intermediates of phenytoin have been implicated in producing birth defects
in mice (Martz et al. 1977). Thus, for some drugs, it may not be the effect
of the parent compound but other effects of its metabolites.
Besides metabolism, protein binding of drugs in both mother and conceptus
may be critical to the expressed toxicity. In the rodent, synthetic es-
trogens such as diethylstilbestrol (DES) are both carcinogenic and terato-
genie at doses lower than those noted for natural estrogens, such as
estradiol. Such selectivity in response, especially in the rat, relates to: (1)
specific plasma binding protein for the natural estrogen, estradiol, which
circulates in the fetus; (2) the rapid metabolism of estradiol; and (3) the
responsiveness of the developing reproductive tract, which is substantially
different from that of the adult. In the fetus, one of the primary reasons
estradiol is less teratogenic than DES is that the affinity of alpha-feto-
protein for estradiol is much greater than for DES. Therefore, less
estradiol is available for entry into the tissue (cf. Miller et al. 1982, in
press).
Persistent and selective alterations in the CNS can be induced following
exposure to low doses of diazepam during the last week of gestation in the
rat. Aberrant responses to stress have been observed in the adult progeny
when no trace of the drug is detectable. Yet, of greater interest is the
selectivity of this prenatal diazepam exposure for reducing hypothalamic
norepinephrine levels and turnover in the adult progeny and the prevention
of these aberrant behavioral responses and neurochemical alterations in the
hypothalamus following coadministration of a diazepam antagonist with
diazepam during gestation. Thus, these examples of prenatal exposure to
cadmium, DES, and diazepam demonstrate the important differences in
their individual pharmacokinetics, which include distribution, metabolism,
protein binding, specific tissues, and even receptor interactions.
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Opioids and Development: New
Lessons From Old Problems
Ian S. Zagon
OLD PROBLEMS
Human consumption of opium for religious, medicinal, social, and/or
personal reasons probably dates back 6,000 years (Blum 1969; Terry and
Pellens 1970; Musto 1973). An important corollary to opioid’ utilization by
pregnant women relates to the passive dependence of the fetus. Exactly
how long ago this relationship was perceived is unclear. However,
Hippocrates (ate Martin 1893) mentions opium in connection with “uterine
suffocation”; this may be a reference to opium’s toxicity on the embryo
and/or fetus. Clearly, by the end of the 19th century, clinical reports
evidenced the unusual behavior of the fetus and the neonate passively
addicted to opium. Infants with “chronic opium intoxication” were
reported to exhibit excessive nervousness, rapid breathing, and convulsive
movements right after birth, with death occurring within the first week of
life (Terry and Pellens 1970). A review of the early literature reveals an
impressive amount of information and insight into the field of perinatal
opioid dependence. For example, in 1895, Bureau found that morphine
could pass through the human placenta. Other workers recognized the
possibilities that maternal drug addict ion might influence the fetus
(Sainsbury 1909), and that enough opium passed into breast milk to
alleviate withdrawal (Laase ISIS; Langstein 1930; Petty 1912) or to even
establish drug dependency in a normal infant breast-fed by a woman who
became dependent on opioids after parturition (Lichenstein 1915). The
importance of therapeutic intervention by administration of morphine,
heroin, or paregoric to prevent withdrawal was also well recognized
(Menninger-Lerchenthal 1934) by the beginning of the 20th century. Even
the long-term implications of perinatal opioid exposure were noted by
these early investigators. For example, in a discussion following the
presentation of a paper by Earle (1888) concerning the adverse effects of
fetal opioid exposure, a number of particpants reported the association of
neurobiological abnormalities in offspring (including individuals reacahing
adulthood) maternally exposed to opium. The incidence of perinatal
exposure to opioids is difficult to gauge. Perlstein (1947) and Petty (1913)
refer to the “rare” occurrence of such situations in earlier periods (up to
the 1940s). However, Graham-Mulhall (1926) recorded over 800 pregnant
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women consuming opioids in New York during a 1-year period in the early
1900s. The type of opioid abused has changed over the years. Until the
1950s. morphine appeared to be the drug of choice, with the 1956 report by
Goodfriend et al. signaling a change to heroin usage. Following Dole and
Nyswander’s (1965) advocation of the methadone maintenance treatment
program as an alternative to heroin dependency, numerous reports have
documented methadone-dependent offspring. Paralleling the change from
morphine to utilization of heroin and methadone in the 1950s, a marked
increase in the number of births to opioid-dependent women has been
recorded. In one municipal hospital in New York City, for example, only
42 infants were born to heroin-dependent mothers frorn 1955 to 1959, but
26 infants were delivered during 1960 (Zelson 1975). In this same hospital,
over a sixfold increase in drug-dependent babies was recorded between
1960 (1 in 164 births) and 1972 (1 in  27 births). Recent estirnates (Carr 1975)
place the birth rate of heroin and methadone-addicted mothers at
3,000/year in New York City alone; given that New York City has
one-third to one-half of the total number of chronic heroin and
methadone users in the United States (Carr 1975; Salerno 1977), one could
extrapolate 6,000 to 9,000 births/year to opioid-consuming women. Carr
also reports that, as of 1975, 115,000 children of mothers dependent on
illegal opiates and rnethadone maintenance were in the New York City
area. Assuming again that this number for New York City is
representative of one-third to one-half of the entire United States
population, one can estimate that at least 250,000 infants, children, and
young adults have already been born to females consuming opioids such as
methadone or heroin. Placed within the context of the average number of
births in the U.S. every year (roughly 3.3 million), one can calculate that
at least 1 in 1,000 births is by a mother using heroin or methadone. The
incidence for this “fetal opiate syndrome” or “fetal narcotic syndrome,” as
it may be termed, rivals estimates for many well-known and highly
publicized problems of early life, including the fetal alcohol syndrome,
Down’s syndrome, and neural tube defects, and it far exceeds the
incidence of cancer in children aged 1 to 15 years. Assuming the
population of the U.S. is 230 million, and given a population of 230,000
children already exposed perinatally to opioids, 1 in 1,000 people in the
U.S. have been subjected to opioids in early life. By thernselves, these
numbers are significant. However, unreported use of opioids by pregnant
women and the possible influence exerted by paternal opiate consumption
may indicate an error of underestimation.
Clinical Observation
Even before birth the offspring of opioid-dependent women are subjected
to a host of potential problems. During the course of pregnancy, the
mothers of these children often encounter medical complications,
including infectious diseases, nutritional deficits, and an abnormal
incidence of venereal disease. Obstetrical complications include toxernia
of pregnancy and intrauterine growth retardation. Additionally,
spontaneous miscarriage, abortion, and stillbirths have been suspected of
being higher than normal among opioid-dependent women (Salerno 1977).
Many of these coassociated medical and obstetrical complications appear
to be secondary to the lifestyle and habits of the pregnant addict
(Perlmutter 1974), with prenatal care often being neglected. The very
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fact that enrollment in the methadone program places women in touch
with health professionals who encourage prenatal care has been an
extremely positive feature of this program.
A decrease in birthweight of infants born to heroin-dependent mothers
has been recorded (Finnegan et al. 1972; Wilson et al. 1979), with low
birthweight infants often being small for gestational age. These growth
delays associated with prenatal heroin do not appear to be related to
inadequate maternal nutrition or prenatal care (e.g., Naeye et al. 1973).
In contrast to heroin-exposed offspring, methadone-dependent neonates
have higher birthweights and are of greater gestational ages, although
mean weight is often less than among nondrug dependent controls (Kandall
et al. 1974).
Conclusive evidence that maternal opioid dependency is related to
congenital malformations has not been presented, although some
incidences have been reported (e.g., Ostrea and Chavez 1979). Abrahms
(1975) recorded increased chromosomal aberrations in infants exposed to
heroin, but not necessarily methadone, while Chavez et al. (1979) noted an
increased incidence of sudden infant death syndrome (SlDS) in opioid-
exposed infants. A lower incidence and severity of neonatal jaundice is
known to occur for heroin-exposed infants (Zelson et al. 1973), and
premature infants of heroin-dependent mothers often demonstrate a
lower incidence of respiratory distress syndrome (Glass et al. 1971).
The proportion of stillbirths and mortality in the opioid-exposed
population generally appears to be increased in comparison to control data
(Ostrea and Chavez 1979; Perlmutter 1967), but the higher mortality rate
may not be necessarily related to the neonatal withdrawal syndrome
(Ostrea and Chavez 1979). Few studies have pursued details of post-
mortem examination of drug-dependent infants, although evidence from
neuropathological studies (e.g., Rorke et al. 1977) suggests that, in
addition to a host of nonspecific secondary gestational complications,
primary and specific effects of addictive drugs on the developing nervous
system occur.
Perhaps the most well-recognized sign of fetal exposure to opioids is the
neonatal withdrawal syndrome, with 60 to 90% of opioid-exposed infants
undergoing some degree of abstinence (Perlmutter 1974). Symptoms of
withdrawal include irritability, tremors, high-pitched cry, hyperactivity,
wakefulness, diarrhea, disorganized sucking reflex, respiratory alkalosis,
and lacrirnation, as well as hiccups, sneezing, twitching, myoclonic jerks,
or seizures. Opioids reported to cause these symptoms in the neonate are
heroin, methadone, meperidine, morphine, codeine, and pentazocine. The
onset of symptorns may be present at birth or may begin up to 14 to 28
days after birth. This depends upon the drug the infant was exposed to in
utero and the profile of pharmacokinetic excretion. Subacute syrnptoms
may last for 4 to 6 months after birth (Desmond and Wilson 1975).
Depending on the severity of the withdrawal syndrome, treatment with
such agents as paregoric, phenobarbital, diazepam, and chlorpromazine
may be required. The period of treatment may last frorn a few days to
several rnonths (Zelson et al. 1970). The question of advisability of breast
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feeding by women on opioids has been raised. Opioids are known to be
present in breast milk (Blinick et al. 1975) and numerous reports describe
“addictive” effects in infants consuming opioid-containing milk
(Menninger-Lerchenthal 1934). Given the permeability of the blood-brain
barrier during perinatal life, and the fact that only nanogram and
picogram quantities of drug are required to occupy opiate receptors, it
could easily be envisioned that opioids in milk could be capable of
influencing the infant.
The neurobehavioral sequelae associated with perinatal opioid exposure
have been extensively reviewed by Zagon and McLaughlin (1984a). In
summary, a number of highlights should be mentioned. “Classical”
neurological tests (Davis and Shanks 1975) have shown opioid-exposed
infants to exhibit central nervous system hyperactivity, irritability,
tremors and hypertonicity, impaired nutritive sucking, vomiting, severe
sleep deficit, autonomic dysfunction (vasomotor lability and diarrhea), and
a lability of “states” manifested by frequent shifts between sleep and
wakefulness. Hyperactivity was a persistent finding that endured through
the early school age (Davis and Shanks 1975). Utilizing the Brazelton
Neonatal Behavioral Assessment Scale (BNBAS), a number of investigators
have tried to quantitate infant response to external stimuli, motor
organization, and ability to regulate state of consciousness. These studies
show an impaired ability of opioid-dependent babies to adequately
organize their response to environment, with a lessened capacity to
attend and react to noxious stimuli and to habituate to disturbing events
(Davis and Shanks 1975). Opioid-exposed infants exhibited a depressed
response decrement to light, with problems in visual and auditory
orientation evident (Chasnoff et al. 1982). Using the BNBAS to decipher
the specific effects of methadone on the neonate, Marcus et al. (1982)
have suggested that behavioral problems in methadone infants may not be
due to generalized central system irritability, but actually to
neuromuscular dysfunction. Other investigators have suggested that the
orientation responsiveness and excitability recorded in the BNBAS have
substantial impact on caregivers’ perceptions of infants, which rnay lead
to long-term consequences for caregiver-infant interactions.
During the period of infancy, a significant decrease in quiet sleep
(Schulman 1969) along with an increase (Dinges et al. 1980) or decrease
(Sisson et al. 1974) in rapid eye movement has been noted. Kron and
colleagues (1976) have reported an uncoordinated and ineffective sucking
reflex as a manifestation of the opioid abstinence syndrome, whereas
Lodge and colleagues (1975) found that the withdrawal period was
characterized by heightened auditory responsiveness and orientation,
lowered overall alertness, and poor attentiveness to visual stimuli.
Differences in neurological status between opioid-dependent and control
groups have not been noted by some workers (Kaltenback et al. 1979).
However, Rosen and Johnson (1982a) reported tone discrepancies,
developmental delays, and eye problems in children up to 18 months of age
delivered by methadone-dependent mothers. Between 6 and 12 months, no
real language development was detected.
Beyond the withdrawal period, Wilson et al. (1973) have found adaptive
behavior, language performance, and personal-social developrnent of
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heroin-exposed children to be normal, but gross motor coordination was
more advanced than fine motor coordination. Disturbances of activity
levels and/or attention span, along with sleep disturbances, temper
tantrums, and low tolerance to frustration were recorded by Wilson at 1
year, while the onset of hyperactivity began at 12 to 18 months. Using the
Bayley Scale of Infant Behavior as a monitor for mental and motor
development, a number of investigators have found children that
subjected perinatally to opioids are within the normal range (Blatman and
Lipsitz 1972; Chasnoff et al. 1980). However, Wilson et al. (1981) have
noted the less attentive nature of both methadone- and heroin-exposed
infants, while Kaltenbach et al. (1979) recorded a higher failure rate on
three specific items: naming of two objects, pointing to five pictures, and
naming of three objects. Kaltenbach suggested that subtle differences in
cognitive behavior occur in opioid-exposed children that may be occluded
by summary scores. Rosen and Johnson (1982a) reported a lower than
normal score for methadone-exposed infants on both the mental and
motor development indices at 12 and 18 rnonths of age, and Strauss et al.
(1976) also noted delays in the physical development index.
Opioid-subjected infants tested on the Cesell scales (Finnegan et al. 1977;
Wilson et al. 1973), Merrill-Palmer test, and Peabody Picture Vocabulary
test (Blatman and Lipsitz 1972). as well as the Object Permanence Scales
(Rosen and Johnson 1982), appeared normal. A number of workers have
reported disorders in speech and/or language development (Blatman and
Lipsitz 1972) in children subjected to opioids, although Lodge et al. (1975)
reported strength in the realm of language for methadone-exposed
offspring.
Few studies that extend beyond the first few years of childhood have been
conducted on children maternally subjected to opioids. Nichtern (1973),
examining children up to 15 years of age born of heroin-dependent
mothers, recorded a number of problems related to their capacity for
human relationships, dernonstration of excessive adult-peer interactions,
poor socialization, and the use of withdrawal to deal with difficult
situations. Rosen and Johnson (1982a), in a study of children exposed in
utero to methadone, recorded signs of impaired development, including
smaller head circumferences, strabismus and/or nystagmus, and
abnormalities in muscle tone, coordination, and language. Strauss et al.
(1979) found a cluster of behavioral differences related to greater
task-irrelevant activity in methadone-exposed children during testing
situations. These authors suggest that in structured and demanding
situations, qualities of attentiveness and motor inhibition may be a
domain in which opioid-exposed children might reveal particular
vulnerabilities.
The neurobehavioral implications of exposure to heroin during early life
have been reported by Wilson and colleagues (1979). Wilson did not find
problems with speech and language function, hut on a battery of
perceptual measures, visual, tactile, and auditory perception were less
than normal. Moreover, the parents of these children noted difficulties
for their heroin-exposed children in the areas of self adjustment, social
adjustment, and physical adjustment. Items included were: uncontrolled
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temper, impulsiveness, poor self-confidence, aggressiveness, and dif-
ficulty in making and keeping friends. These children were very active,
although ratings of attention, cooperation, and alertness were not
abnormal. Wilson concludes that heroin-exposed children may have a
problem common to the general process of perception rather than a
specific sensory deficit, and feels that behavioral problems in these
children may be manifestations of “impaired attention and organizational
abilities.”
In addition to the neurobehavioral sequelae described for children born of
opioid-dependent women, a number of studies have rnonitored growth.
Some studies (Blatman and Lipsitz 1972) reveal no abnormalities, while
others (Strauss et al. 1976; Wilson et al. 1981; Finnegan 1981) have recorded
lower (but not significantly reliable) values for offspring exposed to
opioids. A substantial number of reports (Wilson et al. 1973; Wilson 1975;
Ting et al. 1974, 1978; Rosen and Johnson 1982a, 1982b; Chasnoff et al.
1982) document delayed growth properties associated with perinatal opioid
exposure. These delays may take the form of noticeably lower body
weights, shorter body lengths (height), and/or smaller head circum-
ferences.
As in most areas of human research, data collection and interpretation
are often fraught with difficulties. In the study of perinatal opioid
exposure and human development, the potential for problems is further
compounded. The licit and illicit use of opioids so alters psychological,
behavioral, and physiological processes that it elevates the drug to a
paramount position in the life of any user. These individuals consume
opioids during pregnancy despite the ramifications of such consumption on
the health of their children. Moreover, the study of opioid exposure in
developing humans really involves two individuals: mother and offspring;
in some cases, other individuals (e.g., caregivers) may also be involved.
Thus, the interaction of these forces only serves to potentially confuse.
essential issues further. Fortunately, in the case of clinical studies on
opioids and development, recognition of and discussion about problems in
experirnental design and interpretation have not been overlooked (e.g.,
Householder et al. 1982; Strauss et al. 1979; Wilson et al. 1981; Aylward
1982). Some of these confounding variables include: polydrug abuse, poor
prenatal and/or postnatal care, demographics, socioeconomic states,
length of hospitalization, neonatal withdrawal, breast feeding, mother-
infant/child interpretations, paternal influences, sample selection, type of
tests used for investigation, structuring of appropriate comparison groups,
“dropout” rate of patients in the study, and statistical analysis.
Rather than being overwhelmed by these confounding variables and simply
dismissing reports cited in this review, one needs to be aware that
although the goal of clinical research may be to determine a relationship
between cause and effects, this type of distinction may be unattainable.
Searching for the etiology of opioid-related problems (much less defining
all specific abnormalities) could be unrewarding. Given all of the possible
confounding variables enumerated above, it is therefore no wonder that
defining pathognomonic features of perinatal opioid exposure is a very
difficult task. A fine example of the problems in attempting to ascribe
specific characteristics to perinatal opioid exposure concerns the neonatal
abstinence syndrome. Neonatal withdrawal has been considered to be a
hallmark sign of maternal opioid consumption; yet, a variety of nonopioid
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drugs consumed by the mother can elicit somewhat similar effects. Some
of these agents include alcohol, barbiturates, chlordiazepoxide, clomip-
ramine, ethchlorvynol, glutethimide, hydroxyzine, and meprobamate
(Committee on Drugs 1983. Thus, at least in the clinical realm, we may
have to be satisfied with the knowledge that opioids are part of a
cumulative effect from an overall potentially dangerous milieu that
contributes to any damaging sequelae encountered.
Laboratory Observations
Laboratory studies offer another perspective as to the influences of
opioids on development. Through laboratory investigations, the goal of
achieving information in regard to opioids and biological development can
be realized. Laboratory models also allow us to address these questions in
a wide variety of methodologies that include, in addition to maternal
models of opioid consumption, studies in postnatally developing animals,
regenerating tissues, tissues and cells in culture, and in other in vitro
preparations. Thus, the laboratory has allowed workers to be unrestricted
in their designs, yet to be able to cast light on the essential biological
question being asked: Do opioids influence developrnent and, if so, how?
Just as in the earlier synopsis of the clinical literature, it simply is beyond
the scope of this paper to review all of the laboratory literature. Once
again, the reader should be aware of a series of bibliographies (Zagon et
al. 1982, 1984) that can serve as a guide to any laboratory (and clinical)
topic desired. Moreover, the reader can consult a recent review of the
neurobehavioral sequelae associated with perinatal opioid exposure by
Zagon and McLaughlin (1984a). In the following discussion, some of the
highlights of the laboratory literature will be mentioned.
In regard to studies that have attempted to create a “model” of maternal
opioid consumption to determine the effects on offspring, it should be
clearly recognized that a variety of routes of administration, drug
dosages, and schedules of treatment have been employed. Maternal
exposure to opioids does appear to have little effect on estrous cycle,
fertility, length of gestation, and parturition (e.g., Zagon and McLaughlin
1977a, 1977b, 1977c), although difficulties with conception and a
protraction of the gestational period (Buchenauer et al. 1974), as well as
positional malformations of the fetus (Chandler et al. 1975) have been
recorded. A distinct effect of maternal opioid consumption appears to be
a reduction in maternal body weight during pregnancy (McCinty and Ford
1976; White et al. 1978; Seidler et al. 1982; Zagon and McLaughlin 1977a),
but these weight deficits do not appear to be caused by insufficient
nutritional status (Ford and Rhines 1979; White et al. 1978). In general,
maternal exposure to morphine and methadone (Davis and Lin 1972; Zagon
and McLaughlin 1977b, 19778 does not have a detrimental influence on
titter size, although some decreases in litter size with higher doses of
methadone have been noted (Middaugh and Simpson 1980). Teratogenicity
appears to be associated with high drug dosages administered acutely or
over a short time period (Geber and Schramm 1975), but not with lower
dosages administered chronically. Some increase in stillborns has been
observed with high drug dosages (Freeman 1980; Sobrian 1977). while other
studies reveal little problem in this area (Davis and Lin 1972).
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The effect of transplacental exposure to opioids on infant viability is
determined by drug dosage and whether or not the neonates continue to
receive opioids postnatally (e.g., breast milk, direct injection). Neonates
that do not continue to receive opioids often may be hypersensitive to
stimuli and experience tremors at birth, with notable infant mortality
found in the first few days of life for those pups exposed to morphine,
heroin, methadone, and levo-alpha-acetylmethadol (LAAM) (e.g., Davis
and Lin 1972; Zagon and McLaughlin 1977d; Freeman 1980).
Since the timetable of behavioral maturation in rodents is so well known,
evaluation of the developmental pattern in opioid-exposed offspring can
be determined (Zagon and McLaughlin 1978b). Delays in physical charac-
teristics (e.g., eye opening), spontaneous motor physical characteristics
(e.g., walking), and reflexive tests (e.g., visual orientation) have ail been
noted. Interestingly, animals exposed only prenatally to opioids (i.e.,
allowed to go through withdrawal at birth and not receiving drug post-
natally) exhibit the greatest number of delays in attaining behavioral
capacities and physical characteristics. Those animals receiving drug
prenatally and postnatally (a situation somewhat comparable to that in
humans when therapeutic intervention prevents withdrawal) are often
closest to the normal timetable of maturation.
In the rat, behavior in the period shortly after weaning (postnatal days 21
to 44) has generally been characterized by a reduction in activity and a
decreased emotionality relative to control offspring (Freeman 1980; Grove
et al. 1979; Zagon et al. 1979a). Zagon and McLaughlin (1981b) have also
found an abnormally high incidence of wet-dog-shake and bead-shake
behaviors during this period that resembled drug withdrawal. In contrast
to the reduced activity levels in opioid-treated pups at weaning, young
adults (postnatal days 45 to 89) generally were hyperactive and more
emotional (Davis and Lin 1972; Grove et al. 1979; Zagon et al. 1979a).
Once again, methadone-exposed pups often exhibited head-shake and
wet-dog-shake behaviors, suggesting a protracted phase of withdrawal.
Peters (1978) has also accumulated preliminary evidence of learning
disabilities in methadone- and morphine-exposed rats at this age.
Adult rats that were perinatally exposed to opioids exhibit a lasting
impairment in the ability to acquire fear (Sonderegger and Zimmerman
1976), a reduction in social dominance (Thompson and Zagon 1982), prob-
lems in learning (Middaugh and Simpson 1980; Zagon et al. 1979b), and a
facilitation toward self-administrative behavior (Rech et al. 1980).
In regard to other anatomical, physiological, and biochemical correlates
to opioid exposure in early life, a number of important observations have
been made. Somatic growth retardation (e.g., McLaughlin and Zagon 1980;
McLaughlin et al. 1978; Slotkin et al. 1976, 1980), smaller brain dimensions
(Zagon and McLaughlin 1977b, 1978a), and deficits in organ weights
(McLaughlin and Zagon 1980; McLaughlin et al. 1978) have been reported.
Physiological dysfunction in regard to thermoregulation (Thompson and
Zagon 1981; Thompson et al. 1979), nociceptive thresholds (Zagon and
McLaughlin 1980, 1981a, 1982b), and aberrant response to opioids and
nonopioid drugs (Zagon and McLaughlin 1981a, 1984b) have also been
recorded. Opioid-exposed offspring, particularly those subjected to drugs
only prenatally, often exhibit deficits in brain cell number, as well
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as alterations in brain RNA and protein concentrations and content (Zagon
and McLaughlin 1978a). Changes in polyamine metabolism (Slotkin et al.
1976, 1979) and in the ontogeny of catecholaminergic systems, as well as a
retardation in the synaptic development of 5-hydroxytryptamine, dopa-
mine, and epinephrine neurons in the nervous system have been cited
(McGinty and Ford 1980; Rech et al. 1980; Slotkin et al. 1982). Morpho-
logical investigations have shown that the timetable of neurogenesis is
dependent on the schedule of drug exposure (Zagon and McLaughlin 1982b),
and that prenatal exposure to opioids is related to reductions in cortical
thickness and number of cells in the neocortex during the first 2 weeks of
rat development, in addition to neuronal density changes in the hippo-
campus up to postnatal day 28 (Ford and Rhines 1979). It does not appear
that either maternal undernutrition or inadequate nutrition of the off-
spring form the etiologic basis for opioid-related problems (e.g., Ford and
Rhines 1979; Zagon and McLaughlin 1982a; McLaughlin and Zagon 1980,
Seidler et al. 1982; White et al. 1978; Raye et al. 1977; Smith et al. 1977).
Moreover, hypoxia due to opioid consumption does not appear to be
responsible for the sequelae recorded White and Zagon 1979).
Comparisons of Clinical and Laboratory Findings
Information discussed in this review and others (Zagon and McLaughlin
1983a, 1983b, 1983c, 1983d, 1984a), as well as inspection of individual
papers on the subject (see Zagon et al. 1982, 1984). reveals a number of
striking parallels between clinical and laboratory findings. In summary
fashion, these include: passive dependence of the fetus on opioids,
occurrence of the neonatal abstinence syndrome, high rate of morbidity
and mortality of the neonate when not given supportive therapy for
withdrawal, sleep disturbances in the neonate, protracted/subacute
withdrawal, delays in sensorimotor development, retardation in somatic
growth, smaller head circumferences in humans/smaller brain sizes in
laboratory animals, delays in walking, problems in visual and/or auditory
systems, abnormalities in neuropathological studies indicating alterations
in neuro-ontogeny, diminished alertness, poor attention spans in early
phases of development, hyperactivity in later phases of development,
learning disabilities, and social maladjustments.
Etiological Considerations of the Perinatal Opioid Syndrome
Although many studies to date have dealt more with the phenomenological
aspects of opioids and development, they all have, to some degree or
another, helped formulate a picture contributing to the uncovering of the
etiology and pathogenesis associated with the perinatal opioid syndrome.
Information garnered from other biological studies on opioids and early
life also should be mentioned before attempting to place this syndrome in
perspective. First, opioids are known to selectively accumulate in the
brains and nervous tissues of fetal rats (Peters et al. 1972) and preweaning
rata (Shah and Donald 19791, presumably because developing organisms
have an increased permeability of the blood-brain barrier. Moreover,
opioids have been reported to exert a stereospecific effect on growth in
animals (Smith et al. 1977; Crofford and Smith 1973), indicating that opioid
action is quite specific. The effects of opioids also have been shown to be
blocked by concomitant administration of opioid antagonists such as
naloxone (Crofford and Smith), suggesting that opioid action resides at the
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level of the opiate receptor. In this regard, it should be noted that opiate
receptors have been found in body and brain tissues of developing
organisms (e.g., Gibson and Vernadakis 1982; Clendeninn et al. 1976).
Tissue culture studies in our laboratory (Zagon and McLaughlin 1984c;
McLaughlin and Zagon 1984) have verified stereospecific and naloxone-
reversible effects of opioid agonists on cell growth, and also reveal that
tolerance can develop to these influences. Additionally, cells that are
physically dependent on opioid agonists and withdrawn from drugs go
through a withdrawal. A principle manifestation of cellular withdrawal is
a diminution in mitotic activity.
Thus, it could be conjectured that opioid agonists serve to inhibit growth
at the locus of the opioid receptor. The relationship of the receptor to
growth remains an exciting new frontier for exploration. In the case of
maternal opioid agonist consumption, it can be envisioned that these
agonists depress developmental events until the cells are able to become
tolerant to drug exposure. The magnitude of prenatal effects on growth
depends on the drug dosage and the length of time needed to establish
tolerance in the developing organism. Withdrawal from opioid agonist
exposure at birth (or even during fetal life) would force developing cells
to readjust to an absence of drug, which would result in a delayed growth
profile; the extent of these delays would correlate with the magnitude of
withdrawal. Amelioration of withdrawal at birth by administration
(breast feeding or direct administration) of opioid agonistlike agents
would circumvent the need for readjustment and allow the cells and tissue
to continue developing in an established (albeit, containing opioid agonist)
milieu. This hypothesis fits very nicely with laboratory findings that
prenatal exposure followed by postnatal withdrawal is most detrimental to
development, whereas prenatal exposure along with administration of
opioids in the postnatal life usually exerts the Least short- and long-term
damage. In the clinical setting, elimination or at least minimization of
the withdrawal syndrome probably attenuates many detrimental
influences. Therefore, it is hardly any wonder that difficulties might
exist in establishing firm evidence separating the effects of perinatal
opioid exposure from other potentially damaging influences.
NEW LESSONS
If indeed exogenous opioids such as methadone, heroin, and morphine can
inhibit growth by acting stereospecifically and in a naloxone-reversible
fashion at the level of the opiate receptor, then the question arises as to
whether the body’s own morphine--the endorphins--could also regulate
growth by interaction with opiate receptors known to be present on
developing cells. To investigate this possibility further, we administered
naltrexone--a potent opioid antagonist--to preweaning rats. Preweaning
development in the rat (birth to day 21) is characterized by explosive body
and brain growth, and serves as a good model to examine the influences of
various agents on developmental events. Daily injections of a relatively
high dosage of naltrexone (50 mg/kg) stimulated development in pre-
weaning rats, while daily injections of a low dosage (1 mg/kg) inhibited
growth (Zagon and McLaughlin 1983a, 1983b, 1984d, 1984e). For example,
the body weight of 21-day-old 50 mg/kg naltrexone-treated rats was 18%
more than controls and the body weights of 1 mg/kg naltrexone-treated
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rats was 11% less than controls. Not only were body weights affected,
but examination of the wet weights of brain, heart, kidneys, liver, and
skeletal muscle were 11 to 32% more than controls for rats in the 50
mg/kg group, and 5 to 24% below normal for animals given 1 mg/kg
naltrexone (Zagon and McLaughlin 1983b).
The timing of the appearance of certain physical characteristics that
were examined (hair covering, incisor eruption, ear opening, and eye
opening) often revealed that many of these traits occurred significantly
earlier in the 50 mg/kg naltrexone group, and markedly later in rats
receiving 1 mg/kg naltrexone (Zagon and McLaughlin 1983b, 1985). The
appearance of spontaneous motor and sensorimotor behaviors was also
altered in a similar manner. For example, the initial appearance of
walking, a milestone in behavioral ontogeny, appeared 2 days earlier in
the 50 mg/kg naltrexone group relative to controls. Furthermore, at the
age when only SO% of the controls were able to walk, no rat in the 1
mg/kg naltrexone group could walk, and all (100%) of the animals in the 30
mg/kg naltrexone group could walk (Zagon and McLaughlin 1983b, 1985).
Macroscopic dimensions of the brains and the cerebellum at 21 days of age
showed marked increases for the 50 mg/kg naltrexone group and
decreases for the 1 mg/kg naltrexone group (Zagon and McLaughlin 1983a,
1984e). Morphornetric analysis of the cerebrum revealed a somatosensory
cortex in the 50 mg/kg naltrexone group that was 12% thicker than in
controls, but 9% thinner in rats of the 1 mg/kg group. In regard to the
cerebellum of 21-day-old rats, the 50 mg/kg group had areal
measurements of total, molecular layer, internal granule layer, and
medullary layer that were 27%, 24%. 28%, and 41%, respectively, greater
than controls; animals in the 1 mg/kg group had measurements that were
27%, 30%, 24%, and 27%, respectively, less than those of the control
group. The number of neural cells in the molecular layer of rats in the 50
mg/kg group was 76% greater than control levels, and the number of glial
cells in the medullary layer was 62% greater in these animals than in
control rat cerebella.
Dose-response experiments (Zagon and McLaughlin 1984d) have shown that
dosages from 0.1 to 10 mg/kg naltrexone inhibit body and brain growth,
whereas dosages of 20 to 100 mg/kg stimulate development. Utilizing
opiate challenge experiments (nociceptive response is recorded 30 minutes
following an injection of 0.2 mg/kg morphine) to examine the
pharmacological efficacy of various daily dosages of naltrexone, dosages
of 20 mg/kg or greater were found to block the opioid receptor from
interaction with a dose of morphine for 24 hr/day, and dosages of 10
mg/kg naltrexone and less blocked the opioid receptor for only 12 hr/day
or less. To further investigate whether the relationship between growth
processes, drug dosage, and the pharmacological properties of naltrexone
were more than coincidental, some preweaning pups received low dosages
(3 mg/kg) of naltroxone given three times daily, which in effect blocked
the opiate receptor for 24 hr/day. These rats demonstrated notable
increases in body and brain development. A cumulative dosage of 9 mg/kg
naltrexone once daily, which blocked the opioid receptor for less than 12
hr/day, retarded growth. Thus, developmental events appear to be
governed by the duration of opioid receptor blockade.
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These findings, taken together with evidence that endorphins are present
in the plasma and brain of developing organisms (Kramer and
Teschemacher 1978; Bayon et al. 1979), that irnmunoreactive analogs of
endorphins have been detected in fetal and neonatal cells (Knodel and
Richelson 1980; Neale et al. 1978), and that opioid receptors have been
identified in brain and body tissues during ontogeny (Coyle and Pert 1976;
(Gibson and Vernadakis 1982, led us to the exciting and novel proposition
that endogenous opioids and their opioid receptors regulate developmental
events. These effects on growth do not appear to be due to nutritional or
hormonal events (Zagon and McLaughlin 1984d). In fact, we are not aware
of any agent (e.g., drug or hormone) or condition that makes a postnatally
developing animal larger than “normal” and increases brain development
such as we have demonstrated.
The specific mechanisms as to how endogenous opioid systems control
growth are unclear. Our studies do show that complete prevention of the
interaction between endorphins and opioid receptors by administration of
relatively high dosages of naltrexone once daily, or low dosages of
naltrexone given repeatedly each day, allows growth to proceed in an
“unrestricted fashion” that results in the larger animals. Thus, just as
with exogenous opioids such as heroin and methadone, endogenous opioids
serve to inhibit growth. Enhancement of this interaction, such as that
recorded with ternporary opioid receptor blockade by naltrexone
administration, results in smaller animals. Although the precise pathways
for this diminution in growth are unknown, naltrexone administration has
been reported to elevate plasma beta-endorphin levels (Recant et al. 1980)
and to increase opioid receptor number and supersensitivity to opioids
(Lahti and Collins 1978.; Schulz et al. 1979; Tang and Collins 1978; Zukin et
al. 1982). In distinction to a total blockade of this interaction, a
temporary blockade provides an interval each day when the inhibitory
action of basal or elevated levels of cndorphins can act on cells possessing
a greater complement of opioid receptors. Fascinatingly, naltrexone’s
effects on infant rat development and the establishment of endogenous
opioid control of growth is consistent with other studies in which
endogenous opioid systems have been demonstrated to control
tumorigenesis (Zagon and McLaughlin 1981c, 1981d, 1983c, 1983d, 1984f).
FOOTNOTE
‘The term opioid is used in the generic sense and refers to exogenous and
endogenous substrates, natural or synthetic in origin, that possess opium-
or morphine-like properties.
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Pharmacodynamics of Fetal
Exposure to Narcotics
Hazel H. Szeto and Jason G. Umans
INTRODUCTION
Infants born to narcotic addicts are known to be at risk of undergoing an
opiate-abstinence syndrome in the neonatal period. The most common
manifestations of this syndrome include irritability, hyperactivity, in-
creased eye movements, diarrhea, tachypnea, tremors, exaggerated re-
flexes, and occasionally generalized seizures. in addition, these infants
exhibit abnormal sleep patterns, with an increase in wakefulness and
rapid-eye-movement sleep, at the expense of quiet sleep (Glass et al.
1972; Schulman 1969; Dinges et al. 1980).
Although most of the clinical signs of withdrawal subside in a matter of
days, some behavioral and neurological disturbances appear to persist into
early childhood. Many children have been found to be hyperactive, with
shorter attention spans and decreased fine motor coordination (Wilson et
al. 1981). These persistent neurological and behavioral effects are often
considered consequences of the withdrawal insult. However, it is also
possible that prolonged intrauterine exposure to methadone may have
direct effects on the development of the nervous system. In both clinical
and animal studies, it has been rather difficult to differentiate between
direct narcotic effects on fetal development and the consequences of the
unavoidable withdrawal syndrome at birth.
Furthermore, it has recently been suggested that the fetus may undergo
intermittent intrauterine withdrawal throughout gestation (Lichtblau and
Sparber 1981). and this may result in long-term behavioral and neurological
disturbances. It is known that detoxification of narcotic addicts during
pregnancy results in fetal distress, as evidenced by meconium staining
(Hill and Desmond 1963; Harper et al. 1974), increased amniotic fluid
catecholamines, and occasional fetal demise (Zuspan et al. 1975). Changes
in fetal hemodynamics and meconium staining have also been reported
following precipitated morphine withdrawal in pregnant ewes (Cohen et
al. 1980). These studies, however, did not examine the behavioral
responses which might allow comparison with the abstinence syndrome
described in the human neonate. Therefore, although intrauterine opiate
withdrawal presents a severe physiologic stress to the fetus, it remains to
be determined whether behavioral disturbances are a significant
component of the syndrome.
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Our objectives were, therefore, to develop an animal model that would
permit us to examine the direct effects of morphine exposure in the fetus
and to fully characterize the fetal opiate-abstinence syndrome. An
understanding of these fundamental pharmacodynamic properties of a
narcotic drug in the fetus may provide a better understanding of the
long-term effects of narcotics exposure on the developing fetus and
neonate.
EXPERIMENTAL METHODS--GENERAL CONSIDERATIONS
The Animal Model
When considering the effects of acute morphine exposure, we are most
concerned about its effects on behavioral, respiratory, and cardiovascular
functions. This type of information obviously cannot be obtained from the
human fetus or the fetus of small laboratory animals. The pregnant
sheep, on the other hand, offers a unique opportunity for examining these
functional parameters in the fetus under physiologic conditions. The
relatively large size of the fetus allows chronic implantation of catheters
and electrodes necessary for intrauterine monitoring of behavioral,
respiratory, and cardiovascular functions.
The effects of morphine exposure on fetal cardiovascular function can be
easily determined with an indwelling catheter in the fetal aorta for
continuous monitoring of blood pressure and heart rate.
Respiratory function can be monitored with a pair of electrodes implanted
in the diaphragm and a catheter implanted in the trachea. Breathing
movements are indicated by a burst of activity in the diaphragmatic
electromyogram and a decrease in tracheal pressure.
Effects of drugs on fetal behavioral activity are much more difficult to
ascertain since it is not possible to directly observe the fetus. We have
recently developed techniques for intrauterine recording of electrocor-
tical activity (ECoG), electromyographic activity (EMG), and eye
movements (EOG) in the fetal lamb, making it possible to interpret
indirectly from these electrophysiologic measurements the behavioral
activity of the fetus (Szeto 1983; Umans and Szeto 1983). Employing the
classical criteria for sleep-wake scoring (table 1), we are able to
differentiate three distinct states of behavior in the fetal lamb in the
third trimester.
TABLE 1
Behavioral State ECoG
Arousal desynchronized
Quiet Sleep synchronized
Active Sleep desynchronized
Nuchal EMG EOG
tone, bursts random, slow
tone, bursts random, slow
atonia REMs
Thus, with the development of sophisticated techniques for intrauterine
recording of physiologic functions in the fetal lamb, the pregnant sheep
has become an ideal animal model for studying both pharmacokinetics and
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pharmacodynamics of drugs in the maternal-fetal unit. We have previ-
ously demonstrated that this model can be used for comparing the extent
of fetal exposure to different narcotic drugs (Szeto 1982; Szeto et al. 1978,
1981, 1982).
Experimental Design
In designing any pharmacodynamic study in the fetus, we should ideally
have some information regarding the pharmacokinetics of the drug in the
maternal-fetal unit. In addition, there are a few points that should be
considered in the design of the route and dose of drug administration.
Firstly, since the extent of fetal exposure following maternal drug
administration may vary considerably from animal to animal, it is
preferable to administer the drug directly to the fetus rather than to the
mother. This can be easily accomplished with an indwelling catheter in
the fetal vena cava (Szeto et al. 1978). Secondly, if we wish to correlate
pharmacodynamic effects with the dose of drug administered, the drug
should be administered by constant rate infusion to steady state. This is
particularly important when studying periodic events such as sleep-wake
behavior (Szeto 1983, Umans and Szeto 1983). Thirdly, a full range of
doses should be examined to document dose-related effects and biphasic
effects relationships. Single-dose studies may be very misleading,
especially if the dose is not within the linear dose range. Finally, for the
opiate withdrawal studies, naloxone will be used to precipitate withdrawal
in morphine-exposed animals. Naloxone should also be administered
directly to the fetus at doses that do not alter any of the measured
parameters, and the study should be carried out following different doses
of agonist exposure.
EXPERIMENTAL PROCEDURES
Animal Preparation
Thirteen pregnant ewes and their fetuses (gestational ages ranging from
121 to 138 days at the time of study, term being approximately 145 days)
were surgically instrumented for monitoring of fetal hemodynamics and
behavioral activity at least 5 days prior to study. Details of the surgical
procedure have been described previously (Szeto 1983; Umans and Szeto
1983, 1985). Briefly, chronic indwelling catheters were placed in the fetal
inferior vena cava for drug infusion and in the distal aorta for continuous
monitoring of blood pressure and heart rate. For continuous monitoring of
fetal behavioral activity, a pair of stainless steel screws were implanted
extradurally over the parietal cortex to record electrocortical activity, a
pair of stainless steel screws was implanted over the superior orbital ridge
to record eye movements, and stainless steel electrodes were implanted in
the dorsal neck muscles and quadriceps femoris muscle to assess nuchal
tone and body movements. In addition, fetal breathing movements were
monitored via a pair of stainless steel electrodes implanted in the
diaphragm and a catheter in the trachea.
Recording Procedures
All recordings of fetal blood pressure (FBP), heart rate (FHR), tracheal
pressure (TP), electrocorticogram (ECoC), electromyogram (EMG), and
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electrooculogram (EOC) were carried out with the ewe standing or lying
quietly in an experimental cart with free access to food and water. A
companion sheep was kept in the same room to minimize restlessness.
All recordings were obtained with a Gould model 2800 analog recorder and
appropriate amplifiers. The ECoG, EMG, and EOG were recorded via
Universal amplifiers set at the following filter band widths: ECoC, 0.3 to
30 Hz; EMG, 30 to 300 Hz; and EOC, 1 to 10 Hz.
Drug Protocols
Control recordings of FBP, FHR, and all neurobehavioral parameters were
obtained for at least 2 hours prior to drug administration.
In a preliminary study, naloxone was administered intravenously at doses
of 0.75, 1.5, 3.0, 6.0, and 12.0 mg to opiate-naive fetuses, without any
significant effect on the monitored physiologic variables. We chose a
naloxone dose of 6.0 mg for use in all subsequent studies. In previous
studies of specific opiate effects, compararable doses precipitated opiate
abstinence in rodents (Wei et al. 1973; Umans and Inturrisi 1982).
Morphine was infused to the fetus at a constant rate, ranging from 0.075
to 80.0 mg/hr for 2 to 6 hours. Naloxone was then administered to the
fetus at the end of the morphine infusion. All hemodynamic and activity
parameters were monitored continuously throughout the control period,
during the morphine infusion, and for 2 hours following naloxone admin-
istration.
RESULTS
All predrug control recordings showed cyclic variation in electrocortical
activity, eye movements, total body movements, and breathing move-
ments (figure I). Three behavioral states could be clearly distinguished in
all recordings according to classic sleep-wake scoring (table 1). During
the control period, the fetus spent 85% to 95% of its time alternating
between quiet sleep and active sleep. Very short episodes of arousal
would sometimes occur during the quiet sleep-active sleep transition or
during prolonged periods of quiet sleep.
The administration of morphine to the fetus resulted in two distinct
response clusters as a function of dose. At doses lower than 0.30 mg/hr,
morphine did not significantly alter any of the measured physiologic
parameters. Doses up to 2.5 mg/hr resulted in desynchronization of the
ECoG; increased nuchal tone and body and eye movements; continuous
fetal breathing movements; and increased heart rate and heart rate
variability (figure 2). Higher doses (through 80.0 mg/hr resulted in a
return of synchronized ECoC, accompanied by decreases in body, eye, and
breathing movements and heart rate variability (figure 3). These signs of
central nervous system depression were evident towards the end of the 2.5
mg/hr infusion in 30% of the animals. Fetal breathing movements were
completely suppressed at doses greater than 10 mg/hr. Upon termination
of the high-dose infusion, a prolonged period of arousal and enhanced
breathing activity was observed before return to control values.
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FIGURE 1. Control recording demonstrating cyclic activity in ECoG.
Nuchal EMG (EMGN), EOG, diaphragmatic, EMG (EMGD), and tracheal
pressure (TP) prior to morphine exposure.
FIGURE 2. Effects of low-dose morphine infusion (2.5 mg/hr) on fetal
hemodynamic, behavioral and respiratory activity. Note continous fetal
arousal and breathing movements.
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FIGURE 3. Effects of high-dose morphine infusion (25.0 mg/hr) on fetal
hemodynamic, behavioral, and respirtatory activity. Note prolonged quiet
sleep and apnea
The administration of 6 mg naloxone to opiate-naive fetuses did not result
in any alteration in the physiologic parameters which were monitored, or
in their pattern of cyclic variation (figure 4).
Following low-dose morphine infusion, naloxone resulted in further
desynchronization of the ECoG an immediate bradycardia, an increase in
both the rate and depth of breathing movements, and an increase in total
body movements (figure 5). Following high-dose morphine infusion,
naloxone provoked a qualitatively similar, but more intense, abstinence
syndrome (figure 6).
In fetuses which were subjected to an episode of precipitated abstinence
following morphine infusion of 25.0 mg/hr or greater, a second abstinence
could be precipitated by naloxone administration 24 hours following the
initial withdrawal. lmmediately prior to the second dose of naloxone, all
fetuses exhibited normal control traces, without evidence of acute opiate
effect. The second episode of abstinence was, in each case, similar to,
but less intense than, the first.
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FIGURE 4. The effects of nalorone opiate-naive fetus.
FIGURE 5. The effects of nalorone on fetal hemodynamics and behavioral
activity parameters when administered subsequent to a 6-hour infusion of
morphine at 2.5 mg/hr.
8 4
FIGURE 6. The effects of nalorone on fetal hemodynamics and behavioral
activity parameters when administered subsequent to a 6-hour infusion of
morphine at 25.0 mg/hr.
DISCUSSION
It is generally assumed that neonatal morbidity and developmental abnor-
malities following intrauterine narcotic exposure result from repeated
episodes of fetal withdrawal (Lichtblau and Sparber 1981). Data which
suggest that both direct opiate pharmacodynamic effects and fetal with-
drawal may contribute significantly to neonatal outcome following intra-
uterine narcotic exposure is presented below.
Using the chronically instrumented fetal lamb preparation, we have
defined the full dose-response relationship of morphine on fetal behav-
ioral, respiratory, and cardiovascular functions. We have previously
shown that doses in the range of 2 mg/hr caused complete suppression of
quiet sleep in the fetus and induced prolonged episodes of arousal (Umans
and Szeto 1983). These arousal periods were associated with continuous
breathing movements and increased heart rate and heart rate variability.
We have now demonstrated that the morphine dose-response curve is
biphasic, with higher doses resulting in quiet sleep and apnea. The
biphasic nature of morphine’s dose-response curve in the fetus may
account for some of the confusion in the current literature, with some
investigators reporting a suppression of fetal breathing movements
(Rigatto et al. 1984), and others reporting both suppression and stimulation
of breathing movements in the fetal lamb (Olsen and Dawes 1984).
We have recently demonstrated a similar biphasic response to a stable
enkephalin analog, D-Ala2-MePhe4-Met(0)5-enkephalinol (FK 33-824), in
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the fetal lamb (Umans et al., in press). At high plasma concentrations,
FK 33-824 resulted in apnea and quiet sleep. As plasma concentrations
declined, there was prolonged period of arousal and enhanced respiratory
activity. These studies suggest that the pharmacodynamic effects of
morphine in the developing fetus are similar to that of the opioid
peptides, and that these peptides may play a role in the physiologic
regulation of sleep, breathing, and cardiovascular function in the
developing fetus. In addition, these studies demonstrate that direct
effects of opiates may account for some of the effects observed in the
neonate following intrauterine opiate exposure, and that the nature of the
effect would be dependent on the extent of fetal drug exposure.
In these experiments, we have also characterized a syndrome of naloxone-
precipitated opiate abstinence following short-term infusion of morphine
to the fetus. The syndrome consists of desynchronization of electrocor-
tical activity; increased total body movements, nuchal tone, and eye
movements; continuous rapid, deep breathing movements; an immediate
bradycardia associated with transient increases in systolic, diastolic, and
pulse pressure; and meconiwn staining of the amniotic fluid. This syn-
drome resembles that observed in the human neonate (Glass et al. 1972;
Schulman 1969; Dinges et al. 1980). The syndromes differ, however, in
that we observed no cortical seizure activity in the fetal lamb. There are
no human data available describing the cardiovascular manifestations of
neonatal withdrawal.
Based on the present observations, we agree with Zuspan and coworkers
(1975) in suggesting that intrauterine opiate withdrawal presents a severe
physiologic stress to the developing fetus. Our data, showing that a
significant abstinence syndrome may be precipitated following short (2
hours), low-dose fetal exposure to morphine, further suggest that the
fetus may undergo a cycle of acute physical dependence and withdrawal
following the administration of opiates in normal clinical patients.
In conclusion, we have presented evidence which suggests that both direct
opiate pharmacodynamic effects and fetal withdrawal may contribute sig-
nificantly to neonatal outcome following intrauterine narcotic exposure.
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Positron-Emission Tomography:
A New Approach to Feto-Maternal
Pharmacokinetics
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Bengt Långström, Petter Malmborg, Anders Rane,
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INTRODUCTION
Positron emission tomography (PET) is a noninvasive technique for studies
of the regional kinetics of positron-emitting radiotracers. A drug or other
molecule is labeled with short-lived radionuclides such as 11C, 13N, 15O,
or 18F. After administration to animal or man, the distribution in the body
is visualized by external detectors and the radioactivity concentration in
various organs is quantitated as a function of time. With a high specific
radioactivity, PET is a true tracer technique and pharmacologic effects of
the radiolabeled compound will not occur.
PET has been widely used in studies of brain metabolism where 11C-la-
beled glucose, glucose analogs, and amino acids are commonly used
radiotracers (Ell and Holman 1982). Previously, PET has also been shown to
be a valuable tool in studies of tissue distribution of drugs (Hartvig et al.
1984) and studies on receptor-binding kinetics (Wagner et al. 1983).
Studies on the pharmacokinetics and on the metabolism of drugs in the
feto-maternal unit in any animal are hampered by the difficulties of
obtaining access to the fetal compartments without disturbing the normal
function. The close relationship between the placenta and fetal develop-
ment of humans and some nonhuman primates, such as the rhesus monkey,
makes this species an attractive animal model for pharmacokinetic studies
during pregnancy. However, the uterus of rhesus monkeys is sensitive to
manipulation such as insertion of catheters for fetal blood sampling. In
addition, the blood volume of the fetus does not permit withdrawal of more
than 5 to 10 ml of blood during an experiment if normal physiologic
conditions are to be maintained. A noninvasive technique such as PET
would therefore be suitable for the study of rapid transfer of 11C-labeled
drugs from the mother to the fetus.
However, PET registers only the distribution of the total radioactivity. If
the radiolabeled molecule is metabolized, knowledge of the metabolic
pathways is necessary for interpretation of the results. More information
can be obtained either by labeling the molecule itself or its metabolites at
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different sites in different experiments or by the use of additional
analytical techniques. Such techniques include chemical and radio-
chemical analyses (e.g., high performance liquid chromatography [HPLC]
and gel chromatography) of blood and other tissue fluids.
The objective of this study was to evaluate the PET technique in combi-
nation with other methods in studies of the kinetics of morphine and heroin
in pregnant rhesus monkeys. The possibilities and shortcomings of the PET
technique in such studies, as well as some preliminary results, are discussed
below.
MATERIALS AND METHODS
Radiopharmaceutical Preparation
11C was obtained as [11C]carbon dioxide by using the nuclear reaction
14N(p,a)11C and a gas target at the van de Graaff accelerator (11MeV),
University of Uppsala. [11C]methyl iodide was prepared as described by
Langstrom et al. (1982). The corresponding N-demethylated analogs of
morphine and heroin were alkylated and then purified by liquid chroma-
tography. Samples of the purified 11C-labeled compound were analyzed
for identity and radiochemical purity by use of reversed-phase liquid
chromatography. Radiochemical yields, when corrected for decay, were in
the range of 15 to 25%. The time of synthesis, including purification by
liquid chromatography, starting with the release of [11C]carbon dioxide
was about 50 minutes. Before administration, the samples were filtered
through a 0.22 M membrane filter to ensure a sterile preparation. The
radioactivity dose was measured immediately before administration.
Heroin was used in this experiment with the permission of the Swedish
National Board of Health and Welfare.
Animals
Three healthy, well-nourished pregnant rhesus monkeys (Macaca mulatta)
from the Primate Laboratory for Reproductive Research in Uppsala were
used in the experiments. The age of the animals varied between 7 and 15
years and their weights ranged from 7.3 to 9.1 kg. Gestational age at the
time of experiment was 120 to 150 days (pregnancy duration in rhesus
monkeys is 167 days). After an overnight fast, the animals were anes-
thetized with 100 mg ketamine intramuscularly, and the anesthesia was
maintained with repeated doses of 50-108 mg ketamine. Two indwelling
catheters were placed in different leg veins, one for administration of the
drugs and the other for blood sampling. Catheters were also inserted in the
bladder and in the amniotic cavity. Ultrasonography was used for visu-
alization of the internal organs of the mother and the fetus. Fetal blood
was obtained by ultrasonographic-guided puncture of the umbilical vein
(Lindgren and Lindberg, in press). The monkey was fixed in a specially
designed cradle and put in the detector opening of the PET in such a way
that the radioactivity in the fetal liver and at least one placenta could be
simultaneously registered. The experiments were carried out after
approval from the Committee for Protection of Laboratory Animals at the
University. The animals were not injured by the procedure, the pregnancy
continued normally, and the offspring were healthy.
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[11C]Morphine (41 µ Ci and 327 µCi, respectively) and [14C]Morphine
(100 µCi; 1.79 µmol; Amersham, England) were simultaneously adminis-
tered intravenously to two animals. Another monkey was given [11C]
heroin (319 µCi) intravenously.
Instrumentation
Imaging of the uterus of the monkey started immediately after adminis-
tration of the 11C-labeled opiate. A PC 384-38 positron emission
tomograph equipped with two rings of detectors (AB Scanditronix,
Uppsala, Sweden) was used. Data collection and analyses of images were
performed as described by Eriksson et al. (1982). Three horizontal
emission images were obtained for 4x10, 4x40, and 200-second periods at
predetermined intervals. Each image had a slice thickness of 13 to 14 mm
and a spatial resolution of about 8 mm. The resolution of the PET
equipment as well as other technical details are given by Bergstrom et al.
(1983). The measured radioactivity was corrected for physical decay to
the time of administration of the radioactive dose. Uptake--defined as
the relative distribution of radioactivity in different organs--was
calculated from the corrected radioactivity/cm3 and divided by the
administered radioactivity per gram of body weight where a density of 1
g/cm3 for all tissues was assumed. A measured uptake of 1.0 indicated
that the administered radioactivity was equally distributed in the whole
feto-maternal unit.
Sampling and Analysis of Drugs and Metabolites
Maternal blood was collected 0, 5, 15, 30, 60, 90, 120, 180, 240, and 360
minutes after dose. Urine and amniotic fluid were sampled at regular
intervals throughout the whole experiment. Fetal blood was obtained
from one monkey’s umbilical vein at 101 minutes after dose adminis-
tration.
The 11C activity in the samples was measured immediately in a well
counter. The blood samples (about 3 ml) were centrifuged and plasma
frozen at -20°C until analyses. [14C]morphine and [14C]Morphine-3-
glucuronide ([14C]M3G) were measured by liquid scintillation after
collection of fractions using an HPLC method (Svensson et al. 1982). The
elimination half-lives were estimated from the concentration-time curve
plotted in the log-linear scale.
RESULTS
Positron Emission Tomography
[11C]Morphine was rapidly distributed in the body of the rhesus monkey
and maximum uptake was obtained within a few minutes in well-perfused
organs, e.g., the placenta (figure 1). The disappearance of the 11C-
derived radioactivity in the placenta paralleled the decline of the total
11C-activity in maternal blood. The uptake was slow in the muscles of
the mother, as has previously been shown by Hartvig et al. (1984). The
[11C]morphine-derived radioactivity was also rapidly transferred to fetal
blood and an uptake of 1.5 times equal distribution was seen within 5 to 10
minutes in the fetal liver. The elimination half-life of the 11C-derived
radioactivity from the fetal liver was about 20 minutes.
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FIGURE 1. Uptake of 11C in placenta and fetal liver after intravenous
injection of [11C]morphine to the mother. Uptake is defines as
radioactivity per cm3 tissue in realtion to total radioactivity administered
per grant body weight. denote, the placental uptake; X the fetal liver;
and maternal paraspinal muscle.
Four minutes after administration of [11C]heroin, a maximum radio-
activity uptake of 7.5 in the placenta was observed. The uptake of
[l1C]heroin-derived radioactivity as compared to morphine was even
more pronounced in the fetal liver, and an uptake 8 times homogeneous
dilution was measured 5 minutes after dose (figure 2). The elimination
half-life from the placenta as well as from the fetal liver was estimated
to be 15 minutes.
Analysis of Plasma, Urine, and Amniotic Fluid (Figure 3)
[14C]Morphine rapidly left the maternal plasma and was eliminated
primarily by conversion to metaboites, e.g., [14C]M3G. Elimination
half-lives of [11C]morphine and [14C]M3G in one monkey was 70 and 110
minutes, respectively, whereas in the other monkey, a third very slow
elimination phase could be distinguished. The ratios [14C]M3G/[14C]
morphine 1 hour after the injection were 8 to 10 in the two mothers. In
one experiment, the fetal plasma concentration could be measured 101
minutes after dose. At that moment, the [14C]morphine concentration
was 29 µM, or about twice that in maternal plasma (15 µM). The ratio
[14C]M3G/[14C]morphine was 5.5 at this time.
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FIGURE 2. PET-images of the distribution of 11C in placenta (1) and
fetal liver (2) 0.3-27 min after intravenous administration of [11C]heroin
to the mother. To the upper right is shown the uptake in the featl liver
(upper curve), and the placental uptake (lower curve), calculated from
regions of interest on the images.
During the 4-hour study period, less than 50% of the administered
14C-derived radioactivity was excreted in the urine, more than 80% of
this fraction as [14C]MSG.
Measurable concentrations of [14C]morphine and [14C]M3G from 45 min-
utes and on indicated the excretion from the fetus into amniotic fluid.
[14C]MSG was present at persistently high and constant levels in amniotic
fluid for at least the duration of the experiment. In one monkey, a late
amniotic fluid sample obtained 16 to 17 hours after dose had the same
concentration as at 5 to 6 hours after dose. The ratio between [14C]M3G
and [14C]morphine in the amniotic fluid varied between 2 and 3 in both
monkeys.
[11C]Morphine-derived radioactivity (11C-activity) was measurable in
maternal blood and urine for at least 3 hours (figure 4). The increasing
11C-activity in amniotic fluid became equal to the maternal blood
11C-activity at about 3 hours after dose, i.e., considerably later than was
the case for [14C]morphiie. No kinetic estimations were made for the
11C-activity curves, since this activity represents the sum of radio-
activities of [11C]morphine and metabolites.
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FIGURE 3. [14C]morphine and [14C]morphine-3-glucuronide concetra-
tions in maternal plasma, amniotic fluid, and fetal plasma after
administration of [14C]morphine to one monkey.
DISCUSSION
PET has not been used previously for the study of pharmacokinetics in the
feto-maternal unit, but it is an accepted technique for studies of brain
metabolism and for receptor studies in the brain and heart (Ell and
Holman 1982). The advantage of the method for its use during pregnancy
is that it is a noninvasive tracer technique, thus avoiding pharmacological
effects of administered compounds. The procedure may be repeated
within a few hours and performed several times during the pregnancy in
the same animal. It is thus suitable for the study of dynamic events
during various phases of fetal life.
The use of PET as an in vivo autoradiographic technique gives a unique
possibility to study the rapid initial distribution of drugs from mother to
fetus.
However, the PET technique has certain shortcomings. The PET image is
derived from all molecules labeled with the radionuclide; i.e., both the
administered drug and its metabolites. In case the drug is metabolized
within 2 hours, blood and urine must be analyzed for the distribution of
radioactivity between parent drug and metabolites by chemical analysis,
e.g., HPLC. Another approach that facilitates the interpretation of the
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PET images is to label the molecule at different sites. The pattern of
distribution of the radioactivity when the same individual is investigated
with these compounds will give additional information on the metabolism.
FIGURE 4. [11C]Morphine-derived activity maternal blood, fetal
blod, an amniotic fluid after administration of [11C]morphine to the
same money as in figure 3.
PET has a fairly low spatial resolution. The distribution of morphine and
heroin in the fetal brain is of great interest to study, but we bhose to
study the liver in our initial experiments. The liver is a homogeneous
organ, in which the limited resolution is of less importance than in studies
of the central nervous system.
The radioactivity in an organ is composed of two fractions; one is limited
to the blood and the other is composed of metabolized and unmetabolized
11C-labeled moieties in the tissues. Corrections for the fraction in the
blood pool can be made by a separate determination of the blood volume
using 11C-labeled red blood cells or 68Ga-transferrin.
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A special difficulty with fetal PET studies is that the fetus might move
during the registration even if the mother is immobilized with ketamine.
In most cases, however, no difficulties in localizing the fetal liver
placenta were experienced.
The short half-life of 11C does not permit observation times exceeding 2
hours. The simultaneous administration of the corresponding unlabeled
compound or compounds labeled with long-lived isotopes makes it possible
to perform conventional studies with sampling beyond that period. By
sampling from the mother and the fetus, the PET image may be
correlated to the results from analyses of administered drugs and their
metabolites in body fluids. By this combination of techniques, two goals
are achieved. First, the initial, rapid phase of transport between
different organs of the body is studied by PET. This is not possible by
blood sampling alone. Second, results from the analyses of radioactivity
and drug concentrations in body fluids may be used in the construction of
compartment models. Such models may then be used in future
experiments, making invasive sampling techniques necessary only in an
initial phase of the study.
The present results indicate that heroin is readily distributed to the fetus
in accordance with its high lipophilicity. The transfer rate of morphine
was somewhat slower. Our data obtained with 14C-labeled morphine
confirm that this drug is transported to the amniotic fluid within 45
minutes. Earlier sampling did not reveal measurable levels of morphine in
the fetus. The [14C]M3G/[14C]morphine concentration ratio in maternal
blood varied between the monkeys, indicating interindividual variation in
the capacity to glucuronidate this drug in the liver (Rane et al. 1984; Sawe
et al., in press). This ratio was significantly higher than that in the
amniotic fluid at “pseudo-steady-state,” which probably reflects the
slower passage of the hydrophilic M3G metabolite as compared to the
parent drug.
No other method than PET has so far been able to reveal the events
within the body without disturbing the integrity of the feto-maternal
unit. The ultrasound-guided puncture of the umbilical vein for fetal blood
sampling has been without noticeable effect on the animals, but the
limiting factor is the volume of blood which can be drawn.
The energy metabolism and the protein synthesis are of great importance
for the development of the fetus and, in particular, its central nervous
system. Infants of drug-addicted mothers are often small for gestational
age. The reasons for this are unknown, but impaired energy utilization
and perturbed protein synthesis are possible explanations. Studies of
glucose and amino acid transport and metabolism in opiate-treated
animals may contribute to the understanding of the causes of this growth
retardation.
Another negative effect of drug abuse on the fetus is frequent abstinence
symptoms. Our results show that there was a rapid increase in radio-
activity in the fetus after intravenous injection of [11C]morphine and
[11C]heroin to the mother. The decline of the radioactivity was also
rapid, indicating that the fetus may suffer from withdrawal effects. PET
has been shown to offer unique possibilities to register such rapid events.
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Placental Transfer of Drugs, Alcohol, and
Components of Cigarette Smoke and Their
Effects on the Human Fetus
Betty R. Kuhnert and Paul M. Kuhnert
INTRODUCTION
The placenta was once thought to act as a barrier which protected the
fetus from the passage of xenobiotic compounds. Now, it is more
accurately thought of as a sieve which allows small molecules to pass by
diffusion. For example, if the mother smokes, the fetus is exposed to the
components of cigarette smoke. Furthermore, if the mother takes drugs,
the fetus is exposed to the drugs as well as to any active metabolites.
Finally, if the mother drinks alcohol, fetal blood alcohol levels may be
similar to those of the mother.
Components of cigarette smoke, alcohol, and other drugs all affect the
fetus to varying degrees. These effects can range from subtle neonatal
neurobehavioral effects following the use of meperidine during labor to
the full teratogenic effects of alcohol known as the fetal alcohol
syndrome (FAS). These effects can be short-lived, as in the case of low
doses of meperidine given to the mother, or permanent, as in the case of
the mental retardation following chronic alcohol use during pregnancy. In
some cases, such as exposure to lead or cadmium from cigarette smoke,
there may be biological effects, but no obvious clinical effects. In other
cases such as alcohol, the lower limits of the teratogenic potential are
unknown.
This chapter reviews recent work on the placental transfer of three drugs
(meperidine, phencyclidine, and alcohol) and certain components of
cigarette smoke (lead, cadmium, and thiocyanate) and examines the
effects of these compounds on the fetus.
MEPERIDINE
Meperidine is a synthetic opiate narcotic administered intravenously or
intramuscularly for analgesia during labor.
It has been in use since 1939 and today it is the most commonly used
obstetrical analgesic (Fishburne 1982). However, despite its widespread
use for many years, surprisingly little was known about its pharmacology
during the perinatal period.
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Some puzzling questions have been raised concerning the use of meperidiie
during labor. For example, meperidine has been noted to cause respiratory
depression in the newborn infant even if given to the mother in low doses
(Morrison et al. 1973). Moreover, it has also been shown to cause more
neonatal respiratory depression if given to laboring patients 2 to 3 hours
prior to delivery rather than 1 hour or less prior to delivery (Cuilhem et al.
1953; Shnider and Moya 1964). And, finally, no relationship could be demon-
strated between neonatal status and the concentration of meperidine in
cord blood (Morrison et al. 1973; Shnider and Moya 1964).
Based on this information, it was hypothesized that the effects of meper-
idine on neonatal status were due to the formation of a toxic metabolite.
Normeperidine was thought to be this active metabolite because animal
studies had shown it to be twice as potent as a convulsant and respiratory
depressant, but half as potent as meperidine when used as an analgesic
(Miller and Anderson 1954). However, the idea of a metabolite reaching the
fetus remained a hypothesis because sensitive analytical techniques which
could distinguish between meperidine and normeperidine in plasma were
not available until the 1970s. Furthermore, it had been reported that
neither the pregnant woman nor the neonate could metabolize meperidine
to normeperidine (Crawford and Rudofsky 1966).
The mother’s ability to demethylate meperidine to normeperidine was
recently documented (Kuhnert et al. 1979b). Maternal plasma levels of
normeperidine are apparent shortly after injection of the parent drug and
levels increase throughout labor. The ratio of normeperidine to meperidine
increases steadily with time. Furthermore, normeperidine has been
reported in cord blood (Kuhnert et al. 1979a). The levels of normeperidine
in cord blood increase with time after injection of the drug in the mother
(Kuhnert et al. 1980). With long drug-to-delivery intervals, more
normeperidine can be found in cord artery than in cord vein. This reflects
uptake of the drug in fetal tissues. Thus, recent studies support the
hypothesis of an active meperidine metabolite reaching the fetus.
However, the levels of normeperidine following single doses are probably
too low to have clinical effects. Moreover, the studies do not explain the
increase in neonatal morbidity if delivery occurs 2 to 3 hours after
administration of the drug to the mother.
Cord blood levels of drugs at delivery do not necessarily reflect the
infant’s tissue levels. Since tissue is not available for study from human
infants, serial urine collections and calculations of umbilical artery to
umbilical vein ratios are used to indirectly estimate tissue equilibrium or
body burden of drugs. Using these techniques, it has been shown that
maximum uptake of meperidine by fetal tissues occurs 2 to 3 hours after a
single intravenous injection of meperidine to the mother (Belfrage et al.
1981; Kuhnert et al. 1979a). Thus, the hypothesis of a toxic metabolite
reaching the fetus and causing the neonatal morbidity noted at 2 to 3 hours
is not supported. The dose-delivery intervals resulting in maximum uptake
of the parent compound, meperidine, correspond with those resulting in
maximum neonatal depression.
The use of multiple doses of meperidine over extended time periods during
labor may result in concentrations of normeperidine that are high enough
to be clinically significant (Kuhnert et al. 1985a; 1985c). In cases of long
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drug-to-delivery intervals (>4 hours), considerable normeperidine is formed
by both mother and fetus (Kuhnert et al. 1985a). Furthermore, following
multiple doses, the uptake of meperidine is altered from what occurs
following single doses, and the high levels of normeperiddine may add to the
adverse effects resulting from high levels of the parent compound.
Following single doses, maximum tissue uptake of meperidine occurs at 2
to 3 hours following administration of the drug to the mother. After this,
there is a diffusion gradient from fetal tissues to fetal blood to maternal
blood and the drug is cleared from the fetus. With multiple doses, the
diffusion gradient is continuously in the direction of fetal tissue uptake.
Thus, continuous uptake of the drug is occurring in fetal tissues for hours
after the last dose is given. Therefore, multiple doses of meperidine to the
mother over long time periods result in maximum exposure of the fetus to
both meperidine and normeperidiie (Kuhnert et al. 1985a, 1985c).
There was little doubt that the high levels of meperidine administered to
parturients a generation ago could result in neonatal depression (Shnider
and Moya 1964). However, obstetricians today use much lower doses and
the clinical impression is that there are usually no adverse effects on the
neonate. A study designed to test this hypothesis showed that there may
be subtle neurobehavioral effects on the fetus due to mean doses as low as
39±19 mg of meperidiie to the mother (Kuhnert et al. 1985b). Using the
Brazelton Neonatal Behavioral Assessment Scale, it was shown that infants
whose mothers received low doses of meperidine performed less well on
tests of regulation of state and had more abnormal reflexes than infants of
nonmedicated mothers. Furthermore, these effects were related to the
drug-to-delivery interval. Performance was less optimal with longer drug
to delivery intervals at both 1 and 3 days of life. Since normeperidine
levels increase with long drug-to-delivery intervals, and levels of meper-
idine, but not normeperidine, are very low by 3 days of age, the results of
this study again suggest that normeperidine may contribute to the adverse
effects following meperidine administration to the mother.
The clinical protocol for the administration of meperidine during labor has
changed as more has become known about the pharmacology of the drug in
the intrapartum period. It was once suggested that meperidiie should be
given in 100 to 150 mg doses at hourly intervals up to three doses and then
as required (Walker 1973). Today, we know that pharmacologically the best
time to be born following intravenous maternal analgesia with meper- idine
would be within 1 hour of a single low dose.
PHENCYCLIDINE
Phencyclidine (angel dust) was originally developed as a short acting
anesthetic. However, its hallucinogenic effects have limited its legal use
to the practice of veterinary medicine. Nevertheless, phencyclidine’s
sedative and hallucinogenic effects make it a popular drug of abuse among
adolescents. These adolescents are often the same ones with unplanned
pregnancies.
There has been one isolated report of the possible teratogenic effects of
phencyclidine (Golden et al. 1980). However, the use of phencyclidine by
pregnant women and possible effects on the fetus have only recently been
studied prospectively (Golden et al. 1984). In this study, the frequency of
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use by pregnant women was estimated to be between 0.8 and 6.4 percent.
Most of these women were polydrug users; therefore, the isolated effects
of phencyclidine on the fetus are difficult to determine. This study
indicated that phencyclidine use during pregnancy was widespread.
Abnormal neonatal neurological and behavioral findings have been
associated with maternal phencyclidine exposure (Golden et al. 1985).
These findings included poor attention, hypertonic ankle reflex, and
depressed neonatal reflexes--grasp and rooting. A second group of
abnormal outcomes which were more frequent in study infants, but not
statistically different, included miotic pupils, increased brachial reflexes,
and decreased joint mobility. The abnormal grasp reflex was predictive of
phencyclidine use when stepwise discriminant function analysis was used.
Abnormal anatomic findings were not associated with maternal phen-
cyclidine use in this study. These results suggested that phencyclidine
exposure to the fetus can result in abnormal neonatal neurologic findings
and behavior. Future studies must determine the long-term effects of
exposing the fetus to phencyclidine.
The pharmacology of phencyclidine in pregnant women or neonates has not
been well studied. Phencyclidine is known to cross the placenta, to be
present in neonatal urine and blood, and in breast milk (Strauss et al. 1981;
Kaufman et al. 1983a, 1983b). In nonpregnant subjects, phencyclidine is
known to be metabolized to two hydroxylated compounds (Lin et al. 1975)
and a pentanoic metabolite (Cook et al. 1982). All three metabolites may
have pharmacological activity (Domino 1978; Cohen et al. 1982).
The results of analyzing PCP metabolites in spot urine samples collected
from asymptomatic pregnant patients suggested that the pentanoic acid
metabolite is a major metabolite of PCP in these patients (Kuhnert et al.
1984). This metabolite was present in concentrations many times higher
than either the parent compound or the hydroxylated metabolites.
However, at delivery the pentanoic acid metabolite did not seem to be the
major compound excreted by parturients and this may be due to differences
in time since the drug was used. Maternal urine samples were positive for
at least 36 hours after delivery and excretion of both drug and metabolites
fluctuated.
Phencyclidine and its metabolites have been analyzed in serial samples
collected from asymptomatic neonates. The results have shown that
excretion of drug and metaholites is erratic and that the samples are
positive for at least 36 hours (Kuhnert et al. 1984). Thus, an earlier report
that urine is negative after 72 hours in symptomatic infants may have been
hampered by insensitive methodology (Strauss et al. 1981). These findings
suggest that the drug may have been sequestered in various tissues or body
compartments and more detailed pharmacological studies are obviously
needed. Furthermore, these results suggest that present methods of
screening for phencyclidine use may be inadequate.
ALCOHOL
Historically, alcohol has often been noted to have an adverse effect on
offspring. The Bible (Judges 13:7) says: “Behold, thou shalt conceive, and
bear a son; and now drink no wine nor strong drink....” In 1973, Jones et al.
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recognized a common pattern of malformation in the offspring of
alcoholic mothers and called this the fetal alcohol syndrome. Unknown to
them, the pattern had already been described in France in 1968 (Lemoine
et al.). Since 1973, many more cases of the syndrome have been
documented throughout the world (Clarren and Smith 1978; Streissguth et
al. 1980).
The principle features of FAS include mental retardation, growth
deficiency, and characteristic facial features. These facial features are
so characteristic that the mothers can be diagnosed as alcoholics from the
children’s features alone (Lemoine et al. 1968). These features include
small head circumference, low nasal bridge, eyes with prominent
epicanthic folds and short palpebral fissures, short nose, indistinct
philtrum (groove between nose and mouth), and a thin upper lip. The
percentage of infants having the problems associated with the FAS is
directly related to the magnitude of maternal ethanol ingestion
(Seidenberg and Majewski 1978), and also to the duration of maternal
alcoholism (Majewski et al. 1976).
The lower limit of the teratogenic potential of alcohol is unknown. There
is now considerable evidence from clinical and experimental studies that
prenatal alcohol exposure may adversely affect fetal development; this is
true even in the absence of observable physical anomalies and is apparent
by behavioral deficits. In addition to lowered IQ, children exhibit various
other behavioral problems such as excessive stubbornness, aggression,
hyperactivity, and sleep disorders. Furthermore, behavioral anomalies
have been reported in neonates of social drinkera (Landesman-Dwyer et
al. 1978). In social drinkers who smoked, moderate alcohol intake coupled
with moderate smoking use exerted an interactive and deleterious effect
upon newborn learning, which was not predictable when the two drugs
were taken separately (Martin et al. 1977). Thus, alcohol can be
characterized as a potent behavioral teratogen.
There have been relatively few investigations of the disposition of ethanol
following maternal administration in humans. Brien et al. (1983) reported
that there is a relatively low ethanol concentration in amniotic fluid after
maternal administration of ethanol and then a relatively high ethanol
concentration in amniotic fluid when ethanol has been virtually eliminated
from maternal blood. Hence, the amniotic fluid appears to provide a
“chemical cloud” environment such that the fetus remains exposed to
ethanol when none is measurable in maternal blood. It is conceivable
that, during an episode of binge-type drinking, the fetus could be exposed
to a very high ethanol concentration in amniotic fluid for a longer time
period than would be predicted by the maternal blood ethanol
concentration.
There is no longer any debate that the fetal alcohol syndrome exists
(Clarren and Smith 1978). What remains to be answered are such questions
as: What is the risk to a woman, given a specific drinking history, of
producing a seriously affected offspring? How does intermittent binge
drinking as opposed to steady consumption alter the phenotype? How do
commonly associated drugs like caffeine, nicotine, and diazepam alter or
potentiate the effects of alcohol? What are the mechanisms through
which alcohol or its breakdown products produce their effect on the
embryo and fetus? And finally, can prenatal diagnostic technics be used
to detect this disorder.
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SMOKING
Smoking may adversely affect many aspects of human reproduction. For
example, it may increase the risk of spontaneous abortion (Himmelberger
et al. 19781, retard fetal growth (Meyer et al. 1976), and increase the
number of pregnancy complications (Andrews and McCarty 1972). In
addition, children of smokers may be physically and intellectually
disadvantaged (Goldstein 1971). Precisely why these effects occur is
unknown, but many factors are believed to be involved and interrelated.
Three such factors may be the increase in the uptake of lead, cadmium,
and cyanide which occurs subsequent to exposure to cigarette smoke.
Lead
Each cigarette generates approximately 1 to 2 micrograms of airborne
lead when burned (Cogbill and Hobbs 1957). The amount of this lead that
reaches the fetus depends on how much the mother smokes. The concen-
tration of lead in fetal blood is directly related to the concentration of
lead in maternal blood (Kuhnert et al. 1976). While it is well established
that lead is an environmental health hazard to children, its effect on the
fetus is not well documented.
The effects of low levels of lead exposure can be seen by looking at the
effect of lead on enzymes involved in the pathway of heme synthesis.
One of the earliest manifestations of toxicity from low concentration of
lead appear to be the inhibition of d-aminolevulinic acid dehydratase
(ALAD) which converts d-aminolevulinic acid to porphobilinogen; the
other manifestation is ferrochelatase which inserts iron into protopor-
phyrin IX to form heme. The inhibition of ALAD can be measured
directly by enzyme assay (Granick et al. 1973); the inhibition of
ferrochelatase can be measured indirectly by increases in erythrocyte
protoporphyrin levels (Sassa et al. 1973).
In the fetus there is no relationship between erythrocyte protoporphyrin
levels and blood lead at term (Kuhnert et al. 1978). This suggests that
there has been no chronic effects of lead in the fetal bone marrow. There
is, however, a strong correlation between the erythrocyte lead levels and
the activity of ALAD in human fetal erythrocytes (Kuhnert et al. 1977).
This suggests that there is a direct acute effect of lead on the enzyme in
the peripheral circulation. Enzyme inhibition due to lead averages 11
percent of the enzyme’s activity. Infants of smoking mothers were found
to have significantly more enzyme inhibition than infants of nonsmoking
mothers.
Cadmium
In addition to lead, the average cigarette contains 1 to 2 micrograms of
cadmium (Lewis et al. 1972). Heavy smokers may have an intake of 20
micrograms/day or more due to smoking, in addition to intake from
dietary sources. In animals, cadmium has been found to cause fetal
growth retardation at low concentrations (Webster 19781, and to induce
developmental anomalies and fetal death at higher concentrations
(Chernoff 1973). In humans, cadmium has been thought to be one of the
factors which may contribute to fetal growth retardation (Longo 1980).
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Cadmium’s adverse biological effects stem from its simularity in molec-
ular structure to the essential element, zinc. Because of this, cadmium
can substitute for zinc as a cofactor for several different enzymes,
including alcohol dehydrogenase, acid phosphatase, and others. This
substitution causes enzyme inhibition. Further biological effects may
occur because cadmium in the body is bound to metalothionein, a
transport protein which also binds zinc.
The uptake of cadmium by pregnant women who smoke and the disposition
of cadmium in the maternal-fetoplacental unit has only recently been
described (Kuhnert et al. 1982). A comparison of cadmium levels in
maternal blood, fetal blood, and placenta between smokers and
nonsmokers showed that the highest concentration of cadmium was found
in the placenta of smokers; the least amount was found in the cord blood
of infants whose mothers were nonsmokers. The placenta of nonsmokers
contained approximately seven times more cadmium than the corre-
sponding cord blood levels; for smokers, this difference was approximately
ninefold. Significantly higher cadmium levels were found in maternal
blood and placenta of smokers. Cord blood levels were higher, but not
significantly, in smokers; the percentage increase in cadmium due to
smoking were 16 percent in cord blood, 32 percent in placenta, and 59
percent in maternal blood. It appears from this study and others (Roels et
al. 1978; Lauwerys et al. 19781 that the placenta acts as a barrier to the
transfer of cadmium to the fetus.
The fact that cadmium does accumulate in the placenta should not be
interpreted to mean that exposure to cadmium is not hazardous to the
fetus. Accumulation of cadmium in the placenta could alter its function
and thus be embryotoxic. It has been shown in animals that the placenta
is rapidly damaged after maternal injections of cadmium (Parizek 1965).
This leads to embryonic death in utero.
Cyanide
Tobacco smoke also contains cyanide, most of which is rapidly converted
to thiocyanate after absorption in the body (Pettigrew and Fell 1972).
Although low levels of thiocyanate are normally present in the body from
dietary sources, elevations in thiocyanate are believed to be one of the
mechanisms of fetal growth retardation related to smoking (Andrews 1973;
Pettigrew et al. 1977; Mebert et al. 1979; Pirani 1978). In the body,
thiocyanate and cyanide maintain a dynamic equilibrium. In higher doses,
thiocyanate and cyanide are definitely toxic. Both can act as hypotensive
agents, reduce intracellular oxygen utilization by inhibiting cytochromes,
interfere with vitamin B12 metabolism, cause degenerative neurological
disease, and alter thyroid function (Andrews 1973; Pettigrew et al. 1977;
Mebert et al. 1979; Pirani 1978; Philbrick et al. 1979).
During pregnancy, maternal thiocyanate levels are correlated with the
number of cigarettes smoked per day by the mother. Furthermore,
maternal and fetal thiocyanate levels are very closely correlated
(Pettigrew et al. 1977; Bottoms et al. 1982). Average fetal levels are
similar to those in the mother (Bottoms et al. 1982).
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Thiocyanate can also be used as an effective biological marker of
exposure to smoking (Cohen and Bartsch 1980). This compound is
particularly attractive as a marker because of its long half-life (14 days)
in the body. Compounds such as carboxyhemoglobin (4 hours) or nicotine
(<30 minutes) have much shorter half-lives. One limitation is that the
specificity and sensitivity may be inadequate when thiocyanate levels are
close to levels due to dietary or other sources. Thiocyanate has recently
been used as a biological marker to study the effects of passive smoking
on the fetus (Bottoms et al. 1982).
Passive smoking--the exposure of nonsmokers to air contaminated with
cigarette smoke--has been suggested as producing some of the same
adverse health consequences as active smoking. There are reports of
increased frequencies of upper respiratory infection, bronchitis, pneu-
monia, diminished small airway function, and angina in association with
passive smoking in the workplace or in the home (White and Froeb 1980;
Tager et al. 1979; Harlap and Davies 1974; Aronow 1978). These findings
suggest that passive smoking might also affect the fetus. While there are
many studies of active smoking during pregnancy, the effects of passive
smoking during pregnancy are not well documented.
Increased fetal thiocyanate has been found in association with passive
smoking (Bottoms et al. 1982). This finding suggests that tobacco smoking
by other members in the home or workplace of a pregnant woman who
does not smoke exposes the fetus to a measurable increase in at least one
metabolic byproduct of tobacco smoke, thiocyanate. This is consistent
with the possibility that passive smoking might adversely affect the
fetus. Unfortunately, there have been no enzymatic or clinical studies to
assess possible biological or clinical effects from the relatively small
increase in thiocyanate levels associated with passive smoking.
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Appendix
Maternal-Fetal Transfer of Abused
Substances: Pharmacokinetic and
Pharmacodynamic Data
Charles C. Lee and C. Nora Chiang
The objective of this appendix is to present pharmacokinetic and pharma-
codynamic data in a format that allows the investigators to readily review
research findings regarding pre- and post-natal effects due to maternal
exposure to substances of abuse. It is intended to be a comprehensive
collection of clinical reports from human studies and laboratory findings
in animals as well as perfused placenta preparations. Information on the
experimental method, dosage to the mother, route of drug administration,
gestational age, and the duration of maternal/fetal exposure is also
presented. The abused substances compiled in this appendix include:
amphetamines, cannabinoids/delta-9-tetrahydrocannabinol (THC)/canna-
bis, cocaine, lysergic acid diethylamide (LSD), meperidine, methadone/
acetylmethadol, morphine/heroin, nicotine/tobacco, and phencyclidiie
(PCP).
The pharmacokinetic data in this appendix, where available in the mother
and fetus, include half-life (t1/2), clearance (C1), and time to peak
concentration (tmax). In most cases, the maternal to fetal concentration
ratio of drug in the tissue or biological fluid is reported because serial
blood sampling required for pharmacokinetic study is not feasible in small
animals. Since drug secretion in human breast milk is a critical concern
for breast-feeding mothers, information on this subject is also
documented for its important clinical implications.
The pharmacodynamic data encompass the broadly defined teratological
effects. Traditionally, the term teratology refers to the study of (bon-
genital malformations produced by exogenous agents during gestation. In
recent years, teratologists have extended their observations beyond
morphological changes and have focused on functional disorders for
drug-induced biochemical and behavioral anomalies detected at birth or
later. Teratological effects for a specific abused substance are docu-
mented and compared between animal species.
In the past decade, several tables of pharmacodynamic data for various
drug substances have been published. In 1976, Coyle et al. published a
review on behavioral teratogenesis in which they summarized prenatal
drug effects on behavior as a function of developmental stage. Of the
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drugs examined, only THC and amphetamine belong to traditionally
defined substances of abuse. In 1977, Joneja presented a thorough study
on the teratologic effects of THC, given orally as single and multiple
doses during gestation, on the fetuses of golden syrian hamsters.
Extensive observations were made on day 15 after drug administration,
among which were percent resorption or death, number of retarded fetus
and external/skeletal abnormalities. No kinetic data were presented. In
1980, Slone et al. tabulated in a symposium proceedings some embryoni-
cally toxic drugs and chemicals of potential risk to the human fetus and
newborn, recording the number of cases studied and the elicited tera-
tologic effects. In the same year, Abel compiled two tables documenting
prenatal effects of cannabis extract and THC. These tables include
information about dosage, route of administration, duration of drug
exposure during gestation, and teratological effects. Again, no kinetic
data were included in the compilation. Until very recently, only data on
the effects of pregnancy on drug pharmacokinetics were compiled.
Information on the fetal cord to maternal plasma ratio of drug
concentrations and drug excretion in human breast milk were compiled as
two tables by Parker (1984) for some 60 drugs, most of which were not
substances of abuse. Since Parker’s review focused on kinetic
information, those dynamic effects incurred as a result of placental drug
transfer were not documented. An overview of this research area
indicates that very little integrated kinetic/dynamic information has been
documented. Thus, this compilation is intended to integrate pharmaco-
kinetic and pharmacodynamic data relevant to maternal-fetal transfer of
abused substances. It is hoped that this information will add to our
understanding and appreciation of this critical subject matter.
Several considerations were given in compiling the following list: (1) Only
values obtained from original papers, dating from 1974, and with data or
experimental methods which we could evaluate are included. Two review
articles for LSD are included because extensive research was performed
before that year. (2) The drug must be historically or currently abused to
a significant extent. Alcohol and benzodiazepines are not included in this
review since there exists such extensive literature on these subjects that
separate reviews would be required. (3) Information on dosage, route of
administration, and gestational age was lacking in some case studies,
particularly when human abusers were involved. However, we feel that
kinetic and dynamic effects elicited in pregnant women are sufficiently
important to warrant documentation of such effects even without
accurate recording of drug dosage regimen. (4) Some duplicate studies
using the same animal model and drug are included for the purpose of
contrasting the inter-laboratory variation of kinetic/dynamic effects.
Apparent deviations in dosage, route of administration, gestational age,
and duration of exposure are indicated. (5) The references are keyed to
individual authors so that readers can readily locate the reference
actually used.
It would obviously be most useful if there were a consensus about the
correct value for a given pharmacokinetic parameter or pharmacodynamic
measurement in a given species. In this compilation, a single value from
the literature or a range of values was selected for each parameter/
measurement. In some cases, we have summarized and interpreted the
data from the literature to determine the values reported in this table.
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We hope that this compilation will serve as a comprehensive reference to
those research scientists faced with selection of animal models for drug
abuse. research in pregnancy. For the general public concerned with the
clinical consequences of maternal-fetal transfer of abused substances,
this compilation may be appreciated as a warning, particularly for
potential drug abusers.
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PHARMACOKINETIC AND PHARMACODYNAMIC DATA
Model/ Dose/Route/Time Kinetic/Dynamic Effects
Preparation of Exposure
Drug Category: AMPHETAMINE/METHAMPHETAMINE
Reference
Human
Human
Human 237 out of 42,101 4% reduction in birth wt when drug
pregnancies used d-am- was taken after 28 wk of gestation;
phetamine for control no effects on birth lengths, head
of wt gain during circumferences, and perinatal mortality
pregnancy rates
amphetamine-addicted
women; gr 1: discontin-
ued during first tri-
mester; gr 2: throughout
pregnancy
rate of preterm delivery and peri-
natal motality increased for gr 2
amphetamine-addicted
women; gr 1: discon-
tinued during first
trimester; gr 2: through-
out pregnancy; gr 3:
throughout pregnancy &
children in foster home
temporary drowsiness in the infants
during the first month after birth,
normal somatic and psychomotor devel-
opment at the age of 12 months;
symptoms indicating emotional dis-
turbance were common in gr 2
Human amphetamines or other
anorectic drugs for
wt control during
pregnancy
no effect on severe congenital anomaly
(SCA) rate for live-born children
at 5. an excess of oral clefts in
the offspring of mother who took
amphetamine during early pregnancy
Naeye 1983
Eriksson et al.
1981
Billing et al.
1980
Milkovich &,
van den Berg
1977
Rat
Rat
Rat
Rat
Rat
Rat
0, 3 mg/kg/d, bid, d-
amphetamine, SC, d 7
thru 20 of gestation
0, 0.5 mg/kg/d, dl-am-
phetamines, SC, during
pregnancy
0, 2 mg/kg/d, d-am-
phetamine, SC, d 7 of
gestation till birth
0, 0.5, 1, 2 mg/kg/d,
d-amphetamine, SC,
d 12 to 15 of gesta-
tion
0, 2, 5 mg/kg/d, d-
amphetamine mixed with
drinking water, 30 d
prior to mating till
parturition
0, 5 mg/kg/d, metham-
phetamine; 3 mg/kg/d
nicotine; bid, SC,
throughout pregnancy &
nursing
either-way avoidance learning in the
offspring was affected; pre- and post-
natal amphetamine effects on avoidance
behavior dependent on nature of the
response and genetic lines
significant decrease in brain alpha but
not beta adrenergic receptor binding
without apparent changes in receptor
affinity in the adult offspring
offspring showed marked alterations
in brain neurotransmitter metabolism,
enhanced locomotor activity until 21
days of age
no detectable maternal or fetal toxi-
city; significant deficit in Y-maze
performance, & increased locomotor
responsiveness to postnatal chal-
lenge of amphetamine in the juvenile
offspring
delayed eye & vagina openings, slower
in behavioral tests of righting re-
flexes before 6 days of age and of
bridgecrossing at 14 days of age; no
differences in open-field activity
increased locomotor activity in off-
spring of methamphetamine-treated
group when monitored one night/month
from 3-39 months of age
Satinder &
Sterling 1983
Ramirez et al.
1983
Bigl et al.
1982
Adams et al.
1982
Monder 1981
Martin & Martin
1981
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Rat 0, 0.5 mg/kg/d, dl-
amphetamine, SC,
throughout pregnancy
Rat
Rat
Rat
0, 5 mg/kg/d, metham-
phetamine; 3 mg/kg/d,
nicotine; SC, or no
injection, throughout
pregnancy & nursing
increased susceptibility to disease.
or possible greater susceptibility to
tumor formation and growth retardation
for much of the lifespan of offspring
of methamphetamine group
1.25 mg/kg/d, N-2-cyano- increased total lipid content in fetal
ethylamphetamine, PO, heart but no differences in lipids in
d 5 to 21 of pregnancy placenta and fetal liver
0, 0.5 mg/kg/d, dl-
amphetamine, SC,
throughout pregnancy
no modifications of brain endogeneous
content of dopamine and noradrenaline
but modifications of catecholamine
metabolism
Rat 0, 0.5 mg/kg/d, dl-
amphetamine, SC,
throughout pregnancy
sexual behavior responses to ovarian
steroids were affected for female
offspring; no differences in hypo-
thalamic monoamine content, sex cycle
duration, and ovulatory phenomena
higher motor activity in the open-
field test in adults, more errors
observed in the Lashley III maze in
the first 4 days of age
Ramirez et al.
1979
Martin et al.
1979
Kulay et al.
1978
Nasello &
Ramirez 1978a
Nasello &
Ramirez 1978b
Rat
Rat
Rat
Rat
Rat
0, 5 mg/kg/d, metham- offspring of methamphetamine gr were Martin et al.
phetamine; 3 mg/kg/d significantly underweight, exhibited 1916
nicotine; SC, or no developmental delay, greater activity
injection, throughout for 8 of the first 12 monthly assess-
pregnancy & nursing ments begun at 90 days of age
1 or 3 mg/kg, d-amphet-
amine, bid, SC, from
d 5 of gestation till
term
0, 5, or 10 mg/kg/d
d-amphetamine, SC,
during d 5-9 (early)
or 12-16 (late) of
gestation
0, 1, 3, 5 mg/kg, bid,
methamphetamine.
throughout gestation
0, 0.5 mg/kg/d, dl-
amphetamine, SC,
throughout pregnancy
no obvious teratogenic effects but a
significant and dose-related increase
in pup mortality; surviving offspring
of 3 mg/kg gr showed increased motor
activity and decreased brain biogenic
amine levels
Hitzemann
et al. 1976
no differences among offspring in mild Seliger 1975
expression of emotionality; increased
incidences of severe emotional responses
(wild running and convulsion) in
placebo-early group
earlier delivery, decreased wt gain Martin 1975
over gestation, litter size decreased as
a function of dose, eye opening delayed,
no gross anomalities, more conditioned
avoidance responses for 5 mg/kg group
no differences in the age of eyes or Nasello et al.
vaginal aperture, or in the rate of 1974
growth; better acquisition & retention
of conditioned avoidance response at
the age of 90 days, and lower hippo-
campal seizure threshold
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Mouse 5 mg/kg, 3H-d-amphet- Tmax=1 hr in placenta & fetal tissues,
amine, IP, on d 16 of Tmax=15 min in matured tissues,
gestation conc in fetal tissues lower than
maternal tissues
Mouse 0, 5 mg/kg/d d-amphet- slightly reduced body wht at birth,
amine. IP, during the altered conc of brain catecholamines
last 6-7 d of pregnancy during development and increased
activity after they had matured
Drug Category: CANNABINOIDS/DELTA-9-TETRAHYDROCANNABINOL(THC)/CANNABIS
Human daily smoking of THC in maternal blood was 2.5-6 times
marijuana in third greater than in cord blood; maternal
trimester of pregnancy level of metabolite was 4-7 times
higher than cord level
Human
Human
use of marijuana more meconium staining and longer
during pregnancy duration of labor
nursing mothers smoking THC conc in milk was higher than that
marijuana in maternal plasma; THC was absorbed
by the baby from the milk
Human use of marijuana
during pregnancy
nervous system abnormalities in
infants; visual responses were affected
in a dose-related manner
Shah and Yates
1978
Middaugh
et al. 1974
Blackard & Tennes
1984
Greenland et al.
1982
Perez-Reyes 1982
Fried 1980
Monkey
Monkey
Sheep
Dog
Rabbit
Rabbit/
Rat
Hamster
2.4 mg/kg/d, PO,
throughout pregnancy
& lactation
2.4 mg/kg/d, IV,
during gestation
and nursing period
0.5 mg/kg, pulmonary
infusion 131-140 d of
gestation
0.5 mglkg. IV,
58-63 d of gestation
15, 30, 60 mg/kg/d, SC,
7-19 d of gestation
0.5-5 mg/kg PO as THC,
5-50 mg/kg PO as crude
extract, 6-18 d of ges-
tation
125-500 mg/kg single
dose, 25-100 mglkg
multiple dose, 7-12 d
of gestation
infants showed an alteration in visual
attention
drug-exposed mother-infant pairs were
similar to nontreated controls;
adequate maternal care was demon-
strated by all mothers
decreased cardiac output, increased
blood pressure, and increased uterine
blood flow in mothers; decreased fetal
blood pressure, increased umbilical
blood flow in fetus; both mother and
fetus developed acidosis and hypoxemia
THC level in maternal brain was 3 times
higher than that in fetal brain; major
area of THC distribution remained the
same
reduction in maternal food consumption
and wt gain, embryotoxicity and
embryocidal effects
no evidence of teratogenic activity;
fetal and pup survival was reduced
only at high dose (50 mglkg of crude
marijuana extract)
higher frequency of fetal mortality
and growth retardation, no clearcut
teratogenic response
Golub et al. 1982
Golub et al. 1981
Cotterill et al.
1984
Martin et al. 1977
Sofia et al. 1979
Wright et al. 1976
Joneja 1977
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Rat
Rat
Rat
Rat 5-50 mg/kg/d, PO, from
pregnancy to d 5 of
gestation, then either
50 or 150 mg/kg/d till
21 d of gestation
dose-related decrease in pregnancies
carried to term, decrease in wt gain
during pregnancy, decrease in birth
wt
20-200 mg/kg
marijuana extract
intubation throughout
gestation
reduced food-water consumption,
reduced maternal wt gain,
decreased pup wt at birth,
increased mortality
4.2 mg/kg/d, IP, pups having lower body wt, higher
2-6 d of gestation emotionality. poor learning capacity
l-10 mg/kg, PO,
during gestation &
lactation
small doses THC suppressed luteinizing Rosencrantz &
hormone, larger doses elevated Esber 1980
follicle-stimulating hormone and
estrogens
Rat
Rat
10-150 mg/kg/d
marijuana extract
intubation 1-21 d of
gestation
3.3 mg/d. inhalation
1-19 d of gestation
Abel 1984
Abel et al. 1981
Kawash et al. 1980
impaired rotarod performance but did not Abel 1979
affect inclined plane, spontaneous
alteration, learning/memory, or open-
field performance
smaller infants at birth, delayed
physiological development and less
active than the control group
fried & Charlebois
1979
Rat
Rat
Rat
Rat/
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
1.25 or 4.0 mg/kg, IV,
during nursing period
2 mg/kg/d, PO,
throughout pregnancy
25, 50, 100 mg/kg/d, SC,
6-15 d of gestation
rat: 12.5-50 mglkg, PO
mouse: 150-600 mg/kg, PO
6-15 d of gestation
50 mg THC, single oral
dose on 18th d of gesta-
tion
50 mg/kg, single oral
dose on the day of
delivery
20 mg/kg, PO, 3 times/wk
3 wk after weaning &
prior to parturition
50 mglkgld, PO, THC,
12th d of gestation
for 4 days
50 mg/kg/d, PO for
7 days from 20th d
of gestation
THC inhibited suckling-induced prolactin
release in the postpartum rat
no teratogenicity, but had passive
avoidance response
maternal wt gain depressed, fetal wt
decreased significantly at dose greater
than 50 mg/kg; some abnormalities
no severe sign of intoxication in both
rats and mice; increased litter
resorption & fetal mortality
maternal exposure altered endocrine
function and conc of brain biogenic
amines in the male offspring
maternal exposure altered male repro-
ductive function and brain biogenic
amines in male and female offspring
decreased nest-building behavior,
litter size, and sexual behavior
maternal exposure resulted in increase
of body wt. ano-genital distance, and
testosterone conc in male and female
fetuses
reduced postnatal viability, impaired
male reproductive behavior at maturity
and decreased seminal vesicle wt
Bromley et al. 1978
Vardaris 1976
Banerjie et al. 1975
Fleischman et al.
1980
Dalterio et al.
1984a
Dalterio et al.
1984b
Frischknecht et al.
1982
Dalterio & Bartke
1981
Hatoum et al. 1981
Model/ Dose/Route/Time
Preperation of Exposure
Mouse 50 mg/kg/d, PO, 1 d
prior to parturition
and 6 d postpartum
Mouse 5 mg/kg, PO,
during lactation
Mouse 0-25 mg/kg/d
intubation
short term: 8 d
long term: 70 d
Mouse
Mouse
Mouse
25 mg/kg/d, SC, from
13th d of pregnancy
to term
3-400 mg/kg, single fetal growth retardation, increased
dose, IV, SC, & intra- external abnormalities, skeletal
gastric abnormalities
50-300 mg/kg, IP,
8-16 d of gestation
in utero death, reduction of body size, Mantilla-Plata,
offspring with cleft palate & Harbison 1976
Kinetic/Dynamic Effects Reference
reduced testes wt and elevated plasma Dalterio 1980
level of luteinizing hormone
decrease of pup body wt. some effects Frischknecht
on tail length, projection of ears, & et al. 1980
eyes opening
short term: delayed entry into proestrus, Kostellow et al.
depressed serum progesterone during 1980
luteal phase, inhibited female
receptivity to males
long term: term pregnancies were reduced,
no significant effects on length of
estrous cycles or mating
THC suppressed mammary gland lipoprotein Raine et al.
lipase activity and depressed mammary 1978
gland growth and development
Joneja 1976
Mouse 5-150 mg/kg, PO,
6-15 d of gestation
no effects on maternal wt gain, pre-
natal mortality, fetal wt, and fre-
quency of gross external, internal,
& skeletal abnormalities
Fleischman
et al. 1975
Drug Category: COCAINE
Rat/Mouse 50, 60, 75 mg/kg, IP,
8-12 d of gestation
Mouse 75-175 mg/kg, SC,
7-12 d of gestati
rat: reduction in maternal and fetal
wt. increased resorption frequency
mouse: decreased fetal wt with no
increase in malformations
l & MacphailFante
1982
on
eye and skeletal defects, teratogenic Mahal
and ontogenic 1980
ik et al.
Mouse
Human
Placenta
10 mg/kg 3H-cocaine Significant levels of cocaine in Shah et al. 1980
IP, 15-17 d of gestation placenta and the fetus
280-560 umole, cocaine decreased acetylcholine release rate
incubate with placenta by 33-50%
Sastry et al.
1977
villi for 10-15 min
Drug Category: LYSERGIC ACID DIETHYLAMIDE (LSD)
Human
Human
Human
parents used LSD before an infant with a unilateral anophthalmia
and during pregnancy
Margolis &
and normal chromosome Martin 1980
maternal LSD use during a premature baby with severe ocular Chan et al.
the first trimester malformations 1978
Maternal LSD use before baby with multiple systemic and ocular
& during pregnancy
Apple and
malformations Bennett 1974
Model/ Dose/Route/Time
Preparation-  of Exposure
Kinetic/Dynamic Effects Reference
Human psychotherapeutic manage- no cytogenetic abnormality for mothers
ment before pregnancy and infants
Human 5 psychiatric patients
treated with LSD
during pregnancy
no abnormal births in 7 pregnancies
Human 140 women used LSD before
& during pregnancy (poly-
drug users)
out of 148 pregnancies, 83 live newborns
and 8 with major defects, 53 therapeutic
abortions, 12 spontaneous abortions
Human/
Animals
a review article five out of 161 children with limb
defects but no strong evidence of
chromosome breakage and teratogenicity
in animals or man
Human/
Animals
a review article
Rabbit 0, 50 ug/kg, IV, single
dose, at 21-25 d
of gestation
no evidence that pure LSD is teratogenic
in humans; some indication of an in-
creased risk of spontaneous abortion in
humans; teratogenic effects reported
but not confirmed in hamsters and rats,
suggested for lower primates and con-
firmed in mice.
induced a disaggregation of polysomes
in fetal kidney, liver, and brain;
pretreatment with haloperidol and
pizotyline effectively inhibited
the disaggregation
Fernandez et al
1974
Robinson et al.
1974
Jacobson &
Berlin 1972
Long 1972
Dishotsky et al
1971
Heikkila et al.
1979
Rat
Mouse
3H-LSD, 24 uCi/kg, IV,
18 d of gestation
5 ug/kg IP, on post-
concept on d 12 or 18
Drug Category: MEPERIDINE
Human 100 mg, IM, 38-42 wk
of pregnancy
Human 1.5 mg/kg. IM during
labor
Human
Human
Human
50 mg, IM between 3-8 d
from childbirth
50 mg, IV, during labor
50-75 mg, IV, 4 hr
before delivery
significant fraction of the dose
appeared in the fetus
variable changes in the wt of some brain
regions; monoamine oxidase levels were
elevated
general depression of fetal heart rate
to sound stimulation was observed 30 min
after meperidine injection
fetal conc reached peak level at l-5
hr after dose; fetal-maternal drug
ratio varied between 0.35-1.5; t1/2
averaged 3.4 hr and was not different
from that in healthy control
meperidine appeared in milk, the conc
ratio between milk and serum was greater
than unity, no harmful effect in newborn
fetal conc of meperidine peaked 2-3 hr.
that of normeperidine peaked 4 hr or
later following dosing to mother
neonatal depression following meperidine
& no correlation between suppression
and route of administration or meperidine
conc at time of delivery
Back & Singh
1977
Hoff 1976
Jensen 1984
Tomson et al.
1982
Peiker et al.
1980
Kuhnert et al.
1979
Rothberg et al.
1978
Model/ Dose/Route/Time
Preparation of Exposure
Human 1 mg/kg, IV,
during amniotomy
Human 25 mg, IV infusion,
during labor
Human 50 mg, epidural
analgesia, during labor
Sheep 8.5-12.5 mg/kg, IV,
last month of gestation
Sheep 2.5 mg/kg, IV or IM,
during labor
Sheep 3.2 mg/min, IV infusion,
111-121 d of gestation
Sheep 2.5 mg/kg, IV,
111-121 d of gestation
Kinetic/Dynamic Effects
decreased pH and increased pC02, in
mother; decreased PH and base excess in
fetus
no ill effects
hypotension complication, decelerated
fetal heart rate; neonates had lower
APGAR score compared to controls
disrupted fetal sleep cycle and
increased heart rate
uptake of meperidine in fetal brain;
peak conc of meperidine in fetal brain
was 3-4 times greater from IV than IM
meperidine clearance averaged 12 ml/min;
ratio of meperidine clearance to
inulin clearance was greater than 1,
indicating tubular secretion
meperidine t1/2 approximated 30 hr;
renal clearance varied between 2.8-16.7
ml/min; meperidine was found in amniotic
and allantoic fluids
Reference
Chang et al. 1976
Eliot et al. 1975
Wingate et al.
1974
Ruckebusch
1976
Szeto et al
et al.
. 1980a
Szeto et al . 1980b
Szeto et al. 1979
Human 0.1 uCi 14C-meperidine lipid-soluble analgesics crossed
Placenta added to placenta tissue placenta by transcellular as well as
obtained 10 min after extracellular pathways; no indication
delivery of active transport
Rabbit 15 mg/hr, for 20 min, meperidine conc ratio between umbilical
Placenta IV infusion effluent and maternal plasma was 0.64;
placental clearance was reduced by
maternal protein binding, flow depend-
ent at low umbilical flow rate and
permeability dependent at high flow
Drug Category: METHADONE/METHADYL ACETATE
Human low-dose methadone smaller head circumference, more depres-
therapy sion of interactive behavior and state
controls
Human methadone therapy narcotic abstinence syndrome, smaller
head circumference, elevated systolic
blood pressure
Human
Human
50 mg/d, PO, throughout measureable but small amount of metha-
pregnancy and perinatal done in amniotic fluid & breast milk
period t1/2 in neonate = 32.5 hr
methadone administered cord blood level of methadone was lower
to pregnant mother than maternal serum level; conc of metha
done in neonatal urine was 10-60 times
that of cord blood
Seeds et al. 1976
Hamshaw-Thomas
et al. 1984
Chasnoff et al.
1982
Rosen & Johnson
1982
Kreek 1979
Harper et al. 1977
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Human
Human
Human
Human
Sheep
Sheep
heroin & methadone
use during pregnancy
heroin and methadone
use during pregnancy
methadone maintenance
treatment
methadone treatment
program
mother: 5 ug/kg/min
fetus: 0.5 ug/kg/min
IV infusion, 130-141 d
of gestation
methadone and morphine
IV infusion, 5 hr,
130-141 d of gestation.
mother: 5 ug/kg/min
fetus: 0.25, or
0.5 ug/kg/min
induced chromosome damage in vivo
low birth rate, fetal growth
retardation
no association of maternal dosage in
last trimester of pregnancy with length
of gestation, birth wt, or withdrawal
syndrome; identical infant mortality
rate
increased infant mortality, decreased
birth wt. increased incidence of breech
presentation
both methadone and morphine resulted
in fetal arousal and suppressed
quiet sleep
maternal to fetal free drug concentra-
tion ratios were 7.6 for morphine and
2.9 for methadone; clearance from
mother to fetus was 24.9 ml/min for
morphine and 390 ml/min for methadone;
fetal nonplacental clearance was
126 ml/min for morphine and 381 ml/min
for methadone
Abrams 1975
Kandall 1975
Newman et al.
1975
Harper et al. 1974
Umans & Szeto 1983
Szeto et al.
1982
Sheep
Hamster
Rat
Rat
Rat
Rat
Rat
Rat
5-20 mg, single dose
injection to fetal
circulation, 145 d of
gestation
35 mg/kg, SC, during
critical period of
CNS organogenesis
5 mg/kg/d, methadone,
IP, throughout gestation
and/or lactation
0.2 or 2.0 mg/kg/d, PO,
1 mo prior to and
throughout pregnancy
10 mg/kg/d, methadone
PO, 5th d of gesta-
tion to term
0, 4, 16 mg/kg/d, SC,
8th d of gestation
to term
0.5-2.0 mg/kg/d, PO,
LAAM, chronic dosing
5 mg/kg/d, methadone,
IP, 5 d before breeding
& throughout gestation
and lactation
decreased carotid blood flow, decreased
frequency and amplitude in EEG;
electrical activity and heart rates
were affected
congenital malformation of CNS,
fetal anomalies
reduced social dominance in offspring
of mothers given methadone
significant cumulation of LAAM and
active metabolites in the whole fetus
and fetal brain
decreased brain levels of monoamine
and metabolites; methadone-exposed
rats exhibited more avoidance escapes
and intertrial shuttles
low body wt. high mortality, depressed
open-field activity, deficits in
behavioral development
cumulative behavioral toxicity
abnormally greater wt gain during
the postweaning period
Mann et al. 1976
Geber & Schramm
1975
Thompson & Zagon
1983
Lichtblau et al.
1982
Rech et al. 1980
Freeman 1980
Lichtblau et al. 1980
McLaughlin & Zagon
1980
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Rat 5 mg/kg/d, methadone, SC, decreased fetal testosterone and
14-19 d of gestation androstenedione level
Rat 14 mg/kg/d, methadone long-lasting growth retardation and
PO, ad lib, throughout less emotionality in open-field
gestation trials
Rat l-5 mg/kg, methadone,
SC, bid, last trimester
of pregnancy
reduction of body and brain growth
Rat 5 mg/kg, methadone, IP,
during gestation and/or
lactation
lower body wt, shorter crown to rump
length & tail length, & smaller
diameter; detrimental effect on pre-
weaning organ and body development
Rat
Rat
Rat
5 mg/kg/d, methadone,
IP, during gestation &
lactation
2.0-8.0 mglkgld,
methadone, IM or SC,
15-21 d of gestation
5 mg/kg/d, methadone,
initially increased
to 10, 15. & 20 mg/kg/d,
PO, 8-22 d of gestation
reduction of maternal wt, lower
cerebellar wt & smaller width
of the offspring, retarded growth
and brain development of young rats
localization of methadone in fetal
rat eye
blood levels were dose related;
reduced maternal wt, increased
mortality for the mother & the young
Singh et al. 1980
Grove et al. 1979
Ford & Rhines 1979
McLaughlin et al.
1978
Zagon & McLaughlin
1977
Pertschuck et al.
1977
Hutchings et al.
1976
Rat
Rat
Rat
Mouse
Mouse
5-20 mg/kg/d, methadone, chronic fetal methadone intoxication; McDonald et al.
SC, 30 d before breeding increased neonatal death rate, 1975
& during pregnancy but no evidence of development
difficulty to 21 days of age
25 mg/kg/d, methadone, fetal growth retardation, possible Chandler et al.
oral gavage throughout positional malformation 1975
gestation
2.5, 5.0, 7.5 mg/kg/d, increased infant mortality, increased Buchenauer et al.
methadone, IP, 1 wk percentage of stillborn pups, 1974
before breeding retardation of growth, obvious
dose-response relationship at low dose
5-28 mg/kg/d, methadone, reduced maternal wt gain and food Bui et al. 1983
SC, 6-15 d of gestation consumption, increased resorptions, and
decreased survival rate; adverse effects
on growth development
0.8, 5 mg/kg, 3H-l- T max=15 min in whole fetus, fetal Shah et al. 1976
methadone, IP, brain, & liver; fetal brain conc were
15-17 d of gestation higher than maternal brain conc after
15 min
Drug Category: MORPHINE/HEROIN
Human
Human
4-6 mg, morphine, newborn had morphine-induced respira- Carlsson et al.
epidural injection tory depression; morphine was inef- 1981
in labor fective as an obstetric analgesic
pregnant heroin elevation of chromosomal breakage, mi- Van Blerk et al.
addicts tosis depression, chromosomal abberation 1980
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Human narcotic (heroin and increased pre- & post-natal growth
methadone) dependent deficiency, vascular changes,
women & hypoxic episodes
Human pregnant drug abusers
& narcotic (heroin &
methadone) dependent
women
mentally & neurologically deficient
infants. high morbidity & mortality
among newborn infants
Human 0.1 mg/kg, morphine
or heroin, IV, in
amniotomy examination
Human heroin addicts
decreased PH & increased pC02
In mother; decreased pH & base
excess in the fetus
withdrawal symptoms in infants, small
body size & circumference. intrauterine
growth retardation
Sheep 5 mg, morphine, epidural
injection, during labor
Sheep 0.66 mg/kg, morphine
Injection, to ewe's flank
near term
Rabbit 2.5-10 mg/kg, morphine,
every 6 hr. SC, from
early pregnancy till
delivery
no adverse effect in mother or fetus
altered fetal glucose & homeostasis,
decreased permeability of the
placenta to glucose
fetus weighed significantly less
than controls; morphine did not
accelerate fetal lung development
Finnegan 1979a
Finnegan 1979b
Chang et al.
1976
Vargas et al.
1975
Craft et al.
1982
Raye et al.
1980
Roloff et al.
1975
Rat
Rat
Rat
Rat
Rat
Rat
Mouse
2.5 mg/kg, morphine, IV fetal morphine conc was 1.5 times higher
bolus, or 23.3 ug/min/kg than that of maternal plasma; fetal
for 30 min, then brain conc was 4 times higher than that
3.5 ug/min/kg for 30 min. maternal plasma
18-20 d of gestation
20 mg/kg/d morphine, IV,
d 12 till end of
gestation
10 mg/kg, morphine,
5 mg/kg, naloxone, IP,
before & during
pregnancy
10 mg/kg. morphine, SC,
during gestation
5 mg/kg/hr for 4 hr,
morphine. IV infusion,
21-22 d of gestation
5 mg/kg/hr for 4 hr,
morphine, IV infusion,
near term
0.12-12 mg, morphine
SC; 0.068-6.5 mq/min.
IV infusion; 7-10 d
of pregnancy
fetus showed morphine-induced depres-
sion & later developed tolerence to
depressant effect in utero
altered regional development of
3H-methionine binding sites in the
brains of offspring; affected the
development of opiate receptors in brain
an enhanced prostaglandin-like activity
in the homogenate of rat placenta
caused a derangement of cerebral
protein synthesis, possibly by
interfering with the availability
of m-RNA
inhibitory effect on transcription
in fetal brain resulting from intra-
nuclear accumulation of morphine
fetal wt reduction, skeletal & soft
tissue abnormalities
Grabrielsson
& Paalzow
1983
Kirby &
Holtzmann
1982
Tsang & Nq
1980
Scoto et al.
1979
Steele &
Johannesson
1975a
Steele &
Johannesson
1975b
Ciociola &
Gautieri
1983
Model/ Dose/Route/Time
Preparation of Exposure
Human 1 pmole of 3H-etorphine
placenta/ incubated with placenta
Rat brain mix and 0.8 mg brain
protein protein at 37°C, 1/2 hr
Human 0.4-1.0 mole, morphine
placenta incubated with acetyl-
choline, 37ºC, 2 hr
Monkey/ 7.25-144 umole, ethyl-
liver morphine incubated in
homogenate fetal homogenate, 12-16
wk of gestation
Drug Category: NICOTINE
Human pregnant female smokers
Human nursing female mokers
Human female smokers in 2nd
or 3rd trimester
Kinetic/Dynamic Effects Reference
human placenta exhibited lower
affinity for opioid peptide than did
rat brain opiate receptor
Valette et al.
1980
morphine reduced 3H-acetylcholine
uptake
Welsch 1976
N-demethylation of fetal liver was
l/10 of maternal liver & adult liver
Dvorchik et al.
1974
atropic and hypovascular changes in Mochizuki
placental villi, impairment of utero- et al. 1984
placental circulation, retarded fetal
growth
milk-serum conc ratio 2.92; t1/2
of nicotine in milk slightly
exceeded that in serum
Luck & Nau
1984
fetal hypoxia, elevated levels of Divers et al.
epinephrine, norepinephrine, and DOPEG 1981
in amniotic fluid
Human
Human
Human
Monkey
Monkey
Sheep
Sheep
Rat
pregnant female smokers
habitual smoking during
last trimester
pregnant female smokers
100 ug/kg/min, 20 min.
IV infusion, near term
1 mg/kg as single
injection or infused
over 20 min, 107-150 d
of gestation
15 mg/10 min, IV
infusion, 97-117 d
of gestation
0.14-0.25 mg/kg, IV
or IA, 110-120 d
of gestation
2.46 mg/d in drink-
ing water (120 mg/l)
throughout pregnancy
infants with low birth wt, congenital
anomalies, or who died
increase of apnea and periodic
breathing movement
smaller baby, greater incidence of
premature baby abortion & stillbirth
decreased uterine blood flow, fetal
acidosis & hypoxia
disappearance of nicotine from fetal
circulation was slower than maternal
circulation; high conc in adrenal
glands, heart, kidneys, stomach wall,
and spleen of fetus
increased maternal arterial pH & blood
pressure, increased maternal and fetal
heart rates, decreased fetal arterial
PCO2 & uterine blood flow
decreased fetal PO2, maternal blood
flow, & fetal breathing movement;
fetal hypoxemia
less maternal wt gain, higher fetal
body fat, higher maternal lipolysis
rate
Weathersbee &
Lodge 1979
Gennser et al.
1975
Garrett 1975
Suzuki et al.
1981
Suzuki et al.
1974
Ayromlooi et al.
1981
Manning et al.
1978
Williams &
Kanagasabai 1984
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Rat
Rat
Rat
Rat
Rat 1.5-3.0 mg/d, SC. 1 wk
prior to mating &
continued till
parturation
15-90 mg/30 cigarette
inhalation, bid,
throughout gestation
5 mg/kg, SC, d 9 of
gestation
0.2 mg, SC, 1-8 d of prolonged gestation period, decreased
gestation fetal number & wt
6.03 mg/kg/d, PO,
O-20 d of pregnancy;
1 mg/kg, IP, single dose
d 20 of pregnancy
no difference in fetal level of
triglyceride, phospholipid, and
cholesterol compared with control
group
Mouse 5.7-28.6 mg/d in drinking
water (100 mg/l), 2 wk
before breeding &
throughout gestation
fetus weighed 12% less than control,
decreased placental wt, decreased
placental amino acid transport
no difference in wt gain of mother
and birth wt of offspring; neurologi-
cal effect on offspring, prolonged
learning time
reduced maternal wt. reduced wt &
length of fetus, resorption, and
stillbirth
no significant adverse effects in
embryonic development and fetal
viability
Peters & Ngan
1982
Reznik & Marquard
1980
Lindenschmidt &
Persaud 1980
Biswas et al.
1977
Mosier et al.
1974
Rowell & Clark
1982
Drug Category: PHENCYCLIDINE
Human
Human
Human
Human
Human
Pig
Pig
Rat
PCP daily, prior to
and during pregnancy
case study of PCP
abusers
PCP during first 6 wk
of pregnancy
irregular consumption
of PCP prior to and
during pregnancy
PCP abuse during
pregnancy
2 mg/kg, IM, single
dose before general
anesthesia for delivery
0.5 g, IM, before
general anesthesia
for delivery
l0-40 mg/kg/d, IP,
15-20 d of gestation
sudden outbursts of agitation, rapid
changes in level of consciousness,
increased lability of states, and poor
consolability
presence of PCP in breast milk and
amniotic fluid
cerebellar malformation
Neonates showed jitteriness, hyper-
tonicity, vomiting,diarrhea,
microcephaly
abnormal neonatal behavior,
dysmorphology, spasticity
PCP in piglet plasma 10 times higher
than that in maternal sow plasma,
t1/2 =6 hr in piglet, t1/2=2 hr
in adult sow
PCP in piglet plasma 10 times higher
than maternal plasma, t1/2=lO-12 hr
in piglet, t1/2= 2-4 hr in mother
morphological & behavioral alterations
Chasnoff et al.
1983
Kaufman et al.
1983
Michaud et al.
1982
Strauss et al.
1981
Golden et al.
1980
Cummings et al.
1979
Cooper et al.
1977
Jordan et al.
1979
Model/ Dose/Route/Time Kinetic/Dynamic Effects Reference
Preparation of Exposure
Mouse 5, 10, 20 mg/kg/d. PO, delayed disappearance of cross Nicholas & Schreiber
5 d prior to mating & extensive reflex, delayed appearance 1983
throughout gestation of reflexes, decreased growth rate
Mouse 60-120 mg/kg/d, PO, malformed fetuses at 120 mg/kg/d, Marks et al. 1980
6-15 d of gestation but not teratogenic
Human 0.5 mM PCP incubated placenta was demonstrated to be an Rayburn et al. 1984
Placenta with 0.02-0.1 mg active site of PCP biotransformation
microsomal protein for
20 min, pH=8.8, T=37°C
Keys: bid=twice daily; conc=concentration; d-day; gr=group; hr=hour; IA=intraarterial; IM-intramuscular;
IP=intraperitoneal; IV=intravenous; min=minute; mo=month; PP=per OS; qd=once daily; SC-subcutaneous;
wk=week; wt=weight
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